MRK


Line plots across dimensions of each concept
Line plots across concepts
Tables

Table of contents



us-gaap:CommonStockValue
us-gaap:StatementEquityComponents
us-gaap:CommonStockSharesIssued

us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

us-gaap:WeightedAverageNumberOfSharesOutstandingBasic

us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

us-gaap:EarningsPerShareBasic

us-gaap:EarningsPerShareDiluted

us-gaap:IncomeLossFromContinuingOperationsPerBasicShare

us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare

us-gaap:ComprehensiveIncomeNetOfTax

us-gaap:CostOfGoodsAndServicesSold
us-gaap:CounterpartyName, us-gaap:IncomeStatementLocation, us-gaap:TypeOfArrangement

us-gaap:IncomeLossFromContinuingOperations

us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
us-gaap:ConsolidationItems
us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments

us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest

us-gaap:IncomeTaxExpenseBenefit
us-gaap:IncomeTaxAuthority, us-gaap:IncomeTaxAuthorityName
us-gaap:IncomeTaxesPaid

us-gaap:InterestExpense
us-gaap:ConsolidationItems

us-gaap:NetIncomeLoss
us-gaap:StatementEquityComponents

us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
us-gaap:StatementEquityComponents

us-gaap:OtherComprehensiveIncomeLossNetOfTax
us-gaap:StatementEquityComponents

us-gaap:OtherNonoperatingIncomeExpense

us-gaap:ProfitLoss

us-gaap:ResearchAndDevelopmentExpense
us-gaap:BusinessAcquisition
us-gaap:ConsolidationItems
us-gaap:CounterpartyName
us-gaap:CounterpartyName, us-gaap:IncomeStatementLocation, us-gaap:TypeOfArrangement

us-gaap:Revenues
us-gaap:ConsolidationItems
us-gaap:ConsolidationItems, us-gaap:ProductOrService, us-gaap:StatementBusinessSegments
us-gaap:ConsolidationItems, us-gaap:ProductOrService, us-gaap:StatementGeographical, us-gaap:StatementBusinessSegments
us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments
us-gaap:ConsolidationItems, us-gaap:StatementGeographical
us-gaap:ConsolidationItems, us-gaap:StatementGeographical, us-gaap:StatementBusinessSegments
us-gaap:CounterpartyName, us-gaap:IncomeStatementLocation, us-gaap:TypeOfArrangement
us-gaap:DerivativeInstrumentRisk, us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncome, us-gaap:StatementEquityComponents
us-gaap:StatementGeographical

us-gaap:SellingGeneralAndAdministrativeExpense
us-gaap:CounterpartyName, us-gaap:IncomeStatementLocation, us-gaap:TypeOfArrangement

us-gaap:Assets
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement
us-gaap:Liabilities
us-gaap:CounterpartyName, us-gaap:SubsequentEventType, us-gaap:TypeOfArrangement

us-gaap:LiabilitiesAndStockholdersEquity

us-gaap:StockholdersEquity

us-gaap:AssetsCurrent

us-gaap:CashAndCashEquivalentsAtCarryingValue

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

us-gaap:AccountsReceivableNetCurrent
us-gaap:CounterpartyName, us-gaap:BalanceSheetLocation, us-gaap:TypeOfArrangement
us-gaap:ReceivablesNetCurrent

us-gaap:InventoryNet

us-gaap:InventoryFinishedGoods

us-gaap:InventoryLIFOReserve

us-gaap:OtherAssetsCurrent

us-gaap:Land

us-gaap:MachineryAndEquipmentGross

us-gaap:PropertyPlantAndEquipmentGross

us-gaap:ConstructionInProgressGross

us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

us-gaap:PropertyPlantAndEquipmentNet
us-gaap:StatementGeographical

us-gaap:Goodwill
us-gaap:StatementBusinessSegments

us-gaap:IntangibleAssetsNetExcludingGoodwill
us-gaap:BusinessAcquisition, us-gaap:FiniteLivedIntangibleAssetsByMajorClass
us-gaap:FiniteLivedIntangibleAssetsByMajorClass
us-gaap:IndefiniteLivedIntangibleAssetsByMajorClass
us-gaap:ProductOrService
us-gaap:ProductOrService, us-gaap:FiniteLivedIntangibleAssetsByMajorClass
us-gaap:ProductOrService, us-gaap:BalanceSheetLocation
us-gaap:FiniteLivedIntangibleAssetsNet

us-gaap:OperatingLeaseRightOfUseAsset
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:OtherAssetsNoncurrent
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument
us-gaap:FairValueByMeasurementFrequency
us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument

us-gaap:EquitySecuritiesFvNi
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument
us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument

us-gaap:AccountsPayableCurrent

us-gaap:AccruedIncomeTaxesCurrent

us-gaap:DebtCurrent
us-gaap:ShortTermDebtType

us-gaap:DividendsPayableCurrent

us-gaap:LiabilitiesCurrent
us-gaap:CounterpartyName, us-gaap:BalanceSheetLocation, us-gaap:TypeOfArrangement

us-gaap:LongTermDebtCurrent

us-gaap:OperatingLeaseLiabilityCurrent

us-gaap:OtherLiabilitiesCurrent
us-gaap:CounterpartyName, us-gaap:BalanceSheetLocation, us-gaap:TypeOfArrangement
us-gaap:LiabilitiesNoncurrent

us-gaap:LongTermDebtNoncurrent

us-gaap:DeferredIncomeTaxLiabilitiesNet
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
us-gaap:RetirementPlanType

us-gaap:MinorityInterest

us-gaap:OtherLiabilitiesNoncurrent

us-gaap:OperatingLeaseLiabilityNoncurrent

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive

us-gaap:OperatingLeaseLiability

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue

us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

us-gaap:StockholdersEquity

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
us-gaap:StatementEquityComponents

us-gaap:CommonStockValue

us-gaap:AdditionalPaidInCapitalCommonStock

us-gaap:RetainedEarningsAccumulatedDeficit

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax

us-gaap:TreasuryStockValue

us-gaap:MinorityInterest

us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
us-gaap:StatementEquityComponents

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

us-gaap:DeferredIncomeTaxExpenseBenefit

us-gaap:DepreciationDepletionAndAmortization
us-gaap:ConsolidationItems

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetIncomeLoss
us-gaap:StatementEquityComponents

us-gaap:ProfitLoss

us-gaap:ShareBasedCompensation

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:PaymentsToAcquireProductiveAssets
us-gaap:BusinessAcquisition
us-gaap:AssetAcquisition
us-gaap:PaymentsToAcquireInvestments
us-gaap:BusinessAcquisition
us-gaap:CounterpartyName

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:ProceedsFromIssuanceOfLongTermDebt

us-gaap:RepaymentsOfLongTermDebt

us-gaap:PaymentsOfDividendsCommonStock

us-gaap:PaymentsForRepurchaseOfCommonStock

us-gaap:EffectiveIncomeTaxRateContinuingOperations

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

us-gaap:DeferredTaxLiabilities

us-gaap:DeferredTaxAssetsNet
us-gaap:BalanceSheetLocation

us-gaap:UnrecognizedTaxBenefits

us-gaap:DeferredTaxAssetsValuationAllowance

us-gaap:ProceedsFromRepaymentsOfShortTermDebt
us-gaap:ConsolidationItems
mrk:AmortizationOfPurchaseAccountingAdjustments
us-gaap:ProductOrService
mrk:ChargesRelatedToProgramDiscontinuation
us-gaap:CounterpartyName, us-gaap:IncomeStatementLocation, us-gaap:TypeOfArrangement
mrk:CollaborativeArrangementProfitSharing
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:IncomeStatementLocation, us-gaap:TypeOfArrangement
us-gaap:CounterpartyName, us-gaap:IncomeStatementLocation, us-gaap:TypeOfArrangement
mrk:CollaborativeArrangementSalesNet
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:IncomeStatementLocation, us-gaap:TypeOfArrangement
us-gaap:CounterpartyName
mrk:ContingentPaymentsCollaborativeArrangement
us-gaap:CounterpartyName, us-gaap:ContingentConsiderationByType
us-gaap:CounterpartyName, us-gaap:ContingentConsiderationByType, us-gaap:TypeOfArrangement
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:ContingentConsiderationByType
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

mrk:CostsExpensesAndOther

mrk:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet

mrk:DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses

mrk:EstimateOfCumulativePreTaxCostsThatWillBeNoncash

mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays

mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther
us-gaap:CounterpartyName
mrk:Licenseoptionpaymentrelatedtocollaborativearrangement
us-gaap:CounterpartyName, us-gaap:StatementScenario
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement
mrk:MilestonePaymentsMadetoCollaborativePartner
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement
mrk:MilestonePaymentsSalesBased

mrk:OtherNonoperatingIncomeExpenseOther
us-gaap:AssetAcquisition
mrk:PremiumOnSharesAcquired
us-gaap:BusinessAcquisition
us-gaap:CounterpartyName, us-gaap:SubsequentEventType, us-gaap:TypeOfArrangement
mrk:ProbableContingentPaymentsCollaborativeArrangement
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement
mrk:ProfitShare
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement
mrk:ProfitShareCounterparty

mrk:RestructuringReserveIncreaseDecreaseNoncashActivity
us-gaap:RestructuringCostAndReserve

mrk:RestructuringReserveNoncashActivity
us-gaap:RestructuringCostAndReserve
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:Range
mrk:RoyaltyRatePercentage
us-gaap:CounterpartyName, us-gaap:Range, us-gaap:TypeOfArrangement
us-gaap:Range, us-gaap:BusinessAcquisition

mrk:SalesDiscounts
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement
mrk:SalesThreshold
us-gaap:ConsolidationItems
mrk:SegmentReportingUnallocatedOtherExpensesNet
us-gaap:CounterpartyName
mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
us-gaap:CounterpartyName, us-gaap:ProductOrService
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
mrk:UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner

us-gaap:AccountsReceivableSale

us-gaap:AdjustmentForAmortization
us-gaap:ConsolidationItems
us-gaap:ProductOrService

us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
us-gaap:CounterpartyName
us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued

us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
us-gaap:DerivativeInstrumentRisk, us-gaap:IncomeStatementLocation
us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
us-gaap:DerivativeInstrumentRisk, us-gaap:IncomeStatementLocation
us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
us-gaap:RetirementPlanType

us-gaap:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
us-gaap:RetirementPlanType

us-gaap:DefinedBenefitPlanDivestituresBenefitObligation
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanInterestCost
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanServiceCost
us-gaap:RetirementPlanType

us-gaap:Depreciation
us-gaap:DerivativeInstrumentRisk, us-gaap:IncomeStatementLocation
us-gaap:DerivativeGainLossOnDerivativeNet

us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
us-gaap:DerivativeInstrumentRisk, us-gaap:IncomeStatementLocation
us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
us-gaap:DerivativeInstrumentRisk, us-gaap:IncomeStatementLocation, us-gaap:SubsequentEventType

us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax

us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare

us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod

us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold

us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense

us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense

us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense

us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue

us-gaap:DividendsCommonStockCash
us-gaap:StatementEquityComponents

us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense

us-gaap:EquitySecuritiesFvNiGainLoss
us-gaap:StatementScenario

us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
us-gaap:StatementScenario

us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount

us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount

us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
us-gaap:ProductOrService, us-gaap:FiniteLivedIntangibleAssetsByMajorClass
us-gaap:FinitelivedIntangibleAssetsAcquired1

us-gaap:ForeignCurrencyTransactionGainLossBeforeTax

us-gaap:GoodwillAndIntangibleAssetImpairment

us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax

us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity

us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare

us-gaap:IncreaseDecreaseInOperatingCapital

us-gaap:InterestPaid

us-gaap:InvestmentIncomeInterest
us-gaap:ConsolidationItems

us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent

us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
us-gaap:StatementEquityComponents

us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
us-gaap:StatementEquityComponents

us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent

us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent

us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent

us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
us-gaap:StatementEquityComponents

us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
us-gaap:DerivativeInstrumentRisk
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
us-gaap:DerivativeInstrumentRisk
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
us-gaap:DerivativeInstrumentRisk
us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
us-gaap:DerivativeInstrumentRisk, us-gaap:IncomeStatementLocation
us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax

us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
us-gaap:StatementEquityComponents

us-gaap:OtherNoncashIncomeExpense

us-gaap:PaymentsForProceedsFromOtherInvestingActivities

us-gaap:PaymentsForRestructuring
us-gaap:RestructuringCostAndReserve
us-gaap:CounterpartyName
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesEquity

us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
us-gaap:AssetAcquisition
us-gaap:PaymentsToAcquireBusinessesGross
us-gaap:BusinessAcquisition
us-gaap:BusinessAcquisition, us-gaap:SubsequentEventType
us-gaap:ProductOrService
us-gaap:StatementScenario, us-gaap:BusinessAcquisition

us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
us-gaap:CounterpartyName, us-gaap:StatementScenario
us-gaap:PaymentsToAcquireIntangibleAssets

us-gaap:PaymentsToAcquireMarketableSecurities

us-gaap:ProceedsFromPaymentsForOtherFinancingActivities

us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments

us-gaap:ProceedsFromStockOptionsExercised

us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
us-gaap:StatementEquityComponents

us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
us-gaap:StatementEquityComponents

us-gaap:ReclassificationFromAociCurrentPeriodTax
us-gaap:StatementEquityComponents

us-gaap:RestructuringAndRelatedCostIncurredCost

us-gaap:RestructuringCharges
us-gaap:ConsolidationItems
us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

us-gaap:StockholdersEquityNoteSpinoffTransaction
us-gaap:StatementEquityComponents

us-gaap:StockholdersEquityOther
us-gaap:StatementEquityComponents
us-gaap:StatementEquityComponents
us-gaap:StockholdersEquityOtherShares
us-gaap:StatementEquityComponents
us-gaap:TreasuryStockSharesAcquired

us-gaap:TreasuryStockValueAcquiredCostMethod
us-gaap:StatementEquityComponents
us-gaap:IncomeTaxAuthority, us-gaap:IncomeTaxAuthorityName
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities

us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment

mrk:AccrualForChargebacks

mrk:AccrualForRebates
us-gaap:AssetAcquisition
mrk:BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet
us-gaap:BusinessAcquisition
us-gaap:CounterpartyName, us-gaap:BalanceSheetLocation, us-gaap:TypeOfArrangement
mrk:CollaborativeArrangementPayable
us-gaap:CounterpartyName, us-gaap:BalanceSheetLocation, us-gaap:TypeOfArrangement
mrk:CollaborativeArrangementReceivable
us-gaap:RetirementPlanType
mrk:CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage

mrk:DebtSecuritiesandEquitySecuritiesFVNI

mrk:DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards

mrk:DeferredTaxAssetsUnrecognizedTaxBenefits

mrk:DeferredTaxLiabilitiesEquityMethodInvestment

mrk:DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans

mrk:DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic

mrk:DisposalGroupIncludingDiscontinuedOperationAccrualReversalIncomeTaxesPayableCurrent

mrk:DisposalGroupIncludingDiscontinuedOperationsDebt
us-gaap:RetirementPlanSponsorLocation
mrk:ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests

mrk:InventoryNetAndInventoryNoncurrent

mrk:LesseeOperatingLeaseLeaseNotyetCommencedAmount
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement
mrk:MilestonePaymentsAccruedSalesBased
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement
mrk:PotentialFutureMilestonePaymentsRegulatory
us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement
mrk:PotentialFutureMilestonePaymentsSalesBased
us-gaap:CounterpartyName, us-gaap:TypeOfArrangement
us-gaap:AwardType
mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsConvertedAwards

mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsConvertedAwards

us-gaap:AccrualForEnvironmentalLossContingencies
us-gaap:StatementEquityComponents
us-gaap:AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax

us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:AssetsFairValueDisclosure
us-gaap:FairValueByMeasurementFrequency

us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent

us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
us-gaap:FinancialInstrument

us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument
us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument
us-gaap:FinancialInstrument

us-gaap:BuildingsAndImprovementsGross
us-gaap:BusinessAcquisition
us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
us-gaap:BusinessAcquisition
us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
us-gaap:BusinessAcquisition, us-gaap:ContingentConsiderationByType

us-gaap:BusinessCombinationContingentConsiderationLiability
us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyType
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:FairValueByMeasurementFrequency

us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyType
us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyType, us-gaap:MeasurementInputType
us-gaap:ProductOrService, us-gaap:FiniteLivedIntangibleAssetsByMajorClass
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
us-gaap:BusinessAcquisition
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
us-gaap:FairValueByFairValueHierarchyLevel
us-gaap:CashEquivalentsAtCarryingValue
dei:LegalEntity
us-gaap:DebtInstrumentFaceAmount

us-gaap:DebtInstrumentFairValue

us-gaap:DebtLongtermAndShorttermCombinedAmount

us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible

us-gaap:DeferredIncomeTaxLiabilities

us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent

us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent

us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets

us-gaap:DeferredTaxAssetsGross

us-gaap:DeferredTaxAssetsInventory

us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign

us-gaap:DeferredTaxAssetsOther

us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits

us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation

us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts

us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets

us-gaap:DeferredTaxLiabilitiesOther

us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment

us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
us-gaap:RetirementPlanSponsorLocation
us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation
us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation
us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanBenefitObligation
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation
us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
us-gaap:RetirementPlanType
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanFundedStatusOfPlan
us-gaap:RetirementPlanType
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
us-gaap:Range, us-gaap:DefinedBenefitPlanByPlanAssetCategories, us-gaap:RetirementPlanSponsorLocation
us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
us-gaap:RetirementPlanType
us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1

us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection

us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction

us-gaap:DerivativeAssets
us-gaap:BalanceSheetLocation, us-gaap:DerivativeInstrumentRisk, us-gaap:HedgingDesignation
us-gaap:DerivativeInstrumentRisk, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:DerivativeInstrumentRisk, us-gaap:FairValueByMeasurementFrequency
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:FairValueByMeasurementFrequency
us-gaap:HedgingDesignation

us-gaap:DerivativeCollateralObligationToReturnCash

us-gaap:DerivativeCollateralRightToReclaimCash

us-gaap:DerivativeLiabilities
us-gaap:BalanceSheetLocation, us-gaap:DerivativeInstrumentRisk, us-gaap:HedgingDesignation
us-gaap:DerivativeInstrumentRisk, us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:DerivativeInstrumentRisk, us-gaap:FairValueByMeasurementFrequency
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:FairValueByMeasurementFrequency
us-gaap:HedgingDesignation

us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection

us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction

us-gaap:DerivativeNotionalAmount
us-gaap:BalanceSheetLocation, us-gaap:DerivativeInstrumentRisk, us-gaap:HedgingDesignation
us-gaap:DerivativeInstrumentRisk
us-gaap:HedgingDesignation

us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet

us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayable

us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities

us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent

us-gaap:DisposalGroupIncludingDiscontinuedOperationCash

us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents

us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration

us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities

us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1

us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets
us-gaap:FiniteLivedIntangibleAssetsByMajorClass

us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1

us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets

us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets

us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities

us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities

us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
us-gaap:CounterpartyName
us-gaap:DueFromRelatedPartiesCurrent
us-gaap:CounterpartyName
us-gaap:DueToRelatedPartiesCurrent

us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount

us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount

us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount

us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
us-gaap:FiniteLivedIntangibleAssetsByMajorClass

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
us-gaap:CounterpartyName
us-gaap:ForwardContractIndexedToIssuersEquityIndexedShares

us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
us-gaap:BalanceSheetLocation
us-gaap:HedgedLiabilityFairValueHedge
us-gaap:BalanceSheetLocation
us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease

us-gaap:IntangibleAssetsGrossExcludingGoodwill
us-gaap:FiniteLivedIntangibleAssetsByMajorClass
us-gaap:IndefiniteLivedIntangibleAssetsByMajorClass

us-gaap:InventoryGross

us-gaap:InventoryNoncurrent
us-gaap:PublicUtilitiesInventory

us-gaap:InventoryWorkInProcessAndRawMaterials
us-gaap:AssetAcquisition
us-gaap:Investments
us-gaap:BusinessAcquisition

us-gaap:LIFOInventoryAmount

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:LiabilitiesFairValueDisclosure
us-gaap:FairValueByMeasurementFrequency

us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation

us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent

us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
us-gaap:ValuationAllowancesAndReservesType
us-gaap:LitigationReserve

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
us-gaap:DebtInstrument
us-gaap:LongTermDebtPercentageBearingVariableInterestRate

us-gaap:MarketableSecuritiesNoncurrent

us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
us-gaap:IncomeTaxAuthority
us-gaap:OperatingLossCarryforwardsValuationAllowance

us-gaap:OtherInventorySupplies
us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType
us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
us-gaap:RetirementPlanType

us-gaap:RestrictedCash

us-gaap:RestrictedCashAndCashEquivalents

us-gaap:RestrictedCashCurrent

us-gaap:RestructuringAndRelatedCostCostIncurredToDate1

us-gaap:RestructuringAndRelatedCostExpectedCost1
us-gaap:StatementScenario

us-gaap:RestructuringReserve
us-gaap:RestructuringCostAndReserve
us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
us-gaap:AwardType
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
us-gaap:CounterpartyName
us-gaap:SharePrice

us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
us-gaap:ShortTermDebtType
us-gaap:ShortTermDebtWeightedAverageInterestRate

us-gaap:StockholdersEquityBeforeTreasuryStock

us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability
us-gaap:BalanceSheetLocation
us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent
us-gaap:BalanceSheetLocation
us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent
us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency
us-gaap:TradingSecurities
us-gaap:FairValueByMeasurementFrequency

us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued

us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate

Plots across concepts


IncomeStatement
Net Income Loss
Expenses
Other Nonoperating Income Expense
Balance Sheet
Operating Lease Liability
Assets
Derivative Assets
Current Assets
Inventory Net
NonCurrent Assets
Operating Lease Right Of Use Asset
PropertyPlantAndEquipmentNet
Property Plant And Equipment Net
Liabilities
Derivative Liabilities
Current Liabilities
Operating Lease Liability Current
Noncurrent Liabilities
Minority Interest
Stockholders Equity
Accumulated Other Comprehensive Income Loss Net Of Tax
CashFlow
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInOperatingActivities
Share Based Compensation
NetCashProvidedByUsedInInvestingActivities
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInFinancingActivities
Net Cash Provided By Used In Financing Activities
Shares
Weighted Average Number Of Shares Outstanding Basic
DividendsAndRepurchase
Payments For Repurchase Of Common Stock
OperatingLeaseLiability
Operating Lease Liability Current
LesseeOperatingLeaseLiabilityPaymentsDue
Lessee Operating Lease Liability Payments Due Year Four
InventoryNet
Inventory Finished Goods
AccountsReceivable
Allowance For Doubtful Accounts Receivable Current

Tables

  2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
us-gaap:CommonStockValue ▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄1788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.0NANANA
 us-gaap:CommonStockSharesIssued us-gaap:StatementEquityComponents us-gaap:CommonStock████████████████████████████████████████████▁3577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03577.03576.9483563577.03576.9483563577.03576.9483563577.03576.9483563573.0NA
 us-gaap:CommonStockSharesIssued us-gaap:StatementEquityComponents us-gaap:TreasuryStock████████▇▇▇▆▆▆▆▅▅▅▅▅▅▅▅▅▄▄▄▄▃▃▃▃▃▂▂▂▂▂▂▁▁▁▁▁▁1044.01046.01047.01047.01048.01053.01038.01026.01010.0994.0985.0918.0907.0885.0880.0851.0850.0837.0828.0815.0811.0808.0796.0775.0753.0749.0739.0716.0677.0648.0650.0650.0651.0560.0550.0533.0538.0535.0536.0525.0494.0492.0495.0497.0492.0NA
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding ▁█2540.02541.0NA2538.02536.02547.0NA2572.02588.02603.0NA2678.02696.02710.0NA2727.02752.02766.0NA2786.02789.02795.0NA2836.02850.02865.0NA2911.02949.02971.0NA2960.03010.03053.0NA3079.03072.03074.0NA3091.03110.03104.0NA3102.03125.03141.0
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic █▁2533.02531.0NA2529.02527.02533.0NA2558.02574.02585.0NA2662.02683.02695.0NA2727.02734.02745.0NA2765.02768.02774.0NA2814.02826.02835.0NA2879.02917.02934.0NA2927.02977.03022.0NA3045.03041.03043.0NA3070.03086.03084.0NA3078.03105.03114.0
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount ▁█12.014.0NA5.08.02.0NA3.03.02.0NA2.013.014.0NANA5.02.0NA4.013.010.0NA10.06.03.0NA5.04.01.0NA23.023.086.0NA97.0107.0117.0NA170.0138.0185.0NA173.0195.0182.0
us-gaap:EarningsPerShareBasic ▄▅▁▅▅▅▅▄▅▅▄▄▄▃▂▃▄▄▂▄▄▄▃▄▃▃█▃▄▄▃▄▃▄▃▄▄▄▄▄▄▃▂▃▃▃0.611.26-0.83000000000000011.161.191.270.92999999999999970.741.041.130.70.730.640.27-0.38-0.020.710.56-0.209999999999999960.790.440.410.35000000000000010.650.240.342.540.310.690.580.270.380.30.530.29999999999999980.570.590.570.50.550.650.34-0.169999999999999980.110.240.1
us-gaap:EarningsPerShareDiluted ▄▅▁▅▅▅▅▄▅▅▄▄▄▃▂▃▄▄▂▄▄▄▃▄▃▃█▃▄▄▃▄▃▄▃▄▄▄▄▄▄▃▂▃▃▃0.611.25-0.83000000000000011.161.181.260.91999999999999990.741.031.120.690.730.630.27-0.38-0.020.710.56-0.21000000000000020.780.430.40.34000000000000010.640.240.332.50.310.680.570.270.380.30.520.290000000000000040.560.580.560.490.550.650.34-0.159999999999999980.110.240.09
us-gaap:IncomeLossFromContinuingOperationsPerBasicShare 4.8e-07NANANA9.300000000000001e-07NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare 4.8e-07NANANA9.200000000000001e-07NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
  2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
 EBT Margin us-gaap:ConsolidationItems us-gaap:OperatingSegments▆▇██▅▇▆▇▆▄▅▄▄▃▄▃▃▁▃▄▂▁▃▃▂▁▄▄11452.012093.012535.012540.010780.011892.011697.012263.011632.010727.010921.010734.010428.010068.010373.010256.09815.09218.09905.010420.09679.09009.010108.09771.09475.09195.010471.010455.0NANANANANANANANANANANANANANANANANANA
 EBT Margin us-gaap:ConsolidationItems,us-gaap:StatementBusinessSegments us-gaap:OperatingSegments,mrk:AnimalHealthsegment█▇▄▅▃▅▃▃▃▂▂▂▃▃▂▂▁▁1472.01418.01168.01220.01101.01214.01122.01122.01124.01025.01036.01021.01090.01065.0981.01000.0955.0939.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 EBT Margin us-gaap:ConsolidationItems,us-gaap:StatementBusinessSegments us-gaap:OperatingSegments,mrk:Pharmaceuticalsegment▅▇██▄▆▆▇▆▄▅▄▄▃▄▃▂▁▃▄▂▁▃▃▂▁▄▃9980.010675.011367.011320.09679.010655.010533.011095.010460.09663.09830.09658.09282.08919.09289.09156.08759.08185.08904.09443.08700.08104.09027.08925.08564.08266.09370.09134.0NANANANANANANANANANANANANANANANANANA
 EBT Margin us-gaap:ConsolidationItems,us-gaap:StatementBusinessSegments us-gaap:OperatingSegments,us-gaap:AllOtherSegmentsNANANANANA23.042.046.048.039.055.055.056.084.0103.0100.0101.01033.0-2477.0977.0979.0905.01081.0846.0911.0929.01101.01321.0NANANANANANANANANANANANANANANANANANA
  2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
 TTM Greenblatt ROC _ _▃▄▁▄▄▄▃▃▄▄▃▃▃▃▃▂▃▃▁▃▃▃▂▃▂▃█▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃1717.03462.0-1993.03428.03519.03838.02791.02347.03259.03067.02604.02665.02086.01345.01879.0200.02439.02003.0-1356.02887.01504.01624.0816.02397.0807.01381.011811.01490.01891.02091.01225.01525.01245.01550.01334.02218.02680.02507.01581.02352.01672.01729.0NANANANA
  2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
us-gaap:ComprehensiveIncomeNetOfTax ▆▆▁▅▅▆▄▅▅▆▄▅▄▄▂▃▅▄▂▅▄▄▄▄▃▄█▃3090.03191.0-2345.02951.03000.03021.01553.01873.02654.03114.01433.01921.01645.0860.0-1011.093.01932.01697.0-1569.02018.01313.01079.01402.01585.0522.01109.05991.0341.0NANANANANANANANANANA1056.01800.02400.01100.0NA1500.0-335.0-506.0
us-gaap:CostOfGoodsAndServicesSold ▁▃█▂▁▂▃▄▂▁▂▃▂▁▂▂▁3104.03670.05533.03481.03159.03312.03669.03990.03401.03052.03289.03619.03417.03184.03440.03307.03116.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:IncomeLossFromContinuingOperations 1213.0NANANA2341.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity 1.0NANANA4.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest ▃▄▁▄▄▄▃▃▄▄▃▃▃▃▃▂▃▃▁▃▃▃▂▃▂▃█▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▂▂▃1717.03462.0-1993.03428.03519.03838.02791.02347.03259.03067.02604.02665.02086.01345.01879.0200.02439.02003.0-1356.02887.01504.01624.0816.02397.0807.01381.011811.01490.01891.02091.01225.01525.01245.01550.01334.02218.02680.02507.01581.02352.01672.01729.0-701.0498.01241.0NA
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest 1214.0NANANA2345.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:IncomeTaxExpenseBenefit ▃▂▂▃▃▃▃▃▃▂▃▃▃▃▆▂▃▃▁▃▂▃▂▃▂▃█▃▂▃▃▃▂▂▃▃▃▃▂▃▂▃▂▂▃▂503.0276.098.0483.0509.0619.0428.0440.0615.0205.0826.0707.0370.0604.02917.0251.0488.0447.0-769.0699.0295.0494.0-166.0566.0119.0423.04484.0648.0-142.0360.0410.0375.0310.0-66.0385.0455.0860.0740.038.0628.0-382.0658.0-201.0126.0461.0286.0
 us-gaap:IncomeTaxesPaid us-gaap:IncomeTaxAuthority,us-gaap:IncomeTaxAuthorityName us-gaap:DomesticCountry,us-gaap:InternalRevenueServiceIRS▁█0.0190.0NANANANA0.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:InterestExpense ▅▅▅▅▆▆▇██▆▅▄▄▃▄▄▄▃▃▂▂▂▂▁▂▁▁▄▃▃▅▆▅▃▄▂▂▄▄▄▃▃▂▂▃▃202.0200.0207.0203.0209.0212.0219.0231.0233.0209.0203.0190.0194.0185.0190.0189.0193.0182.0180.0170.0171.0172.0169.0165.0174.0164.0165.0191.0188.0188.0201.0215.0201.0184.0190.0178.0172.0195.0192.0189.0182.0186.0176.0173.0185.0181.0
us-gaap:NetIncomeLoss ▄▅▁▅▅▅▄▄▅▅▄▄▄▃▂▃▄▄▂▄▃▃▃▄▃▃█▃▄▄▃▃▃▄▃▄▄▄▄▄▄▃▂▃▃▃1545.03179.0-2094.02941.03002.03219.02356.01901.02670.02915.01827.01950.01707.0736.0-1046.0-56.01946.01551.0-595.02184.01205.01125.0977.01826.0687.0953.07316.0895.02004.01705.0781.01124.0906.01593.0907.01729.01793.01738.01512.01692.02024.01043.0-532.0342.0752.0299.0
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest ▅▅▅▅▅▅▅▅▃▁▁▅▆▅▅▅▅▅▅▅▅▅▅▅▅▅▆▁▇▇▇▇▇▇█▇▇▇▇▇▇▇▇▇▇▇1.07.03.04.08.00.07.06.0-26.0-53.0-49.08.09.05.08.05.05.05.08.04.04.05.05.05.01.05.011.0-53.029.026.034.026.029.023.042.034.027.029.031.032.030.028.032.030.028.031.0
us-gaap:OtherComprehensiveIncomeLossNetOfTax ▆▄▃▄▄▃▂▄▄▄▃▄▄▄▄▄▄▄▂▃▄▄▄▃▃▄▂▃▃▄█▄▄▄▁▄▄▄▃▄▄1545.012.0-251.010.0-2.0-198.0-803.0-28.0-16.0199.0-394.0-29.0-62.0124.035.0149.0-14.0146.0-974.0-166.0108.0-46.0425.0-241.0-165.0156.0-1325.0-554.0-265.018.02501.062.0-131.053.0-1642.086.091.0-85.0-419.063.0394.0NANANANANA
us-gaap:OtherNonoperatingIncomeExpense ▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▂▁▂▂▂▁▂▁▂█▂▂▂▂▂▂▁▁▂▂▂▂▂▂▁▁▁▂▂103.0448.0256.0312.0390.0-71.0223.0-35.0-140.0-188.0-110.0172.048.0291.018.086.0-58.0-58.0-632.0-22.0-19.0-48.0-903.0170.0-739.0-55.010619.0142.0558.039.0-159.0-172.0-201.0-282.0-670.0-200.0-103.0-142.0-137.0-66.0-121.0-622.0-309.0-1108.0281.0-167.0
us-gaap:ProfitLoss NA3186.0-2091.02945.03010.03219.02363.01907.02644.02862.01778.01958.01716.0741.0-1038.0-51.01951.01556.0-587.02188.01209.01130.0982.01831.0688.0958.07327.0842.02033.01731.0815.01150.0935.01616.0949.01763.01820.01767.01543.01724.02054.01071.0-500.0372.0780.0330.0
us-gaap:ResearchAndDevelopmentExpense ▆▃█▄▂▂▃▄▂▂▂▂▂▄▂▆▁▁▆▁▂▁▁▁▁▁▂▁▁▁▂▁▂▂▂▂▂▂▂▂▂▂▆▂▂▂4321.02465.05837.03390.02123.02209.02548.03204.02189.01931.02214.02068.02274.03196.02281.04383.01749.01796.04649.01664.02151.01659.01798.01500.01670.01737.02283.01659.01664.01574.01835.01660.02101.01907.02224.01918.02165.01862.02419.01954.01936.02158.04439.02322.02179.02051.0
us-gaap:Revenues ▆▇██▄▇▇█▆▄▅▄▃▃▃▃▂▁▃▄▂▁▃▃▂▁▄▄▅▃▅▅▅▄▆▆▇▆▇▇▇▆▇▅▅▆11402.012080.012515.012551.010872.012057.011868.012397.011760.010816.010998.010794.010465.010037.010433.010325.09930.09434.010115.010536.09844.09312.010215.010073.09785.09425.010482.010557.010934.010264.011320.011032.011010.010671.011737.011488.012311.011731.012294.012022.012151.011580.012094.011125.011346.011422.0
us-gaap:SellingGeneralAndAdministrativeExpense ▁▃▅▂▁▂▄▃▃▂▃▂▂▂▂▂▂▂▃▂▂▁▃▂▃▃▄▄▄▃▄▄▅▄▆▅▆▅█▆▇▅█▅▅▆2281.02633.03085.02450.02378.02555.02889.02589.02712.02425.02643.02443.02508.02508.02579.02401.02438.02411.02593.02393.02458.02318.02615.02472.02624.02601.02925.02975.02973.02734.02982.02803.03140.02987.03390.03063.03249.03074.03704.03340.03525.03164.03656.03192.03175.03222.0
  2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
  2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
us-gaap:Assets ▃▃▃▃▃▂▂▁▁▁▁▂▂▂▂▃▄▅▄▅▅▅▆▆▆█▅▆▅█▇▇█▇▇▇▇▇▇▇▇▇▇90688.090847.091588.089800.090615.084913.084397.083331.083965.082354.082637.085130.085040.086041.087872.091676.092804.096561.095377.098335.096475.098755.0101779.0101232.0102582.0108345.098335.0101808.097860.0108460.0105645.0106419.0106876.0106200.0106132.0106301.0105525.0105509.0105128.0106534.0106195.0105865.0105781.0NANANA
 us-gaap:Liabilities us-gaap:CounterpartyName,us-gaap:ProductOrService,us-gaap:TypeOfArrangement mrk:AstraZeneca,mrk:Lynparza,mrk:SalesBasedMilestonesNANA400.0NA400.0NA300.0NA300.0NA600.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:Liabilities us-gaap:CounterpartyName,us-gaap:ProductOrService,us-gaap:TypeOfArrangement mrk:Eisai,mrk:Lenvima,mrk:SalesBasedMilestonesNANA400.0NA370.0NA682.0NANA282.0268.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:Liabilities us-gaap:CounterpartyName,us-gaap:SubsequentEventType,us-gaap:TypeOfArrangement mrk:BayerAG,us-gaap:SubsequentEvent,mrk:SalesBasedMilestonesNANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:LiabilitiesAndStockholdersEquity ▃▃▃▃▃▂▂▁▁▁▁▂▂▂▂▃▄▅▄▅▅▅▆▆▆█▅▆▅█▇▇█▇▇▇▇▇▇▇▇▇▇90688.090847.091588.089800.090615.084913.084397.083331.083965.082354.082637.085130.085040.086041.087872.091676.092804.096561.095377.098335.096475.098755.0101779.0101232.0102582.0108345.098335.0101808.097860.0108460.0105645.0106419.0106876.0106200.0106132.0106301.0105525.0105509.0105128.0106534.0106195.0105865.0105781.0NANANA
us-gaap:StockholdersEquity ▃▁▁▂▂▁▁▁▂▂▁▃▃▃▃▄▄▄▄▅▅▅▅▆▆▆▆▆▆▇▇▆▆▇▇████████33294.026945.025317.029186.027642.026205.025907.026838.027635.027539.026701.032422.032529.033668.034336.038248.039463.039837.040088.043744.043357.043806.044676.045587.046448.047765.048647.045224.048358.049975.049765.047419.047500.053029.053020.055747.055194.054860.054517.055140.055496.054384.054376.0NANANA
  2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
us-gaap:AssetsCurrent ▃▂▃▂▃▂▂▂▁▂▂▂▁▁▁▃▃▄▄▃▃▃▃▃▃▅▅▅▅█▆▇▆▆▅▆▆▅▅▅▄▄▃28665.026909.027764.026577.029343.026174.027483.026142.024298.025351.025875.026836.024064.024085.024766.027919.028167.031530.030614.029440.027926.028772.029764.028567.028319.032927.033173.034723.033587.041240.035685.037765.036995.035244.034857.036229.035639.034344.033181.034109.032368.031024.029064.0NANANA
us-gaap:CashAndCashEquivalentsAtCarryingValue ▃▂▃▃▅▃▄▃▂▃▃▃▁▁▂▃▃▅▂▃▂▄▃▃▂▃▃▅▄▇▇▆▇▆▆██▇▆▆▅▅▄▄▃▃8575.06981.08062.07356.011103.07425.09676.07869.06659.08076.07965.07826.05310.04483.06092.07901.07786.011708.06515.07907.06608.09700.08524.07548.06922.07980.07441.011370.09743.015828.015621.014090.015090.013024.013451.017360.016752.014656.013531.014253.012342.011695.010900.09874.08666.08236.0
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents ▅▃▅▄▇▄▆▄▃▄▄▄▂▁▃▄▄█▃8630.07023.08165.07401.011147.07460.09934.07871.06660.08077.07967.07828.05312.04486.06096.07901.07786.011708.06515.0NANANA8524.0NANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:AccountsReceivableNetCurrent ▅▇▅▇▅▆▂▇▆▅▃▄▄▄▂▅▄▃▃▄▃▂▁▁▁▂▂▁▃▃▃▅▅▆▅▆▆█▇▆▇7843.08235.07851.08422.07577.08182.06778.08442.07964.07608.07071.07374.07287.07245.06873.07671.07439.07066.07018.07364.06916.06850.06484.06414.06510.06670.06626.06515.07022.07188.07184.07578.07779.07965.07672.07952.08152.08726.08261.08136.08475.0NA7344.0NANANA
 us-gaap:ReceivablesNetCurrent us-gaap:CounterpartyName,us-gaap:BalanceSheetLocation,us-gaap:TypeOfArrangement mrk:AstraZeneca,us-gaap:OtherCurrentAssets,us-gaap:CollaborativeArrangement█▇▆▅▃▂▁258.0236.0215.0197.0168.0142.0128.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:ReceivablesNetCurrent us-gaap:CounterpartyName,us-gaap:BalanceSheetLocation,us-gaap:TypeOfArrangement mrk:BayerAG,us-gaap:OtherCurrentAssets,us-gaap:CollaborativeArrangement▆▇▆█▅▁▁65.068.065.070.062.050.049.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:ReceivablesNetCurrent us-gaap:CounterpartyName,us-gaap:BalanceSheetLocation,us-gaap:TypeOfArrangement mrk:Eisai,us-gaap:OtherCurrentAssets,us-gaap:CollaborativeArrangement█▂▃▄▄▁▂212.0153.0157.0170.0173.0140.0150.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:InventoryNet ▄▇▆▆▆▅▅▅▅▄▃▃▃▃▂▃▃▃▂▃▃▂▁▂▃▄▄▅▆▇▆███▇█▆▇▆▆▆▆▅5499.06402.06310.06128.06056.05846.05978.05855.05847.05712.05440.05416.05178.05382.05096.05263.05407.05146.04866.05244.05248.05102.04700.05123.05306.05539.05571.05819.06136.06376.06226.06741.06766.06773.06535.06731.06249.06339.06254.06239.06225.06057.05868.0NANANA
us-gaap:InventoryFinishedGoods ▅▆▆▇▇▄▅▄▄▄▄▃▃▃▁▁▂▁▁▂▂▂▁▃▂▄▃▅▇▄▄▄█▇▆▆▅▅▆▄▂▂▂1778.02015.01963.02038.02032.01753.01772.01698.01750.01698.01658.01585.01519.01530.01334.01364.01396.01355.01304.01421.01437.01417.01343.01528.01497.01698.01588.01811.02125.01642.01738.01757.02214.02055.01924.01952.01808.01779.01983.01640.01440.01384.01484.0NANANA
us-gaap:InventoryLIFOReserve ▆▆▇▇▇▇█▇▆▆▆▆▆▅▅▄▃▂▂▂▁▁▁▁▁▂▂▃▄▄▅▅▅▅▅▆▆▇▆▇▇██-4.028.082.099.0119.0138.0171.067.029.06.0-1.010.0-11.0-25.0-45.0-142.0-258.0-275.0-302.0-320.0-357.0-375.0-384.0-366.0-346.0-334.0-309.0-220.0-169.0-116.0-73.0-52.0-49.0-47.0-52.010.039.078.043.0112.0141.0170.0186.0NANANA
us-gaap:OtherAssetsCurrent NANA5541.0NANANA4277.0NANANA4500.0NANANA4299.0NANANA4389.0NANANA5153.0NANANA4689.0NANANANANANANANANANANANANANA3983.03651.0NANANA
us-gaap:Land NANA350.0NANANA343.0NANANA333.0NANANA365.0NANANA412.0NANANA490.0NANANA541.0NANANA550.0NANANA591.0NANANA623.0NANANA658.0NANANA
us-gaap:MachineryAndEquipmentGross NANA16649.0NANANA15394.0NANANA14441.0NANANA14649.0NANANA14053.0NANANA14261.0NANANA16050.0NANANA17106.0NANANA17188.0NANANA16919.0NANANA15894.0NANANA
  2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
us-gaap:PropertyPlantAndEquipmentGross NANA36968.0NANANA32739.0NANANA29615.0NANANA29041.0NANANA27775.0NANANA28430.0NANANA31140.0NANANA33094.0NANANA33415.0NANANA32473.0NANANA30563.0NANANA
us-gaap:ConstructionInProgressGross NANA7324.0NANANA5013.0NANANA3355.0NANANA2301.0NANANA1871.0NANANA1525.0NANANA1448.0NANANA1811.0NANANA2440.0NANANA2198.0NANANA2066.0NANANA
us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment ▇██▇▇▆▆▆▆▅▅▅▅▅▅▅▅▄▄▄▄▄▄▄▅▅▇███▇▇▆▆▆▆▆▅▄▄▃▂▁18236.018732.018982.018572.018182.017706.017686.017281.017049.016623.016324.016568.016567.016483.016602.016661.016375.016171.015749.016022.016005.016052.015923.016043.016306.016794.018004.018761.018866.018622.018121.017805.017594.017622.017385.017475.017049.016697.016176.015674.015195.014515.013481.0NANANA
us-gaap:PropertyPlantAndEquipmentNet ███▆▅▅▄▄▃▃▂▂▂▂▂▁▁▁▁▁▁▁▂▂▂▂▂▃▃▄▄▅▅▅▅▅▅▆▆▆▆▆▇18064.018295.017986.016919.015789.015269.015053.014287.013862.013506.013291.012755.012626.012561.012439.012189.012094.012042.012026.012029.011987.012360.012507.012482.012630.012910.013136.013438.013893.014296.014973.015323.015683.015802.016030.015884.015867.016124.016297.016383.016671.016833.017082.0NANANA
us-gaap:Goodwill ▇█████▇▇▇▆▆▆▆▆▆▆▆▆▆▆▆▆▆▆▆▆▂▂▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁18873.020212.020238.020248.020067.019767.019425.019480.019490.018170.018253.018258.018274.018304.018284.018340.018358.018358.018162.018260.017809.017784.017723.017761.017707.017740.012992.013171.011789.012120.012301.012121.012198.012207.012134.012168.012158.012156.012155.012228.012382.012207.012378.0NANANA
us-gaap:IntangibleAssetsNetExcludingGoodwill ▂▂▂▂▂▂▂▁▂▁▁▁▁▂▂▂▂▂▃▃▃▄▄▄▄▅▃▃▃▃▄▄▅▅▅▆▆▆▇▇▇██13622.014401.014604.016677.016566.016096.014196.012307.013381.010999.011431.012175.012898.013500.014183.015138.016119.016863.017305.020506.020315.021364.022602.023724.024750.026080.020386.020395.018830.020517.023801.025002.026333.028108.029083.030325.031620.033000.034302.035822.037065.037906.039456.0NANANA
 us-gaap:FiniteLivedIntangibleAssetsNet us-gaap:ProductOrService,us-gaap:BalanceSheetLocation mrk:Adempas,us-gaap:OtherIntangibleAssets▅▆▂▁▁▂▃▄▆▇█920.0946.0849.0838.0832.0844.0883.0893.0956.0977.01000.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:FiniteLivedIntangibleAssetsNet us-gaap:ProductOrService,us-gaap:BalanceSheetLocation mrk:Lenvima,us-gaap:OtherNoncurrentAssets▄▄1000.01000.0NA1100.01200.0921.0NA664.0687.0711.0479.0266.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:FiniteLivedIntangibleAssetsNet us-gaap:ProductOrService,us-gaap:BalanceSheetLocation mrk:Lynparza,us-gaap:OtherNoncurrentAssets▄▄1200.01200.0NA1300.01300.0928.0NA983.01000.0724.0743.0468.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:FiniteLivedIntangibleAssetsNet us-gaap:ProductOrService,us-gaap:BalanceSheetLocation mrk:Verquvo,us-gaap:OtherIntangibleAssets▁█75.076.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:OperatingLeaseRightOfUseAsset NANA1725.0NANANA1073.01085.01063.01096.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:OtherAssetsNoncurrent us-gaap:FairValueByFairValueHierarchyLevel,us-gaap:FairValueByMeasurementFrequency us-gaap:FairValueInputsLevel1,us-gaap:FairValueMeasurementsRecurring█▇▇▁▁▂▃▄▄▃▂▂▂▂▁▁▁▁▁▁▁1256.01139.01091.0181.0132.0281.0380.0546.0586.0483.0364.0236.0275.0232.0171.0171.0163.0158.0148.0161.0155.0NA155.0NANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:OtherAssetsNoncurrent us-gaap:FairValueByFairValueHierarchyLevel,us-gaap:FairValueByMeasurementFrequency,us-gaap:FinancialInstrument us-gaap:FairValueInputsLevel1,us-gaap:FairValueMeasurementsRecurring,us-gaap:CorporateDebtSecurities▄▄4.04.0NANANANA0.00.00.00.00.00.00.00.00.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:OtherAssetsNoncurrent us-gaap:FairValueByFairValueHierarchyLevel,us-gaap:FairValueByMeasurementFrequency,us-gaap:FinancialInstrument us-gaap:FairValueInputsLevel1,us-gaap:FairValueMeasurementsRecurring,us-gaap:EquitySecurities█▇▇▁▁▂▃▄▄▃▃▂▂▂▂1170.01054.01007.0107.058.0219.0320.0485.0528.0427.0309.0182.0211.0168.0171.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:OtherAssetsNoncurrent us-gaap:FairValueByFairValueHierarchyLevel,us-gaap:FairValueByMeasurementFrequency,us-gaap:FinancialInstrument us-gaap:FairValueInputsLevel1,us-gaap:FairValueMeasurementsRecurring,us-gaap:USGovernmentAgenciesDebtSecurities███▇▇▆▆▆▆▆▆▆▆▆▁82.081.084.074.074.062.060.061.058.056.055.054.064.064.00.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:OtherAssetsNoncurrent us-gaap:FairValueByMeasurementFrequency us-gaap:FairValueMeasurementsRecurring█▇▇▁▁▂▃▄▄▄▄▃▄▄▄▅▅▅▆▇▆1256.01139.01091.0181.0132.0281.0380.0546.0654.0636.0585.0489.0645.0642.0652.0734.0820.0830.0937.01045.01014.0NA174.0NANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:OtherAssetsNoncurrent us-gaap:FairValueByMeasurementFrequency,us-gaap:FinancialInstrument us-gaap:FairValueMeasurementsRecurring,us-gaap:CorporateDebtSecurities▄▄4.04.0NANANANA0.00.040.079.085.0101.098.0119.0128.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:OtherAssetsNoncurrent us-gaap:FairValueByMeasurementFrequency,us-gaap:FinancialInstrument us-gaap:FairValueMeasurementsRecurring,us-gaap:EquitySecurities█▇▇▁▁▂▃▄▄▃▃▂▂▂▂1170.01054.01007.0107.058.0219.0320.0485.0528.0427.0309.0182.0211.0168.0171.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:OtherAssetsNoncurrent us-gaap:FairValueByMeasurementFrequency,us-gaap:FinancialInstrument us-gaap:FairValueMeasurementsRecurring,us-gaap:USGovernmentAgenciesDebtSecurities▂▂▂▂▂▁▁▁▂▃▅▅██▇82.081.084.074.074.062.060.061.077.097.0161.0166.0224.0225.0207.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:EquitySecuritiesFvNi ▇▇█▆▆▃▃▃▃▂▁▁▁1579.01596.01787.01477.01307.0779.0838.0691.0756.0636.0456.0378.0375.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
  2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
us-gaap:AccountsPayableCurrent ▆▇█▆▅▆▆▅▅▄▅▄▄▅▄▃▄▃▄▃▃▂▃▂▃▂▃▂▃▃▂▃▂▂▁▁▁▃▃▂▂▃▃3897.04034.04594.03744.03448.03572.03738.03198.03142.03018.03318.03091.03024.03162.03102.02620.02934.02484.02807.02481.02514.02241.02533.02023.02335.02091.02625.02279.02326.02434.02274.02469.02253.02084.01753.01804.01674.02358.02462.02282.02143.02402.02308.0NANANA
us-gaap:AccruedIncomeTaxesCurrent ▃▅▅▃▄▄▃▃▂▃▆▃▂▃▃▂▆█▇▄▄▆▅▇▆█▅█▁▂▁▄▂▄▄▅▄▄▃▅▄▄▄971.01490.01575.0984.01266.01033.0736.0873.0634.0807.01971.0759.0661.0717.0708.0396.01979.02330.02239.01208.01213.01864.01560.02119.01878.02450.01606.02467.0192.0595.0251.01298.0409.01075.01200.01512.01091.01190.0781.01462.01174.01326.01243.0NANANA
us-gaap:DebtCurrent ▃▆▆▂▄▆▃▃▄▃▅▃▃▂▃▅▃▅▁▂▁▂▃▃▃▄▃█▄▇▄▄▅▄▄▂▄▃▂▃▃▂▂2488.07251.06431.02420.04718.06361.03610.03411.03816.03175.05308.03656.03379.02055.03057.05157.03181.05037.0568.01487.0644.02113.02585.02543.02483.04728.02704.09275.04477.08559.04521.03976.05582.04736.04315.02029.03922.02930.01990.02455.02523.02202.02400.0NANANA
us-gaap:DividendsPayableCurrent ███▇▆▇▇▅▅▅▅▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▃▁▁▁▁1662.01675.01674.01567.01564.01585.01587.01434.01439.01462.01458.01304.01309.01317.01320.01302.01301.01314.01316.01292.01292.01307.01309.01288.01295.01306.01308.01288.01303.01327.01321.01289.01286.01338.01343.01315.01308.01281.01281.01166.01176.01177.01176.0NANANA
us-gaap:LiabilitiesCurrent ▅▇█▄▅▆▅▄▄▃▅▃▃▂▃▄▃▄▂▁▁▂▃▃▂▄▃▇▃▅▃▃▃▃▃▁▂▂▂▂▁▁▁21906.026361.027327.020405.022178.023483.022220.020684.020085.018543.022206.018586.018128.016960.018614.019467.018758.019823.017204.015555.014918.017568.019203.017583.017508.020442.018766.025927.017928.022470.017868.018215.018402.018802.018348.015583.016912.016582.016245.016593.015763.015662.015641.0NANANA
us-gaap:LongTermDebtCurrent NANA2300.0NANANA1900.0NANANANANANANA3000.0NANANA300.0NANANA2300.0NANANA1000.0NANANA2100.0NANANA1800.0NANANANANANANANANANANA
us-gaap:OperatingLeaseLiabilityCurrent NANA300.0NANANA236.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:OtherLiabilitiesCurrent █▆█▆▅▅▇▆▅▃▃▃▃▃▄▃▂▁▄▂▂▃▅▃▂▃▄▃▁▁▂▂▁▂▃▁▁▁▃▂▁12888.011911.013053.011690.011182.010932.012549.011768.011054.010081.010151.09776.09755.09709.010427.09992.09363.08658.010274.09087.09255.010043.011216.09610.09517.09867.010523.09808.08829.08707.09501.09183.08872.09569.09737.08923.08917.08823.09731.09228.08747.0NA8514.0NANANA
  2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
 us-gaap:LiabilitiesNoncurrent us-gaap:CounterpartyName,us-gaap:BalanceSheetLocation,us-gaap:TypeOfArrangement mrk:AstraZeneca,us-gaap:AccountsPayableAndAccruedLiabilities,us-gaap:CollaborativeArrangementNANANA400.0400.0NA0.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LiabilitiesNoncurrent us-gaap:CounterpartyName,us-gaap:BalanceSheetLocation,us-gaap:TypeOfArrangement mrk:BayerAG,us-gaap:OtherNoncurrentLiabilities,us-gaap:CollaborativeArrangement▄▄400.0400.0NA375.0375.0375.0375.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:LiabilitiesNoncurrent us-gaap:CounterpartyName,us-gaap:BalanceSheetLocation,us-gaap:TypeOfArrangement mrk:Eisai,us-gaap:OtherNoncurrentLiabilities,us-gaap:CollaborativeArrangementNA300.0600.0570.0570.0300.0525.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:LongTermDebtNoncurrent ▇▇▇██▅▆▆▆▆▄▄▄▅▅▅▅▆▇▆▆▆▇▇▇▇▃▃▃▄▄▆▆▂▂▃▁▁▁▁▁▁▁24033.024002.025360.026321.026156.021637.022736.022677.022771.022721.019806.019936.019959.021501.021353.021838.021706.023437.024274.023656.023642.023656.023929.024124.024069.025506.018699.018566.018590.019589.020539.022647.022526.016089.016254.017571.015057.015228.015525.015692.015783.015644.015482.0NANANA
us-gaap:DeferredIncomeTaxLiabilitiesNet ▄▂▁▅▇▆▄▆▇▆▅▇███1489.01204.01015.01777.02091.01943.01470.01960.02089.01835.01702.02065.02159.02206.02219.0NANANA5077.0NANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent us-gaap:RetirementPlanSponsorLocation,us-gaap:RetirementPlanType country:US,us-gaap:PensionPlansDefinedBenefitNANA1859.0NANANA1550.0NANANA925.0NANANA949.0NANANA1033.0NANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent us-gaap:RetirementPlanSponsorLocation,us-gaap:RetirementPlanType us-gaap:ForeignPlan,us-gaap:PensionPlansDefinedBenefitNANA1413.0NANANA1268.0NANANA1148.0NANANA955.0NANANA1022.0NANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent us-gaap:RetirementPlanType us-gaap:OtherPostretirementBenefitPlansDefinedBenefitNANA377.0NANANA561.0NANANA637.0NANANA797.0NANANA892.0NANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:MinorityInterest ▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁██████████████94.094.087.084.0102.095.094.087.0102.0131.0181.0234.0237.0233.0233.0251.0249.0251.0220.0213.089.095.091.092.0190.0152.0144.0136.0158.02589.02561.02587.02605.02577.02443.02465.02479.02454.02426.02456.02426.02455.02429.0NANANA
us-gaap:OtherLiabilitiesNoncurrent ▅██▇█▇▇▆▆▇▇▇▇▇▆▂▂▃▃▃▃▂▁▂▂▂▂▁▃▂▂9872.012241.012482.012027.012446.011550.011970.011085.011283.011585.012041.011887.012028.011473.011117.07713.08068.08324.08514.08793.08378.07374.07345.07887.07913.07677.07813.06968.08175.07956.08136.0NANANA10327.0NANANANANANANANANANANA
us-gaap:OperatingLeaseLiabilityNoncurrent NANA1362.0NANANA768.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo NANA277.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree NANA252.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour NANA187.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive NANA162.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive NANA665.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
  2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
us-gaap:StockholdersEquity ▃▁▁▂▂▁▁▁▂▂▁▃▃▃▃▄▄▄▄▅▅▅▅▆▆▆▆▆▆▇▇▆▆▇▇████████33294.026945.025317.029186.027642.026205.025907.026838.027635.027539.026701.032422.032529.033668.034336.038248.039463.039837.040088.043744.043357.043806.044676.045587.046448.047765.048647.045224.048358.049975.049765.047419.047500.053029.053020.055747.055194.054860.054517.055140.055496.054384.054376.0NANANA
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest ▃▁▁▂▁▁▁▁▁▁▁▂▂▃▃▄▄▄▄▅▅▅▅▅▅▆▆▅▆▆▆▆▆▇▇█▇▇▇▇█▇▇█▇█33388.027039.025404.029270.027744.026300.026001.026925.027737.027670.026882.032656.032766.033901.034569.038499.039712.040088.040308.043957.043446.043901.044767.045679.046638.047917.048791.045360.048516.052564.052326.050006.050105.055606.055463.058212.057673.057314.056943.057596.057922.056839.056805.058048.057657.060335.0
us-gaap:CommonStockValue ▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄▄1788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.01788.0NANANA
us-gaap:AdditionalPaidInCapitalCommonStock █▂▂▂▂▂▂▂▂▁▁▂▂▂▃▂▂▃▃▂▃▃▃▃▃▃▃▃▃▃▃▃▂▄▃▃▃▄▄▄▄▄▄44039.039613.039588.039489.039373.039697.039660.039561.039484.038768.038808.039762.039741.039874.039902.039823.039776.039899.039939.039897.039911.040145.040222.040139.040114.040355.040423.040340.040199.040450.040508.039909.039891.040727.040646.040471.040550.040652.040663.040717.040657.040690.040701.0NANANA
us-gaap:RetainedEarningsAccumulatedDeficit ▇▇▆█▇▇▆▅▅▄▄▃▃▃▃▄▅▅▄▅▅▅▅▅▅▅▅▂▃▂▂▂▂▂▂▃▂▂▂▂▁▁▁48777.048888.047362.051107.049724.048272.046602.045804.045295.044065.042579.042189.041523.041107.041350.043701.045046.044387.044133.046028.045121.045192.045348.045660.045103.045692.046021.039989.040366.039661.039257.039773.039915.040272.039985.040390.039950.039441.038990.038763.038243.037400.037536.0NANANA
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax ▄▁▁▁▁▁▂▃▃▃▃▃▃▃▄▄▃▃▃▅▅▅▅▄▅▅▅▇███▄▄▄▄▇▇▆▇▇▇▆▆▆▄▆-4628.0-6622.0-6634.0-6383.0-6393.0-6391.0-6193.0-5390.0-5362.0-5346.0-5545.0-5151.0-5122.0-5060.0-4910.0-4945.0-5094.0-5080.0-5226.0-4252.0-4086.0-4194.0-4148.0-4573.0-4332.0-4167.0-4323.0-2998.0-2444.0-2179.0-2197.0-4698.0-4760.0-4629.0-4682.0-3040.0-3126.0-3217.0-3132.0-2713.0-2776.0-3170.0-3216.0-3490.0-4659.0-3572.0
us-gaap:TreasuryStockValue ████████▇▇▇▆▆▅▅▅▅▅▅▄▄▄▄▄▄▄▄▃▃▂▂▂▂▂▁▁▁▁▁▁▁▁▁56682.056722.056787.056815.056850.057161.055950.054925.053570.051736.050929.046166.045401.044041.043794.042119.042053.041157.040546.039717.039377.039125.038534.037427.036225.035903.035262.033895.031551.029745.029591.029353.029334.025129.024717.023862.023968.023804.023792.023415.022416.022324.022433.0NANANA
us-gaap:MinorityInterest ▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁██████████████94.094.087.084.0102.095.094.087.0102.0131.0181.0234.0237.0233.0233.0251.0249.0251.0220.0213.089.095.091.092.0190.0152.0144.0136.0158.02589.02561.02587.02605.02577.02443.02465.02479.02454.02426.02456.02426.02455.02429.0NANANA
us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders NANA0.022.01.01.00.021.0NANA4.011.05.05.08.03.0NANA1.04.010.01.06.06.01.02.03.015.058.01.059.058.02.01.0170.0-53.02.01.058.01.059.02.058.01.059.01.0
 us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders us-gaap:StatementEquityComponents us-gaap:NoncontrollingInterestNANA0.022.01.01.00.021.0NANA4.011.05.05.08.03.0NANA1.04.010.01.06.06.01.02.03.015.058.01.059.058.02.01.0170.0-53.02.01.058.01.059.02.058.01.059.01.0
  2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
us-gaap:NetCashProvidedByUsedInOperatingActivities NA1791.04006.02173.03367.0707.04794.04226.03084.01336.03592.02793.03382.01155.04015.0-1171.03317.0286.03632.02971.01615.02158.04247.03305.02585.02284.0-1164.04348.02315.02361.03026.03949.02338.02341.01809.03139.02920.02154.03233.04577.02852.01721.03539.02592.03325.01366.0
us-gaap:NetCashProvidedByUsedInInvestingActivities NA-738.0-4778.0-2155.0-882.0-1628.0-763.0191.0-2425.0368.02178.01660.0673.0-197.0-58.0671.0-1127.03193.0-2563.0-890.0-1498.01741.0-617.0-61.02525.0-6605.07204.0-3722.0-49.0-3807.01177.0-2037.0-1135.0-1153.0-4398.0-1839.0-298.0-270.0-1684.0-263.0-1048.0105.0-1007.0194.0464.0-3148.0
us-gaap:NetCashProvidedByUsedInFinancingActivities NA-2098.01372.0-3851.01137.0-1490.0-2011.0-3152.0-2084.0-1614.0-5566.0-1905.0-2967.0-2722.0-5785.0536.0-6218.01461.0-1977.0-835.0-3381.0-2851.0-2407.0-2533.0-5485.05155.0-9643.01279.0-8369.01620.0-2624.0-2915.0970.0-1421.0-1218.0-738.0-586.0-725.0-2231.0-2244.0-1257.0-1172.0-1295.0-1625.0-3463.0942.0
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect ▅▃▅▁▇▂▆▅▃▄▄▆▅▃▃▄▁█1619.0-1142.0764.0-3746.03687.0-2474.02063.01211.0-1417.0110.0139.02516.0826.0-1610.0-1805.0115.0-3922.05193.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANA
  2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
us-gaap:DeferredIncomeTaxExpenseBenefit ▆▆▄▆▆▆▅▅▅▆▅▅▅▆▁▅▅▆▂▆▆▆▆▅▅▅▄▅▄▅▆▅▅▆█▆▅▆▄▅▄▅▅▅▅▆39.0-10.0-715.0-75.040.082.0-170.0-237.0-343.0194.0-118.0-133.0-228.0-30.0-2020.0-329.0-218.0-54.0-1456.055.0-50.0-70.082.0-463.0-204.0-179.0-827.0-527.0-942.0-304.0202.0-213.0-248.0-71.0952.082.0-324.0-41.0-563.0-133.0-627.0-214.0-349.0-424.0-471.0152.0
us-gaap:DepreciationDepletionAndAmortization NANANA852.01048.0821.0936.0845.0973.0898.01095.01061.01226.01137.01128.01154.01162.01193.01155.01175.01550.01561.01560.01570.01608.01637.01573.01611.01753.01754.01954.01705.01655.01674.01661.01723.01804.01790.01861.01903.01832.01831.01866.01880.01948.01687.0
 us-gaap:DepreciationDepletionAndAmortization us-gaap:ConsolidationItems us-gaap:MaterialReconcilingItems▁▂▄▃▃▂▃▂▄▂▁▁▁▂▁▁▁▂▂▂▄▄▃▃▃▃▇█332.0358.0429.0395.0390.0381.0404.0382.0427.0359.0328.0324.0332.0350.0342.0334.0332.0370.0357.0365.0438.0430.0398.0383.0393.0396.0557.0595.0NANANANANANANANANANANANANANANANANANA
us-gaap:NetCashProvidedByUsedInOperatingActivities NA1791.04006.02173.03367.0707.04794.04226.03084.01336.03592.02793.03382.01155.04015.0-1171.03317.0286.03632.02971.01615.02158.04247.03305.02585.02284.0-1164.04348.02315.02361.03026.03949.02338.02341.01809.03139.02920.02154.03233.04577.02852.01721.03539.02592.03325.01366.0
us-gaap:NetIncomeLoss ▄▅▁▅▅▅▄▄▅▅▄▄▄▃▂▃▄▄▂▄▃▃▃▄▃▃█▃▄▄▃▃▃▄▃▄▄▄▄▄▄▃▂▃▃▃1545.03179.0-2094.02941.03002.03219.02356.01901.02670.02915.01827.01950.01707.0736.0-1046.0-56.01946.01551.0-595.02184.01205.01125.0977.01826.0687.0953.07316.0895.02004.01705.0781.01124.0906.01593.0907.01729.01793.01738.01512.01692.02024.01043.0-532.0342.0752.0299.0
us-gaap:ProfitLoss NA3186.0-2091.02945.03010.03219.02363.01907.02644.02862.01778.01958.01716.0741.0-1038.0-51.01951.01556.0-587.02188.01209.01130.0982.01831.0688.0958.07327.0842.02033.01731.0815.01150.0935.01616.0949.01763.01820.01767.01543.01724.02054.01071.0-500.0372.0780.0330.0
us-gaap:ShareBasedCompensation ▆▆▆▇▆▅▅▅▅▄▄▄▄▃▃▃▃▂▃▃▃▂▃▃▃▂▂▃▃▁▂▂▃▂▃▄▄▃▃▃▅▄▅▇█▇123.0120.0121.0126.0121.0108.0111.0101.0111.093.087.091.090.080.080.076.082.074.075.077.080.068.078.075.083.063.069.075.078.056.066.068.075.067.078.088.093.076.082.086.0107.093.0109.0126.0142.0132.0
  2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
us-gaap:NetCashProvidedByUsedInInvestingActivities NA-738.0-4778.0-2155.0-882.0-1628.0-763.0191.0-2425.0368.02178.01660.0673.0-197.0-58.0671.0-1127.03193.0-2563.0-890.0-1498.01741.0-617.0-61.02525.0-6605.07204.0-3722.0-49.0-3807.01177.0-2037.0-1135.0-1153.0-4398.0-1839.0-298.0-270.0-1684.0-263.0-1048.0105.0-1007.0194.0464.0-3148.0
us-gaap:PaymentsToAcquireProductiveAssets ▅▆██▃▅▆▅▄▃▅▃▃▂▄▂▂▂▃▂▂▁▃▂▁▁▃▂▂▁▂▂▂▂▄▂▂▂▃▂▂▂▃▂▂▂934.01134.01514.01516.0668.0986.01137.0959.0782.0595.0929.0653.0583.0450.0715.0441.0393.0339.0551.0409.0375.0279.0493.0316.0271.0203.0490.0320.0302.0205.0429.0355.0413.0351.0778.0414.0431.0331.0603.0431.0365.0324.0660.0338.0337.0343.0
 us-gaap:PaymentsToAcquireInvestments us-gaap:AssetAcquisition mrk:OncoImmuneNANA50.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:PaymentsToAcquireInvestments us-gaap:BusinessAcquisition mrk:OncoImmuneNANA50.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
 us-gaap:PaymentsToAcquireInvestments us-gaap:CounterpartyName mrk:SeagenNANANA1000.0NANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANANA
  2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
us-gaap:NetCashProvidedByUsedInFinancingActivities NA-2098.01372.0-3851.01137.0-1490.0-2011.0-3152.0-2084.0-1614.0-5566.0-1905.0-2967.0-2722.0-5785.0536.0-6218.01461.0-1977.0-835.0-3381.0-2851.0-2407.0-2533.0-5485.05155.0-9643.01279.0-8369.01620.0-2624.0-2915.0970.0-1421.0-1218.0-738.0-586.0-725.0-2231.0-2244.0-1257.0-1172.0-1295.0-1625.0-3463.0942.0
us-gaap:ProceedsFromIssuanceOfLongTermDebt NANA0.0-26.04445.00.00.00.00.04958.00.00.00.00.0NANANANA1071.00.08.00.00.0-2.0-1.07941.03145.00.01.00.00.00.0NANA58.02504.0NANANANANANANANANANA
us-gaap:RepaymentsOfLongTermDebt ▁▂▁▁▁▃▁▁▁▁▂▁▃▂▂▁▁▁▁▁▃▂▁▁▁▄█▁▁▁▂▁▁▂▁▁▁▁▁▁▂▁▂▁▁▂0.01153.03.02.01.01951.00.00.00.00.01280.0-1.02005.01003.0802.00.01.0300.00.035.01500.0851.01.00.03.02902.06610.02.02.03.01260.00.09.0506.018.02.00.02.0270.012.01261.04.0652.063.04.0622.0
us-gaap:PaymentsOfDividendsCommonStock ██▆▆▇▆▄▄▅▅▃▃▃▃▃▃▃▃▂▃▃▃▂▂▃▃▂▃▃▃▂▂▃▃▃▃▃▃▁▁▁▁▁▁▁▁1673.01645.01542.01545.01577.01551.01405.01394.01468.01428.01277.01285.01311.01299.01283.01283.01307.01294.01271.01274.01300.01279.01263.01272.01302.01280.01259.01282.01339.01290.01260.01259.01332.01306.01280.01277.01280.01279.01165.01175.01176.01175.01175.01181.01189.01189.0
us-gaap:PaymentsForRepurchaseOfCommonStock NANA0.00.00.01281.01050.01405.01235.01090.05933.0996.01596.0566.01702.0159.01134.01019.01016.0845.0660.0913.01181.01281.0709.01015.01620.02670.02246.01167.0196.0215.05525.0580.01152.0454.0529.0456.0562.01045.0NANA0.0296.0NANA
  2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31

Common Stock Value

us-gaap:CommonStockValue

us-gaap:CommonStockValue


Common
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-31
Value17881788178817881788178817881788178817881788178817881788178817881788178817881788178817881788178817881788178817881788178817881788178817881788178817881788178817881788178817881781
Percentage of CommonStockValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets2.02.02.02.02.02.12.12.12.12.22.22.12.12.12.02.01.91.91.91.81.91.81.81.81.71.71.81.81.81.61.71.71.71.71.71.71.71.71.71.71.71.71.71.6

Common Stock Shares Issued

us-gaap:CommonStockSharesIssued us-gaap:StatementEquityComponents

us-gaap:CommonStockSharesIssued

us-gaap:CommonStock


Common
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302009-12-312008-12-31
Value35773577357735773577357735773577357735773577357735773577357735773577357735773577357735773577357735773577357735773577357735773577357735773577357735773576357735763577357635773576357335632984
Percentage of CommonStockSharesIssued100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:TreasuryStock


Common
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302009-12-312008-12-31
Value104410461047104710481053103810261010994985918907885880851850837828815811808796775753749739716677648650650651560550533538535536525494492495497492454876
Percentage of CommonStockSharesIssued29.229.229.329.329.329.429.028.728.227.827.525.725.424.724.623.823.823.423.122.822.722.622.321.721.120.920.720.018.918.118.218.218.215.715.414.915.015.015.014.713.813.813.813.913.812.729.4

Weighted Average Number Of Diluted Shares Outstanding

us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding


Weighted
Period End2021-06-302021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-312017-09-302017-06-302017-03-312016-09-302016-06-302016-03-312015-09-302015-06-302015-03-312014-09-302014-06-302014-03-312013-09-302013-06-302013-03-312012-09-302012-06-302012-03-312011-09-302011-06-302011-03-312010-09-302010-06-302010-03-31
Value25402541253825362547257225882603267826962710272727522766278627892795283628502865291129492971296030103053307930723074309131103104310231253141
Percentage of WeightedAverageNumberOfDilutedSharesOutstanding100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Weighted Average Number Of Shares Outstanding Basic

us-gaap:WeightedAverageNumberOfSharesOutstandingBasic

us-gaap:WeightedAverageNumberOfSharesOutstandingBasic


Weighted
Period End2021-06-302021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-312017-09-302017-06-302017-03-312016-09-302016-06-302016-03-312015-09-302015-06-302015-03-312014-09-302014-06-302014-03-312013-09-302013-06-302013-03-312012-09-302012-06-302012-03-312011-09-302011-06-302011-03-312010-09-302010-06-302010-03-31
Value25332531252925272533255825742585266226832695272727342745276527682774281428262835287929172934292729773022304530413043307030863084307831053114
Percentage of WeightedAverageNumberOfSharesOutstandingBasic100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount


Antidilutive
Period End2021-06-302021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-312017-06-302017-03-312016-09-302016-06-302016-03-312015-09-302015-06-302015-03-312014-09-302014-06-302014-03-312013-09-302013-06-302013-03-312012-09-302012-06-302012-03-312011-09-302011-06-302011-03-312010-09-302010-06-302010-03-31
Value12145.08.02.03.03.02.02.013145.02.04.01310.010.06.03.05.04.01.023238697107117170138185173195182
Percentage of AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Earnings Per Share Basic

us-gaap:EarningsPerShareBasic

us-gaap:EarningsPerShareBasic


Earnings
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value0.611.26-0.831.161.191.270.930.741.041.130.70.730.640.27-0.38-0.020.710.56-0.210.790.440.410.350.650.240.342.540.310.690.580.270.380.30.530.30.570.590.570.50.550.650.34-0.170.110.240.1
Percentage of EarningsPerShareBasic100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Earnings Per Share Diluted

us-gaap:EarningsPerShareDiluted

us-gaap:EarningsPerShareDiluted


Earnings
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value0.611.25-0.831.161.181.260.920.741.031.120.690.730.630.27-0.38-0.020.710.56-0.210.780.430.40.340.640.240.332.50.310.680.570.270.380.30.520.290.560.580.560.490.550.650.34-0.160.110.240.09
Percentage of EarningsPerShareDiluted100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Income Loss From Continuing Operations Per Basic Share

us-gaap:IncomeLossFromContinuingOperationsPerBasicShare

us-gaap:IncomeLossFromContinuingOperationsPerBasicShare


Income
Period End2021-06-302020-06-30
Value0.480.93
Percentage of IncomeLossFromContinuingOperationsPerBasicShare100.0100.0

Income Loss From Continuing Operations Per Diluted Share

us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare

us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare


Income
Period End2021-06-302020-06-30
Value0.480.92
Percentage of IncomeLossFromContinuingOperationsPerDilutedShare100.0100.0

Comprehensive Income Net Of Tax

us-gaap:ComprehensiveIncomeNetOfTax

us-gaap:ComprehensiveIncomeNetOfTax


Comprehensive
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302011-12-312011-09-302011-06-302011-03-312010-09-302010-06-302010-03-31
Value30903191-2345.02951300030211553187326543114143319211645860-1011.09319321697-1569.0201813131079140215855221109599134110561800240011001500-335.0-506.0
Percentage of ComprehensiveIncomeNetOfTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues27.126.4-18.723.527.625.113.115.122.628.813.017.815.78.6-9.70.919.518.0-15.519.213.311.613.715.75.311.857.23.28.615.019.89.513.5-3.0-4.4

Cost Of Goods And Services Sold

us-gaap:CostOfGoodsAndServicesSold

us-gaap:CostOfGoodsAndServicesSold


Cost
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value31043670553334813159331236693990340130523289361934173184344033073116
Percentage of CostOfGoodsAndServicesSold100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues27.230.444.227.729.127.530.932.228.928.229.933.532.731.733.032.031.4

us-gaap:CostOfGoodsAndServicesSold us-gaap:CounterpartyName, us-gaap:IncomeStatementLocation, us-gaap:TypeOfArrangement

mrk:AstraZeneca, us-gaap:CostOfSales, us-gaap:CollaborativeArrangement


Cost
Period End2021-06-302021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-31
Value42424113728287319
Percentage of CostOfGoodsAndServicesSold1.41.11.24.30.80.72.10.6
Percentage of Revenues0.40.30.31.30.20.20.60.2
Percentage of Revenues mrk:AstraZeneca us-gaap:CostOfSales us-gaap:CollaborativeArrangement0.00.00.00.00.00.00.00.0

mrk:BayerAG, us-gaap:CostOfSales, us-gaap:CollaborativeArrangement


Cost
Period End2021-06-302021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-31
Value39189292828282929
Percentage of CostOfGoodsAndServicesSold1.35.10.80.90.80.70.91.0
Percentage of Revenues0.31.60.20.30.20.20.20.3
Percentage of Revenues mrk:BayerAG us-gaap:CostOfSales us-gaap:CollaborativeArrangement0.00.00.00.00.00.00.00.0

mrk:Eisai, us-gaap:CostOfSales, us-gaap:CollaborativeArrangement


Cost
Period End2021-06-302021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-31
Value47474613535232351
Percentage of CostOfGoodsAndServicesSold1.51.31.34.31.10.60.71.7
Percentage of Revenues0.40.40.41.20.30.20.20.5
Percentage of Revenues mrk:Eisai us-gaap:CostOfSales us-gaap:CollaborativeArrangement0.00.00.00.00.00.00.00.0

Income Loss From Continuing Operations

us-gaap:IncomeLossFromContinuingOperations

us-gaap:IncomeLossFromContinuingOperations


Income
Period End2021-06-302020-06-30
Value12132341
Percentage of IncomeLossFromContinuingOperations100.0100.0
Percentage of Revenues10.621.5

Income Loss From Continuing Operations Attributable To Noncontrolling Entity

us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity

us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity


Income
Period End2021-06-302020-06-30
Value1000000.04000000.0
Percentage of IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity100.0100.0
Percentage of Revenues0.00.0

Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest


Income
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-30
Value17173462-1993.034283519383827912347325930672604266520861345187920024392003-1356.02887150416248162397807138111811149018912091122515251245155013342218268025071581235216721729-701.04981241
Percentage of IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues15.128.7-15.927.332.431.823.518.927.728.423.724.719.913.418.01.924.621.2-13.427.415.317.48.023.88.214.7112.714.117.320.410.813.811.314.511.419.321.821.412.919.613.814.9-5.84.510.9

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest us-gaap:ConsolidationItems

us-gaap:CorporateNonSegment


Income
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value-79.0-34.0-48.0-12.06113913710194304155-2.0-87.0-81.0-78.043142140219322727219522615225779
Percentage of IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-4.6-1.02.4-0.41.73.64.94.32.91.01.62.1-0.1-6.5-4.3-39.01.87.1-10.30.76.214.033.38.128.011.02.25.3
Percentage of Revenues-0.7-0.3-0.4-0.10.61.21.20.80.80.30.40.5-0.0-0.9-0.8-0.80.41.51.40.20.92.42.71.92.31.62.50.7
Percentage of Revenues us-gaap:CorporateNonSegment158.0261.50.0-109.166.384.20.075.473.433.70.091.7-5.4280.60.0-113.037.465.70.018.156.474.90.064.672.966.10.077.5

us-gaap:OperatingSegments


Income
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value7809812780268424696779567248816875186991657868936302628062566411612156325860655158445503591960705689560360976311
Percentage of IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest454.8234.7-402.7245.7198.0207.3259.7348.0230.7227.9252.6258.6302.1466.9332.93205.5251.0281.2-432.2226.9388.6338.9725.4253.2705.0405.751.6423.6
Percentage of Revenues68.567.364.167.164.166.061.165.963.964.659.863.960.262.660.062.161.659.757.962.259.459.157.960.358.159.458.259.8
Percentage of Revenues us-gaap:OperatingSegments68.267.20.067.264.666.90.066.664.665.20.064.260.462.40.062.562.461.10.062.960.461.10.062.160.060.90.060.4

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments

us-gaap:OperatingSegments, mrk:AnimalHealthsegment


Income
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value552572314451407478366423405415386409450413350389395417
Percentage of IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest32.116.5-15.813.211.612.513.118.012.413.514.815.321.630.718.6194.516.220.8
Percentage of Revenues4.84.72.53.63.74.03.13.43.43.83.53.84.34.13.43.84.04.4
Percentage of Revenues us-gaap:OperatingSegments mrk:AnimalHealthsegment37.540.30.037.037.039.40.037.736.040.50.040.141.338.80.038.941.444.4

us-gaap:OperatingSegments, mrk:Pharmaceuticalsegment


Income
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value7257755577127974656074776887774771156574618364795826580458645929561351805482616254205117557056415282516556895772
Percentage of IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest422.7218.2-387.0232.6186.4194.8246.8330.1218.3214.3237.4243.1279.3431.5312.12964.5230.1258.6-404.3213.4360.4315.1682.6235.3654.5374.048.2387.4
Percentage of Revenues63.662.561.663.560.362.058.062.560.560.856.260.055.757.856.257.456.554.954.258.555.155.054.556.054.054.854.354.7
Percentage of Revenues us-gaap:OperatingSegments mrk:Pharmaceuticalsegment72.770.80.070.467.870.20.069.868.068.00.067.162.865.10.064.864.163.30.065.362.363.10.063.261.762.50.063.2

us-gaap:OperatingSegments, us-gaap:AllOtherSegments


Income
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value0.0-1.00.01.0-5.0-2.0-2.02.09.05.02663392482508452378389424386349429407438408539
Percentage of IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-0.0-0.00.00.0-0.2-0.1-0.10.10.30.21.24.720.9241.020.822.6-27.913.528.223.842.817.950.431.73.536.2
Percentage of Revenues0.0-0.00.00.0-0.0-0.0-0.00.00.10.00.20.63.84.75.14.83.73.74.34.13.44.34.24.63.95.1
Percentage of Revenues us-gaap:OperatingSegments us-gaap:AllOtherSegments0.00.00.04.30.0-4.3-4.25.10.09.146.475.00.0482.0503.043.80.039.843.342.70.050.744.747.10.040.8

Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest

us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest

us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest


Income
Period End2021-06-302020-06-30
Value12142345
Percentage of IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest100.0100.0
Percentage of Revenues10.621.6

Income Tax Expense Benefit

us-gaap:IncomeTaxExpenseBenefit

us-gaap:IncomeTaxExpenseBenefit


Income
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value503276984835096194284406152058267073706042917251488447-769.0699295494-166.05661194234484648-142.0360410375310-66.038545586074038628-382.0658-201.0126461286
Percentage of IncomeTaxExpenseBenefit100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues4.42.30.83.84.75.13.63.55.21.97.56.53.56.028.02.44.94.7-7.66.63.05.3-1.65.61.24.542.86.1-1.33.53.63.42.8-0.63.34.07.06.30.35.2-3.15.7-1.71.14.12.5

Income Taxes Paid

us-gaap:IncomeTaxesPaid us-gaap:IncomeTaxAuthority, us-gaap:IncomeTaxAuthorityName

us-gaap:IncomeTaxesPaid

us-gaap:DomesticCountry, us-gaap:InternalRevenueServiceIRS


Income
Period End2021-06-302021-03-312019-12-31
Value0.01900.0
Percentage of IncomeTaxesPaid0.0100.00.0
Percentage of Revenues0.01.60.0
Percentage of Revenues us-gaap:DomesticCountry us-gaap:InternalRevenueServiceIRS0.00.00.0

Interest Expense

us-gaap:InterestExpense

us-gaap:InterestExpense


Interest
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value202200207203209212219231233209203190194185190189193182180170171172169165174164165191188188201215201184190178172195192189182186176173185181
Percentage of InterestExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues1.81.71.71.61.91.81.81.92.01.91.81.81.91.81.81.81.91.91.81.61.71.81.71.61.81.71.61.81.71.81.81.91.81.71.61.51.41.71.61.61.51.61.51.61.61.6

us-gaap:InterestExpense us-gaap:ConsolidationItems

us-gaap:MaterialReconcilingItems


Interest
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value202200207203209212219231233209203190194185190189193182180170171172169165174164165191
Percentage of InterestExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues1.81.71.71.61.91.81.81.92.01.91.81.81.91.81.81.81.91.91.81.61.71.81.71.61.81.71.61.8
Percentage of Revenues us-gaap:MaterialReconcilingItems0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Net Income Loss

us-gaap:NetIncomeLoss

us-gaap:NetIncomeLoss


Net
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value15453179-2094.02941300232192356190126702915182719501707736-1046.0-56.019461551-595.02184120511259771826687953731689520041705781112490615939071729179317381512169220241043-532.0342752299
Percentage of NetIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues13.626.3-16.723.427.626.719.915.322.727.016.618.116.37.3-10.0-0.519.616.4-5.920.712.212.19.618.17.010.169.88.518.316.66.910.28.214.97.715.114.614.812.314.116.79.0-4.43.16.62.6

us-gaap:NetIncomeLoss us-gaap:StatementEquityComponents

us-gaap:RetainedEarnings


Net
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value15453179-2094.02941300232192356190126702915182719501707736-1046.0-56.019451551-595.02185120511259771826686953731689520041705781112490615939071730179317381512169320241043-532.0342752299
Percentage of NetIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.099.9100.0100.0100.0100.0100.0100.0100.099.9100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.1100.0100.0100.0100.1100.0100.0100.0100.0100.0100.0
Percentage of Revenues13.626.3-16.723.427.626.719.915.322.727.016.618.116.37.3-10.0-0.519.616.4-5.920.712.212.19.618.17.010.169.88.518.316.66.910.28.214.97.715.114.614.812.314.116.79.0-4.43.16.62.6
Percentage of Revenues us-gaap:RetainedEarnings0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Net Income Loss Attributable To Noncontrolling Interest

us-gaap:NetIncomeLossAttributableToNoncontrollingInterest

us-gaap:NetIncomeLossAttributableToNoncontrollingInterest


Net
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value1.07.03.04.08.00.07.06.0-26.0-53.0-49.08.09.05.08.05.05.05.08.04.04.05.05.05.01.05.011-53.0292634262923423427293132302832302831
Percentage of NetIncomeLossAttributableToNoncontrollingInterest100.0100.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues0.00.10.00.00.10.00.10.0-0.2-0.5-0.40.10.10.00.10.00.10.10.10.00.00.10.00.00.00.10.1-0.50.30.30.30.20.30.20.40.30.20.20.30.30.20.20.30.30.20.3

us-gaap:NetIncomeLossAttributableToNoncontrollingInterest us-gaap:StatementEquityComponents

us-gaap:NoncontrollingInterest


Net
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value1.07.03.04.08.07.06.0-26.0-53.0-49.08.09.05.08.05.06.05.08.04.04.05.05.05.02.05.011-52.0292634272923423327293131302832302831
Percentage of NetIncomeLossAttributableToNoncontrollingInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0120.0100.0100.0100.0100.0100.0100.0100.0200.0100.0100.098.1100.0100.0100.0103.8100.0100.0100.097.1100.0100.0100.096.9100.0100.0100.0100.0100.0100.0
Percentage of Revenues0.00.10.00.00.10.10.0-0.2-0.5-0.40.10.10.00.10.00.10.10.10.00.00.10.00.00.00.10.1-0.50.30.30.30.20.30.20.40.30.20.20.30.30.20.20.30.30.20.3
Percentage of Revenues us-gaap:NoncontrollingInterest0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Other Comprehensive Income Loss Net Of Tax

us-gaap:OtherComprehensiveIncomeLossNetOfTax

us-gaap:OtherComprehensiveIncomeLossNetOfTax


Other
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-30
Value154512-251.010.0-2.0-198.0-803.0-28.0-16.0199-394.0-29.0-62.012435149-14.0146-974.0-166.0108-46.0425-241.0-165.0156-1325.0-554.0-265.018250162-131.053-1642.08691-85.0-419.063394
Percentage of OtherComprehensiveIncomeLossNetOfTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues13.60.1-2.00.1-0.0-1.6-6.8-0.2-0.11.8-3.6-0.3-0.61.20.31.4-0.11.5-9.6-1.61.1-0.54.2-2.4-1.71.7-12.6-5.2-2.40.222.10.6-1.20.5-14.00.70.7-0.7-3.40.53.2

us-gaap:OtherComprehensiveIncomeLossNetOfTax us-gaap:StatementEquityComponents

us-gaap:AccumulatedOtherComprehensiveIncome


Other
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-30
Value154512-251.010.0-2.0-198.0-803.0-28.0-16.0199-394.0-29.0-62.012435149-14.0146-974.0-166.0108-46.0425-241.0-165.0156-1325.0-554.0-265.018250162-131.053-1642.08691-85.0-419.063
Percentage of OtherComprehensiveIncomeLossNetOfTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues13.60.1-2.00.1-0.0-1.6-6.8-0.2-0.11.8-3.6-0.3-0.61.20.31.4-0.11.5-9.6-1.61.1-0.54.2-2.4-1.71.7-12.6-5.2-2.40.222.10.6-1.20.5-14.00.70.7-0.7-3.40.5
Percentage of Revenues us-gaap:AccumulatedOtherComprehensiveIncome0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Other Nonoperating Income Expense

us-gaap:OtherNonoperatingIncomeExpense

us-gaap:OtherNonoperatingIncomeExpense


Other
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value103448256312390-71.0223-35.0-140.0-188.0-110.0172482911886-58.0-58.0-632.0-22.0-19.0-48.0-903.0170-739.0-55.01061914255839-159.0-172.0-201.0-282.0-670.0-200.0-103.0-142.0-137.0-66.0-121.0-622.0-309.0-1108.0281-167.0
Percentage of OtherNonoperatingIncomeExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues0.93.72.02.53.6-0.61.9-0.3-1.2-1.7-1.01.60.52.90.20.8-0.6-0.6-6.2-0.2-0.2-0.5-8.81.7-7.6-0.6101.31.35.10.4-1.4-1.6-1.8-2.6-5.7-1.7-0.8-1.2-1.1-0.5-1.0-5.4-2.6-10.02.5-1.5

Profit Loss

us-gaap:ProfitLoss

us-gaap:ProfitLoss


Profit
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value3186-2091.02945301032192363190726442862177819581716741-1038.0-51.019511556-587.02188120911309821831688958732784220331731815115093516169491763182017671543172420541071-500.0372780330
Percentage of ProfitLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues26.4-16.723.527.726.719.915.422.526.516.218.116.47.4-9.9-0.519.616.5-5.820.812.312.19.618.27.010.269.98.018.616.97.210.48.515.18.115.314.815.112.614.316.99.2-4.13.36.92.9

Research And Development Expense

us-gaap:ResearchAndDevelopmentExpense

us-gaap:ResearchAndDevelopmentExpense


Research
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value4321246558373390212322092548320421891931221420682274319622814383174917964649166421511659179815001670173722831659166415741835166021011907222419182165186224191954193621584439232221792051
Percentage of ResearchAndDevelopmentExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues37.920.446.627.019.518.321.525.818.617.920.119.221.731.821.942.517.619.046.015.821.917.817.614.917.118.421.815.715.215.316.215.019.117.918.916.717.615.919.716.315.918.636.720.919.218.0

us-gaap:ResearchAndDevelopmentExpense us-gaap:BusinessAcquisition

mrk:PandionTherapeutics


Research
Period End2021-04-30
Value1700
Percentage of ResearchAndDevelopmentExpense0.0
Percentage of Revenues0.0
Percentage of Revenues mrk:PandionTherapeutics0.0

us-gaap:ResearchAndDevelopmentExpense us-gaap:ConsolidationItems

us-gaap:MaterialReconcilingItems


Research
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value4175235857083272199420972454311020931843197518552041298244001829152715994433144418331373156112911460156118391332
Percentage of ResearchAndDevelopmentExpense96.695.797.896.593.994.996.397.195.695.489.289.789.893.3192.941.787.389.095.486.885.282.886.886.187.489.980.680.3
Percentage of Revenues36.619.545.626.118.317.420.725.117.817.018.017.219.529.742.217.715.416.943.813.718.614.715.312.814.916.617.512.6
Percentage of Revenues us-gaap:MaterialReconcilingItems0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:ResearchAndDevelopmentExpense us-gaap:CounterpartyName

mrk:Seagen


Research
Period End2020-09-30
Value622
Percentage of ResearchAndDevelopmentExpense18.3
Percentage of Revenues0.0
Percentage of Revenues mrk:Seagen0.0

us-gaap:ResearchAndDevelopmentExpense us-gaap:CounterpartyName, us-gaap:IncomeStatementLocation, us-gaap:TypeOfArrangement

mrk:AstraZeneca, us-gaap:ResearchAndDevelopmentExpense, us-gaap:CollaborativeArrangement


Research
Period End2021-06-302021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-31
Value3129203736443345
Percentage of ResearchAndDevelopmentExpense0.71.20.61.71.61.41.52.3
Percentage of Revenues0.30.20.20.30.30.40.30.4
Percentage of Revenues mrk:AstraZeneca us-gaap:ResearchAndDevelopmentExpense us-gaap:CollaborativeArrangement0.00.00.00.00.00.00.00.0

mrk:BayerAG, us-gaap:ResearchAndDevelopmentExpense, us-gaap:CollaborativeArrangement


Research
Period End2021-06-302021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-31
Value137.0121625313230
Percentage of ResearchAndDevelopmentExpense0.30.30.40.81.11.01.51.6
Percentage of Revenues0.10.10.10.10.20.30.30.3
Percentage of Revenues mrk:BayerAG us-gaap:ResearchAndDevelopmentExpense us-gaap:CollaborativeArrangement0.00.00.00.00.00.00.00.0

mrk:Eisai, us-gaap:ResearchAndDevelopmentExpense, us-gaap:CollaborativeArrangement


Research
Period End2021-06-302021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-31
Value5764485664376247
Percentage of ResearchAndDevelopmentExpense1.32.61.42.62.91.22.82.4
Percentage of Revenues0.50.50.40.50.50.30.50.4
Percentage of Revenues mrk:Eisai us-gaap:ResearchAndDevelopmentExpense us-gaap:CollaborativeArrangement0.00.00.00.00.00.00.00.0

Revenues

us-gaap:Revenues

us-gaap:Revenues


Revenues
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value11402120801251512551108721205711868123971176010816109981079410465100371043310325993094341011510536984493121021510073978594251048210557109341026411320110321101010671117371148812311117311229412022121511158012094111251134611422
Percentage of Revenues100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:Revenues us-gaap:ConsolidationItems

us-gaap:CorporateNonSegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value-50.0-13.0-20.0119216517113412889776037-31.0606911521621011616530310730231023011102
Percentage of Revenues-0.4-0.1-0.20.10.81.41.41.11.10.80.70.60.4-0.30.60.71.22.32.11.11.73.31.03.03.22.40.11.0
Percentage of Revenues-0.4-0.1-0.20.10.81.41.41.11.10.80.70.60.4-0.30.60.71.22.32.11.11.73.31.03.03.22.40.11.0
Percentage of Revenues us-gaap:CorporateNonSegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value114521209312535125401078011892116971226311632107271092110734104281006810373102569815921899051042096799009101089771947591951047110455
Percentage of Revenues100.4100.1100.299.999.298.698.698.998.999.299.399.499.6100.399.499.398.897.797.998.998.396.799.097.096.897.699.999.0
Percentage of Revenues100.4100.1100.299.999.298.698.698.998.999.299.399.499.6100.399.499.398.897.797.998.998.396.799.097.096.897.699.999.0
Percentage of Revenues us-gaap:OperatingSegments100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:Revenues us-gaap:ConsolidationItems, us-gaap:ProductOrService, us-gaap:StatementBusinessSegments

us-gaap:OperatingSegments, mrk:Adempas, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-31
Value74555355575611710710490919475687970678449484033
Percentage of Revenues0.60.50.40.40.50.51.00.90.90.80.80.90.70.70.80.70.70.90.50.50.40.4
Percentage of Revenues0.60.50.40.40.50.51.00.90.90.80.80.90.70.70.80.70.70.90.50.50.40.4
Percentage of Revenues us-gaap:OperatingSegments mrk:Adempas mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:AllianceRevenueAdempas, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
Value74746583795360505142
Percentage of Revenues0.60.60.50.70.70.40.50.40.40.4
Percentage of Revenues0.60.60.50.70.70.40.50.40.40.4
Percentage of Revenues us-gaap:OperatingSegments mrk:AllianceRevenueAdempas mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:AlliancerevenueLynparza, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value2482282061961781451311231117962494433155.00.00.0
Percentage of Revenues2.21.91.61.61.61.21.11.00.90.70.60.50.40.30.10.00.00.0
Percentage of Revenues2.21.91.61.61.61.21.11.00.90.70.60.50.40.30.10.00.00.0
Percentage of Revenues us-gaap:OperatingSegments mrk:AlliancerevenueLynparza mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.00.0

us-gaap:OperatingSegments, mrk:Arcoxia, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value56546865706772757586838483918089103108114117111110123115123119132
Percentage of Revenues0.50.40.50.60.60.60.60.60.70.80.80.80.80.90.80.91.11.11.11.21.21.11.21.21.31.11.3
Percentage of Revenues0.50.40.50.60.60.60.60.60.70.80.80.80.80.90.80.91.11.11.11.21.21.11.21.21.31.11.3
Percentage of Revenues us-gaap:OperatingSegments mrk:Arcoxia mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Atozet, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-30
Value11210511111512210897929489841017354596349503933
Percentage of Revenues0.90.80.91.11.00.90.80.80.90.80.81.00.70.50.60.60.50.50.40.3
Percentage of Revenues0.90.80.91.11.00.90.80.80.90.80.81.00.70.50.60.60.50.50.40.3
Percentage of Revenues us-gaap:OperatingSegments mrk:Atozet mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Belsomra, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value787983818479838076676966715460565242
Percentage of Revenues0.70.70.70.60.80.70.70.60.60.60.60.60.70.50.60.50.50.4
Percentage of Revenues0.70.70.70.60.80.70.70.60.60.60.60.60.70.50.60.50.50.4
Percentage of Revenues us-gaap:OperatingSegments mrk:Belsomra mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Bridion, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value38734035532022429931428427825525621724020420918516314813913911390918987859590
Percentage of Revenues3.42.82.82.52.12.52.62.32.42.42.32.02.32.02.01.81.61.61.41.31.11.00.90.90.90.90.90.9
Percentage of Revenues3.42.82.82.52.12.52.62.32.42.42.32.02.32.02.01.81.61.61.41.31.11.00.90.90.90.90.90.9
Percentage of Revenues us-gaap:OperatingSegments mrk:Bridion mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Cancidas, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value54576550435558626761697987919594112121152142131133137139134163176183
Percentage of Revenues0.50.50.50.40.40.50.50.50.60.60.60.70.80.90.90.91.11.31.51.31.31.41.31.41.41.71.71.7
Percentage of Revenues0.50.50.50.40.40.50.50.50.60.60.60.70.80.90.90.91.11.31.51.31.31.41.31.41.41.71.71.7
Percentage of Revenues us-gaap:OperatingSegments mrk:Cancidas mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:CompanionAnimals, mrk:AnimalHealthsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value651599374462453475345396453414352361457413313345373361
Percentage of Revenues5.75.03.03.74.23.92.93.23.93.83.23.34.44.13.03.33.83.8
Percentage of Revenues5.75.03.03.74.23.92.93.23.93.83.23.34.44.13.03.33.83.8
Percentage of Revenues us-gaap:OperatingSegments mrk:CompanionAnimals mrk:AnimalHealthsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:CozaarHyzaar, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value43225414971216587296105103125122124128119112122131132126143150189185192195
Percentage of Revenues0.41.80.30.50.61.80.50.60.91.01.01.21.21.21.21.21.21.21.21.31.41.41.51.92.01.81.8
Percentage of Revenues0.41.80.30.50.61.80.50.60.91.01.01.21.21.21.21.21.21.21.21.31.41.41.51.92.01.81.8
Percentage of Revenues us-gaap:OperatingSegments mrk:CozaarHyzaar mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Cubicin, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value3639324650526788809594989291103961183203572923223252931877.07.0
Percentage of Revenues0.30.30.30.40.40.40.60.80.70.90.91.00.90.91.01.01.23.03.63.13.23.23.02.00.10.1
Percentage of Revenues0.30.30.30.40.40.40.60.80.70.90.91.00.90.91.01.01.23.03.63.13.23.23.02.00.10.1
Percentage of Revenues us-gaap:OperatingSegments mrk:Cubicin mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Emend, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value303933435298121117126123148125143137143133144137143126139141134122151136
Percentage of Revenues0.20.30.30.40.40.81.01.11.11.11.41.21.41.31.41.41.41.31.51.41.41.41.41.31.41.3
Percentage of Revenues0.20.30.30.40.40.81.01.11.11.11.41.21.41.31.41.41.41.31.51.41.41.41.41.31.41.3
Percentage of Revenues us-gaap:OperatingSegments mrk:Emend mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:FollistimAq, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value525750444159626357706070676672798187101739495951118210397
Percentage of Revenues0.40.50.40.40.30.50.50.50.50.60.60.70.70.60.70.80.90.91.00.71.00.90.91.10.91.00.9
Percentage of Revenues0.40.50.40.40.30.50.50.50.50.60.60.70.70.60.70.80.90.91.00.71.00.90.91.10.91.00.9
Percentage of Revenues us-gaap:OperatingSegments mrk:FollistimAq mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:GardasilGardasil9, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-30
Value12349179971187656109769313208868388341048608660633675469532542860
Percentage of Revenues10.87.68.09.56.09.15.810.67.57.77.69.75.86.66.16.54.75.65.48.2
Percentage of Revenues10.87.68.09.56.09.15.810.67.57.77.69.75.86.66.16.54.75.65.48.2
Percentage of Revenues us-gaap:OperatingSegments mrk:GardasilGardasil9 mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:ImplanonNexplanon, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value183165189132195206199183199168186174174183155178170160148164134151176124137123158
Percentage of Revenues1.51.31.51.21.61.71.61.61.81.51.71.71.71.81.51.81.81.61.41.71.41.51.71.31.51.21.5
Percentage of Revenues1.51.31.51.21.61.71.61.61.81.51.71.71.71.81.51.81.81.61.41.71.41.51.71.31.51.21.5
Percentage of Revenues us-gaap:OperatingSegments mrk:ImplanonNexplanon mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Invanz, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value4857525143645757787259137149151157159150136152152143114145153139132139141
Percentage of Revenues0.40.50.40.40.40.50.50.50.70.70.51.31.41.51.51.51.51.41.51.41.51.21.41.51.41.41.31.3
Percentage of Revenues0.40.50.40.40.40.50.50.50.70.70.51.31.41.51.51.51.51.41.51.41.51.21.41.51.41.41.31.3
Percentage of Revenues us-gaap:OperatingSegments mrk:Invanz mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:IsentressIsentressHD, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-30
Value192209211205196245223250247255280275305281308310282305337372338
Percentage of Revenues1.71.71.71.61.82.01.92.02.12.42.52.52.92.83.03.02.83.23.33.53.4
Percentage of Revenues1.71.71.71.61.82.01.92.02.12.42.52.52.92.83.03.02.83.23.33.53.4
Percentage of Revenues us-gaap:OperatingSegments mrk:IsentressIsentressHD mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Janumet, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value477486472506490503474503533530535563585544586513563496577548569506526562554509571505
Percentage of Revenues4.24.03.84.04.54.24.04.14.54.94.95.25.65.45.65.05.75.35.75.25.85.45.15.65.75.45.44.8
Percentage of Revenues4.24.03.84.04.54.24.04.14.54.94.95.25.65.45.65.05.75.35.75.25.85.45.15.65.75.45.44.8
Percentage of Revenues us-gaap:OperatingSegments mrk:Janumet mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Januvia, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value784809857821854774943807908824930927949880938101294883993210061064906921101410448841082933
Percentage of Revenues6.96.76.86.57.96.47.96.57.77.68.58.69.18.89.09.89.58.99.29.510.89.79.010.110.79.410.38.8
Percentage of Revenues6.96.76.86.57.96.47.96.57.77.68.58.69.18.89.09.89.58.99.29.510.89.79.010.110.79.410.38.8
Percentage of Revenues us-gaap:OperatingSegments mrk:Januvia mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Keytruda, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value417638993993371533883284311130702634226921511889166714641297104788158448335631424921415911083514.0
Percentage of Revenues36.632.331.929.631.227.226.224.822.421.019.617.515.914.612.410.18.96.24.83.43.22.72.11.61.10.90.50.0
Percentage of Revenues36.632.331.929.631.227.226.224.822.421.019.617.515.914.612.410.18.96.24.83.43.22.72.11.61.10.90.50.0
Percentage of Revenues us-gaap:OperatingSegments mrk:Keytruda mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Lenvima, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value18113015914215112812410997747143350.00.00.00.0
Percentage of Revenues1.61.11.31.11.41.11.00.90.80.70.60.40.30.00.00.00.0
Percentage of Revenues1.61.11.31.11.41.11.00.90.80.70.60.40.30.00.00.00.0
Percentage of Revenues us-gaap:OperatingSegments mrk:Lenvima mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.00.00.00.0

us-gaap:OperatingSegments, mrk:Livestock, mrk:AnimalHealthsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value821819794758648739777726671611684660633652668655582578
Percentage of Revenues7.26.86.36.06.06.16.55.95.75.66.26.16.06.56.46.35.96.1
Percentage of Revenues7.26.86.36.06.06.16.55.95.75.66.26.16.06.56.46.35.96.1
Percentage of Revenues us-gaap:OperatingSegments mrk:Livestock mrk:AnimalHealthsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Nasonex, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value90-74.09198102-36.01161091031027181120121428513911294101229233121215289269261
Percentage of Revenues0.7-0.60.70.90.8-0.30.90.91.00.90.70.81.21.20.40.91.51.10.91.02.52.31.22.23.12.62.5
Percentage of Revenues0.7-0.60.70.90.8-0.30.90.91.00.90.70.81.21.20.40.91.51.10.91.02.52.31.22.23.12.62.5
Percentage of Revenues us-gaap:OperatingSegments mrk:Nasonex mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Noxafil, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value666782797394102177193190191188188176178162155141161147143145127132117111122107
Percentage of Revenues0.60.60.70.60.70.80.91.41.61.81.71.71.81.81.71.61.61.51.61.41.51.61.21.31.21.21.21.0
Percentage of Revenues0.60.60.70.60.70.80.91.41.61.81.71.71.81.81.71.61.61.51.61.41.51.61.21.31.21.21.21.0
Percentage of Revenues us-gaap:OperatingSegments mrk:Noxafil mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Nuvaring, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value4552586363179241240219216234236216188214199160206195200175194190182166192186
Percentage of Revenues0.40.40.50.60.51.51.92.02.02.02.22.32.21.82.12.01.72.01.92.01.91.91.91.91.81.81.8
Percentage of Revenues0.40.40.50.60.51.51.92.02.02.02.22.32.21.82.12.01.72.01.92.01.91.91.91.91.81.81.8
Percentage of Revenues us-gaap:OperatingSegments mrk:Nuvaring mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:OtherPharmaceutical, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value54611971231118611031194126712291268114010679801053118610489521064
Percentage of Revenues4.89.99.89.410.19.910.79.910.810.59.79.110.111.810.09.210.7
Percentage of Revenues4.89.99.89.410.19.910.79.910.810.59.79.110.111.810.09.210.7
Percentage of Revenues us-gaap:OperatingSegments mrk:OtherPharmaceutical mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Pneumovax23, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value152171339375117256334237170185321214193179263229166163238175120107188138106110346197
Percentage of Revenues1.31.42.73.01.12.12.81.91.41.72.92.01.81.82.52.21.71.72.41.71.21.11.81.41.11.23.31.9
Percentage of Revenues1.31.42.73.01.12.12.81.91.41.72.92.01.81.82.52.21.71.72.41.71.21.11.81.41.11.23.31.9
Percentage of Revenues us-gaap:OperatingSegments mrk:Pneumovax23 mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Prevymis, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
Value93828177636050453832
Percentage of Revenues0.80.70.60.60.60.50.40.40.30.3
Percentage of Revenues0.80.70.60.60.60.50.40.40.30.3
Percentage of Revenues us-gaap:OperatingSegments mrk:Prevymis mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Primaxin, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value60656274645166777159537268727473716266778173857588658691
Percentage of Revenues0.50.50.50.60.60.40.60.60.60.50.50.70.60.70.70.70.70.70.70.70.80.80.80.70.90.70.80.9
Percentage of Revenues0.50.50.50.60.60.40.60.60.60.50.50.70.60.70.70.70.70.70.70.70.80.80.80.70.90.70.80.9
Percentage of Revenues us-gaap:OperatingSegments mrk:Primaxin mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:ProQuadMMRIIVarivax, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value516449488576378435481623675496455525426392403519399355404496383357409390358348367421
Percentage of Revenues4.53.73.94.63.53.64.15.05.74.64.14.94.13.93.95.04.03.84.04.73.93.84.03.93.73.73.54.0
Percentage of Revenues4.53.73.94.63.53.64.15.05.74.64.14.94.13.93.95.04.03.84.04.73.93.84.03.93.73.73.54.0
Percentage of Revenues us-gaap:OperatingSegments mrk:ProQuadMMRIIVarivax mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Remicade, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value7585888273888910198123123135157167186214208229269311339349396442455501557604
Percentage of Revenues0.70.70.70.70.70.70.70.80.81.11.11.31.51.71.82.12.12.42.73.03.43.73.94.44.65.35.35.7
Percentage of Revenues0.70.70.70.70.70.70.70.80.81.11.11.31.51.71.82.12.12.42.73.03.43.73.94.44.65.35.35.7
Percentage of Revenues us-gaap:OperatingSegments mrk:Remicade mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Rotateq, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value20815819621016822222718017221118819115619316117912322416317113018816916089192169174
Percentage of Revenues1.81.31.61.71.51.81.91.51.52.01.71.81.51.91.51.71.22.41.61.61.32.01.71.60.92.01.61.6
Percentage of Revenues1.81.31.61.71.51.81.91.51.52.01.71.81.51.91.51.71.22.41.61.61.32.01.71.60.92.01.61.6
Percentage of Revenues us-gaap:OperatingSegments mrk:Rotateq mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Simponi, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value202214223209191215205203214208220210233231217219199184185193199188185178169158189170
Percentage of Revenues1.81.81.81.71.81.81.71.61.81.92.01.92.22.32.12.12.02.01.81.82.02.01.81.81.71.71.81.6
Percentage of Revenues1.81.81.81.71.81.81.71.61.81.92.01.92.22.32.12.12.02.01.81.82.02.01.81.81.71.71.81.6
Percentage of Revenues us-gaap:OperatingSegments mrk:Simponi mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Singulair, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value10712482100155195152160191187161185175182161203186210239229237273201212245319218
Percentage of Revenues0.91.00.70.91.31.61.21.41.81.71.51.81.71.71.62.02.02.12.32.32.52.72.02.22.63.02.1
Percentage of Revenues0.91.00.70.91.31.61.21.41.81.71.51.81.71.71.62.02.02.12.32.32.52.72.02.22.63.02.1
Percentage of Revenues us-gaap:OperatingSegments mrk:Singulair mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Vaqta, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
Value5634315128607162584772666537
Percentage of Revenues0.50.30.20.40.30.50.60.50.50.40.70.60.60.4
Percentage of Revenues0.50.30.20.40.30.50.60.50.50.40.70.60.60.4
Percentage of Revenues us-gaap:OperatingSegments mrk:Vaqta mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Vytorin, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value4143473953545776978392155167186142182241298273293277309302320320370369
Percentage of Revenues0.30.30.40.40.40.50.50.60.90.80.91.51.71.81.41.82.62.92.63.03.03.03.03.33.43.53.5
Percentage of Revenues0.30.30.40.40.40.50.50.60.90.80.91.51.71.81.41.82.62.92.63.03.03.03.03.33.43.53.5
Percentage of Revenues us-gaap:OperatingSegments mrk:Vytorin mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Zepatier, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
Value452839556683108114108104113131297468517378229164112500.00.00.00.0
Percentage of Revenues0.40.20.40.50.60.70.91.11.01.01.11.32.84.55.24.02.31.61.10.50.00.00.00.0
Percentage of Revenues0.40.20.40.50.60.70.91.11.01.01.11.32.84.55.24.02.31.61.10.50.00.00.00.0
Percentage of Revenues us-gaap:OperatingSegments mrk:Zepatier mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.00.00.00.0

us-gaap:OperatingSegments, mrk:Zerbaxa, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
Value-1.0-8.01843323733352726
Percentage of Revenues-0.0-0.10.10.30.30.30.30.30.20.2
Percentage of Revenues-0.0-0.10.10.30.30.30.30.30.20.2
Percentage of Revenues us-gaap:OperatingSegments mrk:Zerbaxa mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Zetia, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value9298103137145147147156140161165226305323320367334575671702612690633635568662660
Percentage of Revenues0.80.80.81.31.21.21.21.31.31.51.52.23.03.13.13.73.55.76.47.16.66.86.36.56.06.36.3
Percentage of Revenues0.80.80.81.31.21.21.21.31.31.51.52.23.03.13.13.73.55.76.47.16.66.86.36.56.06.36.3
Percentage of Revenues us-gaap:OperatingSegments mrk:Zetia mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:Revenues us-gaap:ConsolidationItems, us-gaap:ProductOrService, us-gaap:StatementGeographical, us-gaap:StatementBusinessSegments

us-gaap:OperatingSegments, mrk:Adempas, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value7455535557561171071049091947568797067
Percentage of Revenues0.60.50.40.40.50.51.00.90.90.80.80.90.70.70.80.70.7
Percentage of Revenues0.60.50.40.40.50.51.00.90.90.80.80.90.70.70.80.70.7
Percentage of Revenues us-gaap:OperatingSegments mrk:Adempas mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:AllianceRevenueAdempas, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
Value81685978734957484940
Percentage of Revenues0.70.60.50.60.70.40.50.40.40.4
Percentage of Revenues0.70.60.50.60.70.40.50.40.40.4
Percentage of Revenues us-gaap:OperatingSegments mrk:AllianceRevenueAdempas country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:AllianceRevenueAdempas, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
Value-7.06.06.05.06.05.03.02.02.02.0
Percentage of Revenues-0.10.00.00.00.10.00.00.00.00.0
Percentage of Revenues-0.10.00.00.00.10.00.00.00.00.0
Percentage of Revenues us-gaap:OperatingSegments mrk:AllianceRevenueAdempas mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:AlliancerevenueLynparza, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value1241181201071058583716650393331240.00.00.0
Percentage of Revenues1.11.01.00.91.00.70.70.60.60.50.40.30.30.20.00.00.0
Percentage of Revenues1.11.01.00.91.00.70.70.60.60.50.40.30.30.20.00.00.0
Percentage of Revenues us-gaap:OperatingSegments mrk:AlliancerevenueLynparza country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.00.00.0

us-gaap:OperatingSegments, mrk:AlliancerevenueLynparza, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value12411085897360505345292415139.0155.00.0
Percentage of Revenues1.10.90.70.70.70.50.40.40.40.30.20.10.10.10.10.00.0
Percentage of Revenues1.10.90.70.70.70.50.40.40.40.30.20.10.10.10.10.00.0
Percentage of Revenues us-gaap:OperatingSegments mrk:AlliancerevenueLynparza mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0

us-gaap:OperatingSegments, mrk:Arcoxia, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value56546865706772757586838483918089
Percentage of Revenues0.50.40.50.60.60.60.60.60.70.80.80.80.80.90.80.9
Percentage of Revenues0.50.40.50.60.60.60.60.60.70.80.80.80.80.90.80.9
Percentage of Revenues us-gaap:OperatingSegments mrk:Arcoxia mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Atozet, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value112105111115122108979294898410173545963
Percentage of Revenues0.90.80.91.11.00.90.80.80.90.80.81.00.70.50.60.6
Percentage of Revenues0.90.80.91.11.00.90.80.80.90.80.81.00.70.50.60.6
Percentage of Revenues us-gaap:OperatingSegments mrk:Atozet mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Belsomra, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value1418141822272423212420232923262725
Percentage of Revenues0.10.10.10.10.20.20.20.20.20.20.20.20.30.20.20.30.3
Percentage of Revenues0.10.10.10.10.20.20.20.20.20.20.20.20.30.20.20.30.3
Percentage of Revenues us-gaap:OperatingSegments mrk:Belsomra country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Belsomra, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value6361706361535957554449434231343028
Percentage of Revenues0.60.50.60.50.60.40.50.50.50.40.40.40.40.30.30.30.3
Percentage of Revenues0.60.50.60.50.60.40.50.50.50.40.40.40.40.30.30.30.3
Percentage of Revenues us-gaap:OperatingSegments mrk:Belsomra mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Bridion, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value197167171162107143152133129119114969580776354
Percentage of Revenues1.71.41.41.31.01.21.31.11.11.11.00.90.90.80.70.60.5
Percentage of Revenues1.71.41.41.31.01.21.31.11.11.11.00.90.90.80.70.60.5
Percentage of Revenues us-gaap:OperatingSegments mrk:Bridion country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Bridion, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value190173184157117157161151149136142120145124132122109
Percentage of Revenues1.71.41.51.31.11.31.41.21.31.31.31.11.41.21.31.21.1
Percentage of Revenues1.71.41.51.31.11.31.41.21.31.31.31.11.41.21.31.21.1
Percentage of Revenues us-gaap:OperatingSegments mrk:Bridion mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Cancidas, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value1.03.05.01.0-2.03.01.00.03.01.02.02.04.03.03.06.06.0
Percentage of Revenues0.00.00.00.0-0.00.00.00.00.00.00.00.00.00.00.00.10.1
Percentage of Revenues0.00.00.00.0-0.00.00.00.00.00.00.00.00.00.00.00.10.1
Percentage of Revenues us-gaap:OperatingSegments mrk:Cancidas country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Cancidas, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value53556049455255626460677783889288106
Percentage of Revenues0.50.50.50.40.40.40.50.50.50.60.60.70.80.90.90.91.1
Percentage of Revenues0.50.50.50.40.40.40.50.50.50.60.60.70.80.90.90.91.1
Percentage of Revenues us-gaap:OperatingSegments mrk:Cancidas mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:CompanionAnimals, country:US, mrk:AnimalHealthsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value298280196234220222164193190177169153204183136153167
Percentage of Revenues2.62.31.61.92.01.81.41.61.61.61.51.41.91.81.31.51.7
Percentage of Revenues2.62.31.61.92.01.81.41.61.61.61.51.41.91.81.31.51.7
Percentage of Revenues us-gaap:OperatingSegments mrk:CompanionAnimals country:US mrk:AnimalHealthsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:CompanionAnimals, mrk:International, mrk:AnimalHealthsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value353319178228233253181203263237183207253229177192206
Percentage of Revenues3.12.61.41.82.12.11.51.62.22.21.71.92.42.31.71.92.1
Percentage of Revenues3.12.61.41.82.12.11.51.62.22.21.71.92.42.31.71.92.1
Percentage of Revenues us-gaap:OperatingSegments mrk:CompanionAnimals mrk:International mrk:AnimalHealthsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:CozaarHyzaar, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value2.012-1.04.06.0224.0-1.0-1.05.04.07.01.03.09.03.0
Percentage of Revenues0.00.1-0.00.00.00.20.0-0.0-0.00.00.00.10.00.00.10.0
Percentage of Revenues0.00.1-0.00.00.00.20.0-0.0-0.00.00.00.10.00.00.10.0
Percentage of Revenues us-gaap:OperatingSegments mrk:CozaarHyzaar country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:CozaarHyzaar, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value4121341456519455739710199118121121119116
Percentage of Revenues0.31.70.30.40.51.60.40.60.90.90.91.11.21.21.21.2
Percentage of Revenues0.31.70.30.40.51.60.40.60.90.90.91.11.21.21.21.2
Percentage of Revenues us-gaap:OperatingSegments mrk:CozaarHyzaar mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Cubicin, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value10.01110.0151414224241554847414153
Percentage of Revenues0.10.10.10.10.10.10.20.40.40.50.50.50.40.40.5
Percentage of Revenues0.10.10.10.10.10.10.20.40.40.50.50.50.40.40.5
Percentage of Revenues us-gaap:OperatingSegments mrk:Cubicin country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Cubicin, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value262821313638454639404651525050
Percentage of Revenues0.20.20.20.30.30.30.40.40.40.40.40.50.50.50.5
Percentage of Revenues0.20.20.20.30.30.30.40.40.40.40.40.50.50.50.5
Percentage of Revenues us-gaap:OperatingSegments mrk:Cubicin mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Emend, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value0.08.06.05.010.042676373718979858883
Percentage of Revenues0.00.10.10.00.10.30.60.60.70.70.90.80.80.90.8
Percentage of Revenues0.00.10.10.00.10.30.60.60.70.70.90.80.80.90.8
Percentage of Revenues us-gaap:OperatingSegments mrk:Emend country:US mrk:Pharmaceuticalsegment0.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Emend, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value313127384256545353525946574960
Percentage of Revenues0.20.20.20.30.40.50.50.50.50.50.60.50.50.50.6
Percentage of Revenues0.20.20.20.30.40.50.50.50.50.50.60.50.50.50.6
Percentage of Revenues us-gaap:OperatingSegments mrk:Emend mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:FollistimAq, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value25242020212327242932262729193032
Percentage of Revenues0.20.20.20.20.20.20.20.20.30.30.20.30.30.20.30.3
Percentage of Revenues0.20.20.20.20.20.20.20.20.30.30.20.30.30.20.30.3
Percentage of Revenues us-gaap:OperatingSegments mrk:FollistimAq country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:FollistimAq, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value27333124213635392838344339464147
Percentage of Revenues0.20.30.20.20.20.30.30.30.30.30.30.40.40.40.40.5
Percentage of Revenues0.20.30.20.20.20.30.30.30.30.30.30.40.40.40.40.5
Percentage of Revenues us-gaap:OperatingSegments mrk:FollistimAq mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:GardasilGardasil9, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value454313546579168461252761456362451740302380370484312
Percentage of Revenues4.02.64.44.61.53.82.16.13.93.34.16.92.93.83.54.73.1
Percentage of Revenues4.02.64.44.61.53.82.16.13.93.34.16.92.93.83.54.73.1
Percentage of Revenues us-gaap:OperatingSegments mrk:GardasilGardasil9 country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:GardasilGardasil9, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value781604452608488636441558430476385308306280262191156
Percentage of Revenues6.85.03.64.84.55.33.74.53.74.43.52.92.92.82.51.81.6
Percentage of Revenues6.85.03.64.84.55.33.74.53.74.43.52.92.92.82.51.81.6
Percentage of Revenues us-gaap:OperatingSegments mrk:GardasilGardasil9 mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:ImplanonNexplanon, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value14111413787149147136136149120133114128129110125
Percentage of Revenues1.20.91.10.81.21.21.11.21.41.11.21.11.31.21.11.3
Percentage of Revenues1.20.91.10.81.21.21.11.21.41.11.21.11.31.21.11.3
Percentage of Revenues us-gaap:OperatingSegments mrk:ImplanonNexplanon country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:ImplanonNexplanon, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value42505244455962485048536046544553
Percentage of Revenues0.30.40.40.40.40.50.50.40.50.40.50.60.50.50.40.5
Percentage of Revenues0.30.40.40.40.40.50.50.40.50.40.50.60.50.50.40.5
Percentage of Revenues us-gaap:OperatingSegments mrk:ImplanonNexplanon mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Invanz, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value-4.04.02.01.00.06.00.0-1.018141.0748791939393
Percentage of Revenues-0.00.00.00.00.00.00.0-0.00.20.10.00.70.80.90.90.90.9
Percentage of Revenues-0.00.00.00.00.00.00.0-0.00.20.10.00.70.80.90.90.90.9
Percentage of Revenues us-gaap:OperatingSegments mrk:Invanz country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.00.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Invanz, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value5252505043595758605858626360646657
Percentage of Revenues0.50.40.40.40.40.50.50.50.50.50.50.60.60.60.60.60.6
Percentage of Revenues0.50.40.40.40.40.50.50.50.50.50.50.60.60.60.60.60.6
Percentage of Revenues us-gaap:OperatingSegments mrk:Invanz mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:IsentressIsentressHD, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value7471839276759410294108130123132128143143136
Percentage of Revenues0.60.60.70.70.70.60.80.80.81.01.21.11.31.31.41.41.4
Percentage of Revenues0.60.60.70.70.70.60.80.80.81.01.21.11.31.31.41.41.4
Percentage of Revenues us-gaap:OperatingSegments mrk:IsentressIsentressHD country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:IsentressIsentressHD, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value118138128113120170127149153147150151174152165167146
Percentage of Revenues1.01.11.00.91.11.41.11.21.31.41.41.41.71.51.61.61.5
Percentage of Revenues1.01.11.00.91.11.41.11.21.31.41.41.41.71.51.61.61.5
Percentage of Revenues us-gaap:OperatingSegments mrk:IsentressIsentressHD mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Janumet, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value7484116105143113127129166167186225209192223197248
Percentage of Revenues0.60.70.90.81.30.91.11.01.41.51.72.12.01.92.11.92.5
Percentage of Revenues0.60.70.90.81.30.91.11.01.41.51.72.12.01.92.11.92.5
Percentage of Revenues us-gaap:OperatingSegments mrk:Janumet country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Janumet, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value403401356400348390347375366364350339377352363316315
Percentage of Revenues3.53.32.83.23.23.22.93.03.13.43.23.13.63.53.53.13.2
Percentage of Revenues3.53.32.83.23.23.22.93.03.13.43.23.13.63.53.53.13.2
Percentage of Revenues us-gaap:OperatingSegments mrk:Janumet mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Januvia, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value284348360342413355501367471384503498503465507598541
Percentage of Revenues2.52.92.92.73.82.94.23.04.03.64.64.64.84.64.95.85.4
Percentage of Revenues2.52.92.92.73.82.94.23.04.03.64.64.64.84.64.95.85.4
Percentage of Revenues us-gaap:OperatingSegments mrk:Januvia country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Januvia, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value500461497479441419441440437440427429446416431414407
Percentage of Revenues4.43.84.03.84.13.53.73.53.74.13.94.04.34.14.14.04.1
Percentage of Revenues4.43.84.03.84.13.53.73.53.74.13.94.04.34.14.14.04.1
Percentage of Revenues us-gaap:OperatingSegments mrk:Januvia mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Keytruda, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value234721812246215720431906178017431498128412441109959838787604556
Percentage of Revenues20.618.117.917.218.815.815.014.112.711.911.310.39.28.37.55.85.6
Percentage of Revenues20.618.117.917.218.815.815.014.112.711.911.310.39.28.37.55.85.6
Percentage of Revenues us-gaap:OperatingSegments mrk:Keytruda country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Keytruda, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value182917181747155913451378133113271136985907780707626510442325
Percentage of Revenues16.014.214.012.412.411.411.210.79.79.18.27.26.86.24.94.33.3
Percentage of Revenues16.014.214.012.412.411.411.210.79.79.18.27.26.86.24.94.33.3
Percentage of Revenues us-gaap:OperatingSegments mrk:Keytruda mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Lenvima, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value8885898298907065545046300.00.00.00.00.0
Percentage of Revenues0.80.70.70.70.90.70.60.50.50.50.40.30.00.00.00.00.0
Percentage of Revenues0.80.70.70.70.90.70.60.50.50.50.40.30.00.00.00.00.0
Percentage of Revenues us-gaap:OperatingSegments mrk:Lenvima country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.00.00.00.00.0

us-gaap:OperatingSegments, mrk:Lenvima, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value934468605338534443242513350.00.00.00.0
Percentage of Revenues0.80.40.50.50.50.30.40.40.40.20.20.10.30.00.00.00.0
Percentage of Revenues0.80.40.50.50.50.30.40.40.40.20.20.10.30.00.00.00.0
Percentage of Revenues us-gaap:OperatingSegments mrk:Lenvima mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.00.00.00.0

us-gaap:OperatingSegments, mrk:Livestock, country:US, mrk:AnimalHealthsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value161157164164122162176144145117145153107124112137103
Percentage of Revenues1.41.31.31.31.11.31.51.21.21.11.31.41.01.21.11.31.0
Percentage of Revenues1.41.31.31.31.11.31.51.21.21.11.31.41.01.21.11.31.0
Percentage of Revenues us-gaap:OperatingSegments mrk:Livestock country:US mrk:AnimalHealthsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Livestock, mrk:International, mrk:AnimalHealthsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value659662630594526577600582526494539508526529556518479
Percentage of Revenues5.85.55.04.74.84.85.14.74.54.64.94.75.05.35.35.04.8
Percentage of Revenues5.85.55.04.74.84.85.14.74.54.64.94.75.05.35.35.04.8
Percentage of Revenues us-gaap:OperatingSegments mrk:Livestock mrk:International mrk:AnimalHealthsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Nasonex, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value3.0-5.05.04.07.0-7.06.06.04.0157.00.07.038-23.021
Percentage of Revenues0.0-0.00.00.00.1-0.10.00.10.00.10.10.00.10.4-0.20.2
Percentage of Revenues0.0-0.00.00.00.1-0.10.00.10.00.10.10.00.10.4-0.20.2
Percentage of Revenues us-gaap:OperatingSegments mrk:Nasonex country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Nasonex, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value87-69.0869495-29.011010399876481113836564
Percentage of Revenues0.7-0.60.70.90.8-0.20.90.90.90.80.60.81.10.80.60.6
Percentage of Revenues0.7-0.60.70.90.8-0.20.90.90.90.80.60.81.10.80.60.6
Percentage of Revenues us-gaap:OperatingSegments mrk:Nasonex mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Noxafil, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value141515136.08.014771009196898781897877
Percentage of Revenues0.10.10.10.10.10.10.10.60.90.80.90.80.80.80.90.80.8
Percentage of Revenues0.10.10.10.10.10.10.10.60.90.80.90.80.80.80.90.80.8
Percentage of Revenues us-gaap:OperatingSegments mrk:Noxafil country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Noxafil, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value525267666787891009399959910094908378
Percentage of Revenues0.50.40.50.50.60.70.70.80.80.90.90.91.00.90.90.80.8
Percentage of Revenues0.50.40.50.50.60.70.70.80.80.90.90.91.00.90.90.80.8
Percentage of Revenues us-gaap:OperatingSegments mrk:Noxafil mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Nuvaring, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value2125243526149202206185172193187171139160153
Percentage of Revenues0.20.20.20.30.21.31.61.81.71.61.81.81.71.31.51.5
Percentage of Revenues0.20.20.20.30.21.31.61.81.71.61.81.81.71.31.51.5
Percentage of Revenues us-gaap:OperatingSegments mrk:Nuvaring country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Nuvaring, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value24293428372939343445414946495447
Percentage of Revenues0.20.20.30.30.30.20.30.30.30.40.40.50.50.50.50.5
Percentage of Revenues0.20.20.30.30.30.20.30.30.30.40.40.50.50.50.50.5
Percentage of Revenues us-gaap:OperatingSegments mrk:Nuvaring mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:OtherPharmaceutical, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value245384411352385409421385401358351317289320272266304
Percentage of Revenues2.13.23.32.83.53.43.53.13.43.33.22.92.83.22.62.63.1
Percentage of Revenues2.13.23.32.83.53.43.53.13.43.33.22.92.83.22.62.63.1
Percentage of Revenues us-gaap:OperatingSegments mrk:OtherPharmaceutical country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:OtherPharmaceutical, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value301814818834720780851842869782705666765867777688761
Percentage of Revenues2.66.76.56.66.66.57.26.87.47.26.46.27.38.67.46.77.7
Percentage of Revenues2.66.76.56.66.66.57.26.87.47.26.46.27.38.67.46.77.7
Percentage of Revenues us-gaap:OperatingSegments mrk:OtherPharmaceutical mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Pneumovax23, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value1007324927621182251179123125233160122112189174104
Percentage of Revenues0.90.62.02.20.21.52.11.41.01.22.11.51.21.11.81.71.0
Percentage of Revenues0.90.62.02.20.21.52.11.41.01.22.11.51.21.11.81.71.0
Percentage of Revenues us-gaap:OperatingSegments mrk:Pneumovax23 country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Pneumovax23, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value5299899996758358475989547166745661
Percentage of Revenues0.50.80.70.80.90.60.70.50.40.50.80.50.70.70.70.50.6
Percentage of Revenues0.50.80.70.80.90.60.70.50.40.50.80.50.70.70.70.50.6
Percentage of Revenues us-gaap:OperatingSegments mrk:Pneumovax23 mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Prevymis, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
Value37353232282624221918
Percentage of Revenues0.30.30.30.30.30.20.20.20.20.2
Percentage of Revenues0.30.30.30.30.30.20.20.20.20.2
Percentage of Revenues us-gaap:OperatingSegments mrk:Prevymis country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Prevymis, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
Value56474946353326231814
Percentage of Revenues0.50.40.40.40.30.30.20.20.20.1
Percentage of Revenues0.50.40.40.40.30.30.20.20.20.1
Percentage of Revenues us-gaap:OperatingSegments mrk:Prevymis mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Primaxin, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value0.01.01.00.00.02.00.00.01.01.00.05.03.05.01.0
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Percentage of Revenues0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Percentage of Revenues us-gaap:OperatingSegments mrk:Primaxin country:US mrk:Pharmaceuticalsegment0.0100.0100.00.00.0100.00.00.0100.0100.00.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Primaxin, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value6065617363516775705952716867716870
Percentage of Revenues0.50.50.50.60.60.40.60.60.60.50.50.70.60.70.70.70.7
Percentage of Revenues0.50.50.50.60.60.40.60.60.60.50.50.70.60.70.70.70.7
Percentage of Revenues us-gaap:OperatingSegments mrk:Primaxin mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:ProQuadMMRIIVarivax, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value386333345437263333358482500343333429356312316419341
Percentage of Revenues3.42.82.83.52.42.83.03.94.33.23.04.03.43.13.04.13.4
Percentage of Revenues3.42.82.83.52.42.83.03.94.33.23.04.03.43.13.04.13.4
Percentage of Revenues us-gaap:OperatingSegments mrk:ProQuadMMRIIVarivax country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:ProQuadMMRIIVarivax, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value1301171441391151021231411741531229670808810058
Percentage of Revenues1.11.01.21.11.10.81.01.11.51.41.10.90.70.80.81.00.6
Percentage of Revenues1.11.01.21.11.10.81.01.11.51.41.10.90.70.80.81.00.6
Percentage of Revenues us-gaap:OperatingSegments mrk:ProQuadMMRIIVarivax mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Remicade, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value7585888273888910198123123135157167186214208
Percentage of Revenues0.70.70.70.70.70.70.70.80.81.11.11.31.51.71.82.12.1
Percentage of Revenues0.70.70.70.70.70.70.70.80.81.11.11.31.51.71.82.12.1
Percentage of Revenues us-gaap:OperatingSegments mrk:Remicade mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Rotateq, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value1111181311141001401461021041541121349915110412772
Percentage of Revenues1.01.01.00.90.91.21.20.80.91.41.01.20.91.51.01.20.7
Percentage of Revenues1.01.01.00.90.91.21.20.80.91.41.01.20.91.51.01.20.7
Percentage of Revenues us-gaap:OperatingSegments mrk:Rotateq country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Rotateq, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value9741659668828178685776575742565251
Percentage of Revenues0.90.30.50.80.60.70.70.60.60.50.70.50.50.40.50.50.5
Percentage of Revenues0.90.30.50.80.60.70.70.60.60.50.70.50.50.40.50.50.5
Percentage of Revenues us-gaap:OperatingSegments mrk:Rotateq mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Simponi, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value202214223209191215205203214208220210233231217219199
Percentage of Revenues1.81.81.81.71.81.81.71.61.81.92.01.92.22.32.12.12.0
Percentage of Revenues1.81.81.81.71.81.81.71.61.81.92.01.92.22.32.12.12.0
Percentage of Revenues us-gaap:OperatingSegments mrk:Simponi mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Singulair, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value4.04.04.04.05.05.0118.05.04.05.05.06.012166.0
Percentage of Revenues0.00.00.00.00.00.00.10.10.00.00.00.00.10.10.20.1
Percentage of Revenues0.00.00.00.00.00.00.10.10.00.00.00.00.10.10.20.1
Percentage of Revenues us-gaap:OperatingSegments mrk:Singulair country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Singulair, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value1021207896151190140153186183156180170170145197
Percentage of Revenues0.81.00.60.91.31.61.11.31.71.71.41.71.71.61.42.0
Percentage of Revenues0.81.00.60.91.31.61.11.31.71.71.41.71.71.61.42.0
Percentage of Revenues us-gaap:OperatingSegments mrk:Singulair mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Vaqta, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
Value2225243217302736382932364218
Percentage of Revenues0.20.20.20.30.20.20.20.30.30.30.30.30.40.2
Percentage of Revenues0.20.20.20.30.20.20.20.30.30.30.30.30.40.2
Percentage of Revenues us-gaap:OperatingSegments mrk:Vaqta country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Vaqta, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
Value349.07.01911304326201840302318
Percentage of Revenues0.30.10.10.20.10.20.40.20.20.20.40.30.20.2
Percentage of Revenues0.30.10.10.20.10.20.40.20.20.20.40.30.20.2
Percentage of Revenues us-gaap:OperatingSegments mrk:Vaqta mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Vytorin, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value2.03.03.02.03.05.05.03.03.0-1.00.03.08.010.0-6.030
Percentage of Revenues0.00.00.00.00.00.00.00.00.0-0.00.00.00.10.1-0.10.3
Percentage of Revenues0.00.00.00.00.00.00.00.00.0-0.00.00.00.10.1-0.10.3
Percentage of Revenues us-gaap:OperatingSegments mrk:Vytorin country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Vytorin, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value3841443750505273948592152158176148152
Percentage of Revenues0.30.30.40.30.40.40.40.60.90.80.91.51.61.71.41.5
Percentage of Revenues0.30.30.40.30.40.40.40.60.90.80.91.51.61.71.41.5
Percentage of Revenues us-gaap:OperatingSegments mrk:Vytorin mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Zepatier, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value226.01518222439330.018-10.00.088228256
Percentage of Revenues0.20.00.10.10.20.20.30.30.00.2-0.10.00.82.22.6
Percentage of Revenues0.20.00.10.10.20.20.30.30.00.2-0.10.00.82.22.6
Percentage of Revenues us-gaap:OperatingSegments mrk:Zepatier country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.00.0100.0100.00.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Zepatier, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value242224374459688110886123131208241261
Percentage of Revenues0.20.20.20.30.40.50.60.71.00.81.21.32.02.32.6
Percentage of Revenues0.20.20.20.30.40.50.60.71.00.81.21.32.02.32.6
Percentage of Revenues us-gaap:OperatingSegments mrk:Zepatier mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Zerbaxa, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
Value-2.0-2.01720172018201312
Percentage of Revenues-0.0-0.00.10.20.20.20.20.20.10.1
Percentage of Revenues-0.0-0.00.10.20.20.20.20.20.10.1
Percentage of Revenues us-gaap:OperatingSegments mrk:Zerbaxa country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Zerbaxa, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
Value1.0-6.02.023151615151414
Percentage of Revenues0.0-0.00.00.20.10.10.10.10.10.1
Percentage of Revenues0.0-0.00.00.20.10.10.10.10.10.1
Percentage of Revenues us-gaap:OperatingSegments mrk:Zerbaxa mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Zetia, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value2.03.0-1.0-1.0-2.03.05.06.00.0119.08.0175465122
Percentage of Revenues0.00.0-0.0-0.0-0.00.00.00.10.00.10.10.10.20.50.61.2
Percentage of Revenues0.00.0-0.0-0.0-0.00.00.00.10.00.10.10.10.20.50.61.2
Percentage of Revenues us-gaap:OperatingSegments mrk:Zetia country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Zetia, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value9094103138147143142150140151157218287269255246
Percentage of Revenues0.70.80.81.31.21.21.11.31.31.41.52.12.92.62.52.5
Percentage of Revenues0.70.80.81.31.21.21.11.31.31.41.52.12.92.62.52.5
Percentage of Revenues us-gaap:OperatingSegments mrk:Zetia mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:Revenues us-gaap:ConsolidationItems, us-gaap:StatementBusinessSegments

us-gaap:OperatingSegments, mrk:AnimalHealthsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value147214181168122011011214112211221124102510361021109010659811000955939
Percentage of Revenues12.911.79.39.710.110.19.59.19.69.59.49.510.410.69.49.79.610.0
Percentage of Revenues12.911.79.39.710.110.19.59.19.69.59.49.510.410.69.49.79.610.0
Percentage of Revenues us-gaap:OperatingSegments mrk:AnimalHealthsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value99801067511367113209679106551053311095104609663983096589282891992899156875981858904944387008104902789258564826693709134
Percentage of Revenues87.588.490.890.289.088.488.889.588.989.389.489.588.788.989.088.788.286.888.089.688.487.088.488.687.587.789.486.5
Percentage of Revenues87.588.490.890.289.088.488.889.588.989.389.489.588.788.989.088.788.286.888.089.688.487.088.488.687.587.789.486.5
Percentage of Revenues us-gaap:OperatingSegments mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, us-gaap:AllOtherSegments


Revenuesus-gaap:
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value0.00.00.02342464839555556841031001011033-2477.0977979905108184691192911011321
Percentage of Revenues0.00.00.00.20.40.40.40.40.50.50.50.81.01.01.010.9-24.59.39.99.710.68.49.39.910.512.5
Percentage of Revenues0.00.00.00.20.40.40.40.40.50.50.50.81.01.01.010.9-24.59.39.99.710.68.49.39.910.512.5
Percentage of Revenues us-gaap:OperatingSegments us-gaap:AllOtherSegments0.00.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:Revenues us-gaap:ConsolidationItems, us-gaap:StatementGeographical

us-gaap:CorporateNonSegment, country:US


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value-6.058249.022166710.04.07.017205426117.08.057
Percentage of Revenues-0.10.50.20.10.20.10.60.10.00.10.20.20.50.30.10.10.10.6
Percentage of Revenues-0.10.50.20.10.20.10.60.10.00.10.20.20.50.30.10.10.10.6
Percentage of Revenues us-gaap:CorporateNonSegment country:US100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:CorporateNonSegment, mrk:International


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value-44.0-72.0-45.02.070149106125125826139-18.0-56.04963108159
Percentage of Revenues-0.4-0.6-0.40.00.61.20.91.01.10.80.60.4-0.2-0.60.50.61.11.7
Percentage of Revenues-0.4-0.6-0.40.00.61.20.91.01.10.80.60.4-0.2-0.60.50.61.11.7
Percentage of Revenues us-gaap:CorporateNonSegment mrk:International100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, country:US


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value510650785607561646125121507555155140450847705010418941074317458743004138
Percentage of Revenues44.842.044.844.742.442.542.844.543.741.743.446.440.040.941.444.443.343.9
Percentage of Revenues44.842.044.844.742.442.542.844.543.741.743.446.440.040.941.444.443.343.9
Percentage of Revenues us-gaap:OperatingSegments country:US100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:International


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value634570156928692461686771662067476491621961515725624059606056566955155080
Percentage of Revenues55.658.155.455.256.756.255.854.455.257.555.953.059.659.458.054.955.553.8
Percentage of Revenues55.658.155.455.256.756.255.854.455.257.555.953.059.659.458.054.955.553.8
Percentage of Revenues us-gaap:OperatingSegments mrk:International100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:Revenues us-gaap:ConsolidationItems, us-gaap:StatementGeographical, us-gaap:StatementBusinessSegments

us-gaap:OperatingSegments, country:US, mrk:AnimalHealthsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value459437360398342384340337335294314306311307248290270
Percentage of Revenues4.03.62.93.23.13.22.92.72.82.72.92.83.03.12.42.82.7
Percentage of Revenues4.03.62.93.23.13.22.92.72.82.72.92.83.03.12.42.82.7
Percentage of Revenues us-gaap:OperatingSegments country:US mrk:AnimalHealthsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, country:US, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value46474641524752184270471446945132475841754402464938223716396741973929
Percentage of Revenues40.838.441.941.639.339.139.641.440.538.640.043.136.537.038.040.639.6
Percentage of Revenues40.838.441.941.639.339.139.641.440.538.640.043.136.537.038.040.639.6
Percentage of Revenues us-gaap:OperatingSegments country:US mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, country:US, us-gaap:AllOtherSegments


Revenuesus-gaap:
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value0.00.00.0234146473954555684102100101
Percentage of Revenues0.00.00.00.20.30.40.40.40.50.50.50.81.01.01.0
Percentage of Revenues0.00.00.00.20.30.40.40.40.50.50.50.81.01.01.0
Percentage of Revenues us-gaap:OperatingSegments country:US us-gaap:AllOtherSegments0.00.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:International, mrk:AnimalHealthsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value1012981808822759830781785789731722715779758733710685
Percentage of Revenues8.98.16.56.57.06.96.66.36.76.86.66.67.47.67.06.96.9
Percentage of Revenues8.98.16.56.57.06.96.66.36.76.86.66.67.47.67.06.96.9
Percentage of Revenues us-gaap:OperatingSegments mrk:International mrk:AnimalHealthsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:OperatingSegments, mrk:International, mrk:Pharmaceuticalsegment


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value53336034612061025409594158395962570254885428501054615202532249594830
Percentage of Revenues46.850.048.948.649.849.349.248.148.550.749.446.452.251.851.048.048.6
Percentage of Revenues46.850.048.948.649.849.349.248.148.550.749.446.452.251.851.048.048.6
Percentage of Revenues us-gaap:OperatingSegments mrk:International mrk:Pharmaceuticalsegment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:Revenues us-gaap:CounterpartyName, us-gaap:IncomeStatementLocation, us-gaap:TypeOfArrangement

mrk:BayerAG, us-gaap:Sales, us-gaap:CollaborativeArrangement


Revenuesus-gaap:
Period End2021-06-302021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-31
Value14912913813610910710490
Percentage of Revenues1.31.11.11.30.90.90.90.8
Percentage of Revenues1.31.11.11.30.90.90.90.8
Percentage of Revenues mrk:BayerAG us-gaap:Sales us-gaap:CollaborativeArrangement100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:Revenues us-gaap:DerivativeInstrumentRisk, us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncome, us-gaap:StatementEquityComponents

us-gaap:ForeignExchangeContract, us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncome, us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterest


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value-71.0-112.0-71.0-23.042466670754412-6.0-73.0-93.0-19.01349
Percentage of Revenues-0.6-0.9-0.6-0.20.40.40.60.60.60.40.1-0.1-0.7-0.9-0.20.10.5
Percentage of Revenues-0.6-0.9-0.6-0.20.40.40.60.60.60.40.1-0.1-0.7-0.9-0.20.10.5
Percentage of Revenues us-gaap:ForeignExchangeContract us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncome us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:Revenues us-gaap:StatementGeographical

country:CN


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
Value9759279091016834864784914763746628512559486
Percentage of Revenues8.67.77.38.17.77.26.67.46.56.95.74.75.34.8
Percentage of Revenues8.67.77.38.17.77.26.67.46.56.95.74.75.34.8
Percentage of Revenues country:CN100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

country:JP


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value661730870828867811944919921799859761855737802775839705
Percentage of Revenues5.86.07.06.68.06.78.07.47.87.47.87.18.27.37.77.58.47.5
Percentage of Revenues5.86.07.06.68.06.78.07.47.87.47.87.18.27.37.77.58.47.5
Percentage of Revenues country:JP100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

country:US


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value510051365631562546345137514255255144451547875030424341334328459443084195
Percentage of Revenues44.742.545.044.842.642.643.344.643.741.743.546.640.541.241.544.543.444.5
Percentage of Revenues44.742.545.044.842.642.643.344.643.741.743.546.640.541.241.544.543.444.5
Percentage of Revenues country:US100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

mrk:International


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value630169436883692662386920672668726616630162125764622259046105573256235239
Percentage of Revenues55.357.555.055.257.457.456.755.456.358.356.553.459.558.858.555.556.655.5
Percentage of Revenues55.357.555.055.257.457.456.755.456.358.356.553.459.558.858.555.556.655.5
Percentage of Revenues mrk:International100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

mrk:OtherCountries


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value207238225289290427437423395347363319279206341318340419
Percentage of Revenues1.82.01.82.32.73.53.73.43.43.23.33.02.72.13.33.13.44.4
Percentage of Revenues1.82.01.82.32.73.53.73.43.43.23.33.02.72.13.33.13.44.4
Percentage of Revenues mrk:OtherCountries100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

srt:AsiaPacific


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value594751735735666728726756716745-857.011781350752-413.011121056
Percentage of Revenues5.26.25.95.96.16.06.16.16.16.9-7.810.912.97.5-4.010.810.6
Percentage of Revenues5.26.25.95.96.16.06.16.16.16.9-7.810.912.97.5-4.010.810.6
Percentage of Revenues srt:AsiaPacific100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

srt:LatinAmerica


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
Value532569604604510556580671658561667622594532685585583
Percentage of Revenues4.74.74.84.84.74.64.95.45.65.26.15.85.75.36.65.75.9
Percentage of Revenues4.74.74.84.84.74.64.95.45.65.26.15.85.75.36.65.75.9
Percentage of Revenues srt:LatinAmerica100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:EMEA


Revenuesus-gaap:
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value333337293541345430713534325531893163310329952884314431913104294128042629
Percentage of Revenues29.230.928.327.528.229.327.425.726.928.727.226.730.031.829.828.528.227.9
Percentage of Revenues29.230.928.327.528.229.327.425.726.928.727.226.730.031.829.828.528.227.9
Percentage of Revenues us-gaap:EMEA100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Selling General And Administrative Expense

us-gaap:SellingGeneralAndAdministrativeExpense

us-gaap:SellingGeneralAndAdministrativeExpense


Selling
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value2281263330852450237825552889258927122425264324432508250825792401243824112593239324582318261524722624260129252975297327342982280331402987339030633249307437043340352531643656319231753222
Percentage of SellingGeneralAndAdministrativeExpense100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues20.021.824.719.521.921.224.320.923.122.424.022.624.025.024.723.324.625.625.622.725.024.925.624.526.827.627.928.227.226.626.325.428.528.028.926.726.426.230.127.829.027.330.228.728.028.2

us-gaap:SellingGeneralAndAdministrativeExpense us-gaap:CounterpartyName, us-gaap:IncomeStatementLocation, us-gaap:TypeOfArrangement

mrk:AstraZeneca, us-gaap:SellingGeneralAndAdministrativeExpenses, us-gaap:CollaborativeArrangement


Selling
Period End2021-06-302021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-31
Value4340403933363327
Percentage of SellingGeneralAndAdministrativeExpense1.91.51.61.61.31.41.21.1
Percentage of Revenues0.40.30.30.40.30.30.30.2
Percentage of Revenues mrk:AstraZeneca us-gaap:SellingGeneralAndAdministrativeExpenses us-gaap:CollaborativeArrangement0.00.00.00.00.00.00.00.0

mrk:BayerAG, us-gaap:SellingGeneralAndAdministrativeExpenses, us-gaap:CollaborativeArrangement


Selling
Period End2021-06-302021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-31
Value323219171512118.0
Percentage of SellingGeneralAndAdministrativeExpense1.41.20.80.70.60.50.40.3
Percentage of Revenues0.30.30.20.20.10.10.10.1
Percentage of Revenues mrk:BayerAG us-gaap:SellingGeneralAndAdministrativeExpenses us-gaap:CollaborativeArrangement0.00.00.00.00.00.00.00.0

mrk:Eisai, us-gaap:SellingGeneralAndAdministrativeExpenses, us-gaap:CollaborativeArrangement


Selling
Period End2021-06-302021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-31
Value3123181911211919
Percentage of SellingGeneralAndAdministrativeExpense1.40.90.70.80.40.80.70.8
Percentage of Revenues0.30.20.10.20.10.20.20.2
Percentage of Revenues mrk:Eisai us-gaap:SellingGeneralAndAdministrativeExpenses us-gaap:CollaborativeArrangement0.00.00.00.00.00.00.00.0

Assets

us-gaap:Assets

us-gaap:Assets


Assets
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-31
Value906889084791588898009061584913843978333183965823548263785130850408604187872916769280496561953779833596475987551017791012321025821083459833510180897860108460105645106419106876106200106132106301105525105509105128106534106195105865105781112314
Percentage of Assets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Liabilities

us-gaap:Liabilities us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement

us-gaap:Liabilities

mrk:AstraZeneca, mrk:Lynparza, mrk:SalesBasedMilestones


Liabilitiesus-gaap:
Period End2020-12-312020-06-302019-12-312019-06-302018-12-31
Value400400300300600
Percentage of Liabilities100.0100.0100.0100.0100.0
Percentage of Assets0.40.40.40.40.7
Percentage of Assets mrk:AstraZeneca mrk:Lynparza mrk:SalesBasedMilestones0.00.00.00.00.0

mrk:Eisai, mrk:Lenvima, mrk:SalesBasedMilestones


Liabilitiesus-gaap:
Period End2020-12-312020-06-302019-12-312019-03-312018-12-31
Value400370682282268
Percentage of Liabilities100.092.5227.30.044.7
Percentage of Assets0.40.40.80.30.3
Percentage of Assets mrk:Eisai mrk:Lenvima mrk:SalesBasedMilestones0.00.00.00.00.0

us-gaap:Liabilities us-gaap:CounterpartyName, us-gaap:SubsequentEventType, us-gaap:TypeOfArrangement

mrk:BayerAG, us-gaap:SubsequentEvent, mrk:SalesBasedMilestones


Liabilitiesus-gaap:
Period End2021-01-31
Value400
Percentage of Liabilities0.0
Percentage of Assets0.0
Percentage of Assets mrk:BayerAG us-gaap:SubsequentEvent mrk:SalesBasedMilestones0.0

Liabilities And Stockholders Equity

us-gaap:LiabilitiesAndStockholdersEquity

us-gaap:LiabilitiesAndStockholdersEquity


Liabilities
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-31
Value906889084791588898009061584913843978333183965823548263785130850408604187872916769280496561953779833596475987551017791012321025821083459833510180897860108460105645106419106876106200106132106301105525105509105128106534106195105865105781112314
Percentage of LiabilitiesAndStockholdersEquity100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Stockholders Equity

us-gaap:StockholdersEquity

us-gaap:StockholdersEquity


Stockholders
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-31
Value3329426945253172918627642262052590726838276352753926701324223252933668343363824839463398374008843744433574380644676455874644847765486474522448358499754976547419475005302953020557475519454860545175514055496543845437659058
Percentage of StockholdersEquity100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets36.729.727.632.530.530.930.732.232.933.432.338.138.339.139.141.742.541.342.044.544.944.443.945.045.344.149.544.449.446.147.144.644.449.950.052.452.352.051.951.852.351.451.452.6

Assets Current

us-gaap:AssetsCurrent

us-gaap:AssetsCurrent


Assets
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-31
Value2866526909277642657729343261742748326142242982535125875268362406424085247662791928167315303061429440279262877229764285672831932927331733472333587412403568537765369953524434857362293563934344331813410932368310242906428432
Percentage of AssetsCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets31.629.630.329.632.430.832.631.428.930.831.331.528.328.028.230.530.432.732.129.928.929.129.228.227.630.433.734.134.338.033.835.534.633.232.834.133.832.631.632.030.529.327.525.3

Cash And Cash Equivalents At Carrying Value

us-gaap:CashAndCashEquivalentsAtCarryingValue

us-gaap:CashAndCashEquivalentsAtCarryingValue


Cash
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312008-12-312007-12-31
Value857569818062735611103742596767869665980767965782653104483609279017786117086515790766089700852475486922798074411137097431582815621140901509013024134511736016752146561353114253123421169510900987486668236931143685336
Percentage of CashAndCashEquivalentsAtCarryingValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets9.57.78.88.212.38.711.59.47.99.89.69.26.25.26.98.68.412.16.88.06.89.88.47.56.77.47.611.210.014.614.813.214.112.312.716.315.913.912.913.411.611.010.30.00.00.08.30.00.0

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents


Cash
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312015-12-31
Value8630702381657401111477460993478716660807779677828531244866096790177861170865158524
Percentage of CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets9.57.78.98.212.38.811.89.47.99.89.69.26.25.26.98.68.412.16.88.4

Accounts Receivable Net Current

us-gaap:AccountsReceivableNetCurrent

us-gaap:AccountsReceivableNetCurrent


Accounts
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302010-12-31
Value784382357851842275778182677884427964760870717374728772456873767174397066701873646916685064846414651066706626651570227188718475787779796576727952815287268261813684757344
Percentage of AccountsReceivableNetCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets8.69.18.69.48.49.68.010.19.59.28.68.78.68.47.88.48.07.37.47.57.26.96.46.36.36.26.76.47.26.66.87.17.37.57.27.57.78.37.97.68.06.9

Receivables Net Current

us-gaap:ReceivablesNetCurrent us-gaap:CounterpartyName, us-gaap:BalanceSheetLocation, us-gaap:TypeOfArrangement

us-gaap:ReceivablesNetCurrent

mrk:AstraZeneca, us-gaap:OtherCurrentAssets, us-gaap:CollaborativeArrangement


Receivables
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-31
Value258236215197168142128
Percentage of ReceivablesNetCurrent100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.30.30.20.20.20.20.2
Percentage of Assets mrk:AstraZeneca us-gaap:OtherCurrentAssets us-gaap:CollaborativeArrangement0.00.00.00.00.00.00.0

mrk:BayerAG, us-gaap:OtherCurrentAssets, us-gaap:CollaborativeArrangement


Receivables
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-31
Value65686570625049
Percentage of ReceivablesNetCurrent25.228.830.235.536.935.238.3
Percentage of Assets0.10.10.10.10.10.10.1
Percentage of Assets mrk:BayerAG us-gaap:OtherCurrentAssets us-gaap:CollaborativeArrangement0.00.00.00.00.00.00.0

mrk:Eisai, us-gaap:OtherCurrentAssets, us-gaap:CollaborativeArrangement


Receivables
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-31
Value212153157170173140150
Percentage of ReceivablesNetCurrent82.264.873.086.3103.098.6117.2
Percentage of Assets0.20.20.20.20.20.20.2
Percentage of Assets mrk:Eisai us-gaap:OtherCurrentAssets us-gaap:CollaborativeArrangement0.00.00.00.00.00.00.0

Inventory Net

us-gaap:InventoryNet

us-gaap:InventoryNet


Inventory
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-31
Value54996402631061286056584659785855584757125440541651785382509652635407514648665244524851024700512353065539557158196136637662266741676667736535673162496339625462396225605758688048
Percentage of InventoryNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets6.17.06.96.86.76.97.17.07.06.96.66.46.16.35.85.75.85.35.15.35.45.24.65.15.25.15.75.76.35.95.96.36.36.46.26.35.96.05.95.95.95.75.57.2

Inventory Finished Goods

us-gaap:InventoryFinishedGoods

us-gaap:InventoryFinishedGoods


Inventory
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-31
Value17782015196320382032175317721698175016981658158515191530133413641396135513041421143714171343152814971698158818112125164217381757221420551924195218081779198316401440138414842466
Percentage of InventoryFinishedGoods100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets2.02.22.12.32.22.12.12.02.12.12.01.91.81.81.51.51.51.41.41.41.51.41.31.51.51.61.61.82.21.51.61.72.11.91.81.81.71.71.91.51.41.31.42.2

Inventory L I F O Reserve

us-gaap:InventoryLIFOReserve

us-gaap:InventoryLIFOReserve


Inventory
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-31
Value-4.028829911913817167296.0-1.010.0-11.0-25.0-45.0-142.0-258.0-275.0-302.0-320.0-357.0-375.0-384.0-366.0-346.0-334.0-309.0-220.0-169.0-116.0-73.0-52.0-49.0-47.0-52.010.0397843112141170186167
Percentage of InventoryLIFOReserve100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets-0.00.00.10.10.10.20.20.10.00.0-0.00.0-0.0-0.0-0.1-0.2-0.3-0.3-0.3-0.3-0.4-0.4-0.4-0.4-0.3-0.3-0.3-0.2-0.2-0.1-0.1-0.0-0.0-0.0-0.00.00.00.10.00.10.10.20.20.1

Other Assets Current

us-gaap:OtherAssetsCurrent

us-gaap:OtherAssetsCurrent


Other
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312011-03-312010-12-312009-12-31
Value5541427745004299438951534689398336514177
Percentage of OtherAssetsCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets6.05.15.44.94.65.14.83.83.53.7

Land

us-gaap:Land

us-gaap:Land


Land
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-31
Value350343333365412490541550591623658667
Percentage of Land100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.40.40.40.40.40.50.60.50.60.60.60.6

Machinery And Equipment Gross

us-gaap:MachineryAndEquipmentGross

us-gaap:MachineryAndEquipmentGross


Machinery
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-31
Value166491539414441146491405314261160501710617188169191589416158
Percentage of MachineryAndEquipmentGross100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets18.218.217.516.714.714.016.316.216.216.115.014.4

Property Plant And Equipment Gross

us-gaap:PropertyPlantAndEquipmentGross

us-gaap:PropertyPlantAndEquipmentGross


Property
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-31
Value369683273929615290412777528430311403309433415324733056330874
Percentage of PropertyPlantAndEquipmentGross100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets40.438.835.833.029.127.931.731.331.530.928.927.5

Construction In Progress Gross

us-gaap:ConstructionInProgressGross

us-gaap:ConstructionInProgressGross


Construction
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-31
Value732450133355230118711525144818112440219820661818
Percentage of ConstructionInProgressGross100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets8.05.94.12.62.01.51.51.72.32.12.01.6

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment

us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment


Accumulated
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-31
Value1823618732189821857218182177061768617281170491662316324165681656716483166021666116375161711574916022160051605215923160431630616794180041876118866186221812117805175941762217385174751704916697161761567415195145151348112595
Percentage of AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets20.120.620.720.720.120.921.020.720.320.219.819.519.519.218.918.217.616.716.516.316.616.315.615.815.915.518.318.419.317.217.216.716.516.616.416.416.215.815.414.714.313.712.711.2

Property Plant And Equipment Net

us-gaap:PropertyPlantAndEquipmentNet

us-gaap:PropertyPlantAndEquipmentNet


Property
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-312008-12-31
Value180641829517986169191578915269150531428713862135061329112755126261256112439121891209412042120261202911987123601250712482126301291013136134381389314296149731532315683158021603015884158671612416297163831667116833170821827912000
Percentage of PropertyPlantAndEquipmentNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets19.920.119.618.817.418.017.817.116.516.416.115.014.814.614.213.313.012.512.612.212.412.512.312.312.311.913.413.214.213.214.214.414.714.915.114.915.015.315.515.415.715.916.116.30.0

us-gaap:PropertyPlantAndEquipmentNet us-gaap:StatementGeographical

country:CN


Property
Period End2020-12-312019-12-312018-12-312017-12-312016-12-31
Value217174167150152
Percentage of PropertyPlantAndEquipmentNet1.21.21.31.21.3
Percentage of Assets0.20.20.20.20.2
Percentage of Assets country:CN0.00.00.00.00.0

country:JP


Property
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Value166152159158164164172211
Percentage of PropertyPlantAndEquipmentNet0.91.01.21.31.41.31.31.4
Percentage of Assets0.20.20.20.20.20.20.20.2
Percentage of Assets country:JP0.00.00.00.00.00.00.00.0

country:US


Property
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Value1052689748306807081148467872710076
Percentage of PropertyPlantAndEquipmentNet58.559.662.564.967.567.766.467.3
Percentage of Assets11.510.610.19.28.58.38.99.5
Percentage of Assets country:US0.00.00.00.00.00.00.00.0

mrk:OtherCountries


Property
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Value5.06.05.07.07.08.01397
Percentage of PropertyPlantAndEquipmentNet0.00.00.00.10.10.10.10.6
Percentage of Assets0.00.00.00.00.00.00.00.1
Percentage of Assets mrk:OtherCountries0.00.00.00.00.00.00.00.0

srt:AsiaPacific


Property
Period End2020-12-312019-12-312018-12-312017-12-312016-12-31
Value761714684632623
Percentage of PropertyPlantAndEquipmentNet4.24.75.15.15.2
Percentage of Assets0.80.80.80.70.7
Percentage of Assets srt:AsiaPacific0.00.00.00.00.0

srt:LatinAmerica


Property
Period End2020-12-312019-12-312018-12-312017-12-312016-12-31
Value252266264271234
Percentage of PropertyPlantAndEquipmentNet1.41.82.02.21.9
Percentage of Assets0.30.30.30.30.2
Percentage of Assets srt:LatinAmerica0.00.00.00.00.0

us-gaap:EMEA


Property
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Value60594767370631512732284431203346
Percentage of PropertyPlantAndEquipmentNet33.731.727.925.322.722.723.822.3
Percentage of Assets6.65.64.53.62.92.83.23.2
Percentage of Assets us-gaap:EMEA0.00.00.00.00.00.00.00.0

Goodwill

us-gaap:Goodwill

us-gaap:Goodwill


Goodwill
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-312008-12-31
Value18873202122023820248200671976719425194801949018170182531825818274183041828418340183581835818162182601780917784177231776117707177401299213171117891212012301121211219812207121341216812158121561215512228123821220712378120381439
Percentage of Goodwill100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets20.822.222.122.522.123.323.023.423.222.122.121.421.521.320.820.019.819.019.018.618.518.017.417.517.316.413.212.912.011.211.611.411.411.511.411.411.511.511.611.511.711.511.710.70.0

us-gaap:Goodwill us-gaap:StatementBusinessSegments

mrk:AnimalHealthsegment


Goodwillus-gaap:
Period End2020-12-312019-12-312018-12-312017-12-312016-12-31
Value32683192187018771708
Percentage of Goodwill16.116.410.210.39.4
Percentage of Assets3.63.82.32.11.8
Percentage of Assets mrk:AnimalHealthsegment0.00.00.00.00.0

mrk:Pharmaceuticalsegment


Goodwillus-gaap:
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-31
Value16970161811616216066160751586211108100651008610107
Percentage of Goodwill83.983.388.587.988.589.585.581.883.183.2
Percentage of Assets18.519.219.618.316.915.611.39.59.59.6
Percentage of Assets mrk:Pharmaceuticalsegment0.00.00.00.00.00.00.00.00.00.0

Intangible Assets Net Excluding Goodwill

us-gaap:IntangibleAssetsNetExcludingGoodwill

us-gaap:IntangibleAssetsNetExcludingGoodwill


Intangible
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-31
Value1362214401146041667716566160961419612307133811099911431121751289813500141831513816119168631730520506203152136422602237242475026080203862039518830205172380125002263332810829083303253162033000343023582237065379063945647757
Percentage of IntangibleAssetsNetExcludingGoodwill100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets15.015.915.918.618.319.016.814.815.913.413.814.315.215.716.116.517.417.518.120.921.121.622.223.424.124.120.720.019.218.922.523.524.626.527.428.530.031.332.633.634.935.837.342.5

us-gaap:IntangibleAssetsNetExcludingGoodwill us-gaap:BusinessAcquisition, us-gaap:FiniteLivedIntangibleAssetsByMajorClass

mrk:Antelliq, us-gaap:TradeNames


Intangible
Period End2020-12-31
Value2500
Percentage of IntangibleAssetsNetExcludingGoodwill17.1
Percentage of Assets2.7
Percentage of Assets mrk:Antelliq us-gaap:TradeNames0.0

us-gaap:IntangibleAssetsNetExcludingGoodwill us-gaap:FiniteLivedIntangibleAssetsByMajorClass

us-gaap:DevelopedTechnologyRights


Intangible
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
Value516270959030117431435017435148842047525254
Percentage of IntangibleAssetsNetExcludingGoodwill35.350.079.082.882.977.173.086.086.8
Percentage of Assets5.68.410.913.415.017.115.119.423.8
Percentage of Assets us-gaap:DevelopedTechnologyRights0.00.00.00.00.00.00.00.00.0

us-gaap:License


Intangible
Period End2020-12-312019-12-312018-12-31
Value279023611673
Percentage of IntangibleAssetsNetExcludingGoodwill19.116.614.6
Percentage of Assets3.02.82.0
Percentage of Assets us-gaap:License0.00.00.0

us-gaap:OtherIntangibleAssets


Intangible
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
Value89410261235113411768221030148151
Percentage of IntangibleAssetsNetExcludingGoodwill6.17.210.88.06.83.65.10.60.5
Percentage of Assets1.01.21.51.31.20.81.00.10.1
Percentage of Assets us-gaap:OtherIntangibleAssets0.00.00.00.00.00.00.00.00.0

us-gaap:TradeNames


Intangible
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-31
Value253026821021121261191271322128513531442
Percentage of IntangibleAssetsNetExcludingGoodwill17.318.90.90.80.70.50.65.64.43.93.7
Percentage of Assets2.83.20.10.10.10.10.11.31.21.31.4
Percentage of Assets us-gaap:TradeNames0.00.00.00.00.00.00.00.00.00.00.0

us-gaap:IntangibleAssetsNetExcludingGoodwill us-gaap:IndefiniteLivedIntangibleAssetsByMajorClass

us-gaap:InProcessResearchAndDevelopment


Intangible
Period End2020-12-312019-12-312018-12-312017-12-312016-12-31
Value32281032106411941653
Percentage of IntangibleAssetsNetExcludingGoodwill22.17.39.38.49.6
Percentage of Assets3.51.21.31.41.7
Percentage of Assets us-gaap:InProcessResearchAndDevelopment0.00.00.00.00.0

us-gaap:IntangibleAssetsNetExcludingGoodwill us-gaap:ProductOrService

mrk:AnimalHealth


Intangible
Period End2020-12-31
Value5400
Percentage of IntangibleAssetsNetExcludingGoodwill37.0
Percentage of Assets5.9
Percentage of Assets mrk:AnimalHealth0.0

us-gaap:IntangibleAssetsNetExcludingGoodwill us-gaap:ProductOrService, us-gaap:FiniteLivedIntangibleAssetsByMajorClass

mrk:Bridion, us-gaap:DevelopedTechnologyRights


Intangible
Period End2020-12-312019-12-31
Value185230
Percentage of IntangibleAssetsNetExcludingGoodwill1.31.6
Percentage of Assets0.20.3
Percentage of Assets mrk:Bridion us-gaap:DevelopedTechnologyRights0.00.0

mrk:Dificid, us-gaap:DevelopedTechnologyRights


Intangible
Period End2020-12-312019-12-31
Value228312
Percentage of IntangibleAssetsNetExcludingGoodwill1.62.2
Percentage of Assets0.20.4
Percentage of Assets mrk:Dificid us-gaap:DevelopedTechnologyRights0.00.0

mrk:GardasilGardasil9, us-gaap:DevelopedTechnologyRights


Intangible
Period End2020-12-312019-12-31
Value276314
Percentage of IntangibleAssetsNetExcludingGoodwill1.92.2
Percentage of Assets0.30.4
Percentage of Assets mrk:GardasilGardasil9 us-gaap:DevelopedTechnologyRights0.00.0

mrk:ImplanonNexplanon, us-gaap:DevelopedTechnologyRights


Intangible
Period End2020-12-312019-12-31
Value354412
Percentage of IntangibleAssetsNetExcludingGoodwill2.42.9
Percentage of Assets0.40.5
Percentage of Assets mrk:ImplanonNexplanon us-gaap:DevelopedTechnologyRights0.00.0

mrk:Lenvima, us-gaap:License


Intangible
Period End2020-12-312019-12-31
Value1100956
Percentage of IntangibleAssetsNetExcludingGoodwill7.56.7
Percentage of Assets1.21.1
Percentage of Assets mrk:Lenvima us-gaap:License0.00.0

mrk:Lynparza, us-gaap:License


Intangible
Period End2020-12-312019-12-31
Value1300955
Percentage of IntangibleAssetsNetExcludingGoodwill8.96.7
Percentage of Assets1.41.1
Percentage of Assets mrk:Lynparza us-gaap:License0.00.0

mrk:Simponi, us-gaap:DevelopedTechnologyRights


Intangible
Period End2020-12-312019-12-31
Value132163
Percentage of IntangibleAssetsNetExcludingGoodwill0.91.1
Percentage of Assets0.10.2
Percentage of Assets mrk:Simponi us-gaap:DevelopedTechnologyRights0.00.0

mrk:Sivextro, us-gaap:DevelopedTechnologyRights


Intangible
Period End2020-12-312019-12-31
Value154171
Percentage of IntangibleAssetsNetExcludingGoodwill1.11.2
Percentage of Assets0.20.2
Percentage of Assets mrk:Sivextro us-gaap:DevelopedTechnologyRights0.00.0

mrk:Zerbaxa, us-gaap:DevelopedTechnologyRights


Intangible
Period End2020-12-312019-12-31
Value5512400
Percentage of IntangibleAssetsNetExcludingGoodwill3.816.9
Percentage of Assets0.62.8
Percentage of Assets mrk:Zerbaxa us-gaap:DevelopedTechnologyRights0.00.0

Finite Lived Intangible Assets Net

us-gaap:FiniteLivedIntangibleAssetsNet us-gaap:ProductOrService, us-gaap:BalanceSheetLocation

us-gaap:FiniteLivedIntangibleAssetsNet

mrk:Adempas, us-gaap:OtherIntangibleAssets


Finite
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
Value9209468498388328448838939569771000
Percentage of FiniteLivedIntangibleAssetsNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets1.01.00.90.90.91.01.01.11.11.21.2
Percentage of Assets mrk:Adempas us-gaap:OtherIntangibleAssets0.00.00.00.00.00.00.00.00.00.00.0

mrk:Lenvima, us-gaap:OtherNoncurrentAssets


Finite
Period End2021-06-302021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value1000100011001200921664687711479266
Percentage of FiniteLivedIntangibleAssetsNet108.7105.7131.3144.2109.174.471.972.847.90.0
Percentage of Assets1.11.11.21.31.10.80.80.90.60.3
Percentage of Assets mrk:Lenvima us-gaap:OtherNoncurrentAssets0.00.00.00.00.00.00.00.00.00.0

mrk:Lynparza, us-gaap:OtherNoncurrentAssets


Finite
Period End2021-06-302021-03-312020-09-302020-06-302020-03-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value12001200130013009289831000724743468
Percentage of FiniteLivedIntangibleAssetsNet130.4126.8155.1156.2110.0110.1104.674.174.30.0
Percentage of Assets1.31.31.41.41.11.21.20.90.90.5
Percentage of Assets mrk:Lynparza us-gaap:OtherNoncurrentAssets0.00.00.00.00.00.00.00.00.00.0

mrk:Verquvo, us-gaap:OtherIntangibleAssets


Finite
Period End2021-06-302021-03-31
Value7576
Percentage of FiniteLivedIntangibleAssetsNet8.28.0
Percentage of Assets0.10.1
Percentage of Assets mrk:Verquvo us-gaap:OtherIntangibleAssets0.00.0

Operating Lease Right Of Use Asset

us-gaap:OperatingLeaseRightOfUseAsset

us-gaap:OperatingLeaseRightOfUseAsset


Operating
Period End2020-12-312019-12-312019-09-302019-06-302019-03-31
Value17251073108510631096
Percentage of OperatingLeaseRightOfUseAsset100.0100.0100.0100.0100.0
Percentage of Assets1.91.31.31.31.3

Other Assets Noncurrent

us-gaap:OtherAssetsNoncurrent us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency

us-gaap:OtherAssetsNoncurrent

us-gaap:FairValueInputsLevel1, us-gaap:FairValueMeasurementsRecurring


Other
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302015-12-31
Value125611391091181132281380546586483364236275232171171163158148161155155
Percentage of OtherAssetsNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets1.41.31.20.20.10.30.50.70.70.60.40.30.30.30.20.20.20.20.20.20.20.2
Percentage of Assets us-gaap:FairValueInputsLevel1 us-gaap:FairValueMeasurementsRecurring0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:OtherAssetsNoncurrent us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument

us-gaap:FairValueInputsLevel1, us-gaap:FairValueMeasurementsRecurring, us-gaap:CorporateDebtSecurities


Other
Period End2021-06-302021-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Value4.04.00.00.00.00.00.00.00.00.00.0
Percentage of OtherAssetsNoncurrent0.30.40.00.00.00.00.00.00.00.00.0
Percentage of Assets0.00.00.00.00.00.00.00.00.00.00.0
Percentage of Assets us-gaap:FairValueInputsLevel1 us-gaap:FairValueMeasurementsRecurring us-gaap:CorporateDebtSecurities0.00.00.00.00.00.00.00.00.00.00.0

us-gaap:FairValueInputsLevel1, us-gaap:FairValueMeasurementsRecurring, us-gaap:EquitySecurities


Other
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Value11701054100710758219320485528427309182211168171
Percentage of OtherAssetsNoncurrent93.292.592.359.143.977.984.288.890.188.484.977.176.772.4100.0
Percentage of Assets1.31.21.10.10.10.30.40.60.60.50.40.20.20.20.2
Percentage of Assets us-gaap:FairValueInputsLevel1 us-gaap:FairValueMeasurementsRecurring us-gaap:EquitySecurities0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:FairValueInputsLevel1, us-gaap:FairValueMeasurementsRecurring, us-gaap:USGovernmentAgenciesDebtSecurities


Other
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Value82818474746260615856555464640.0
Percentage of OtherAssetsNoncurrent6.57.17.740.956.122.115.811.29.911.615.122.923.327.60.0
Percentage of Assets0.10.10.10.10.10.10.10.10.10.10.10.10.10.10.0
Percentage of Assets us-gaap:FairValueInputsLevel1 us-gaap:FairValueMeasurementsRecurring us-gaap:USGovernmentAgenciesDebtSecurities0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:OtherAssetsNoncurrent us-gaap:FairValueByMeasurementFrequency

us-gaap:FairValueMeasurementsRecurring


Other
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302015-12-31
Value12561139109118113228138054665463658548964564265273482083093710451014174
Percentage of OtherAssetsNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0111.6131.7160.7207.2234.5276.7381.3429.2503.1525.3633.1649.1654.2112.3
Percentage of Assets1.41.31.20.20.10.30.50.70.80.80.70.60.80.70.70.80.90.91.01.11.10.2
Percentage of Assets us-gaap:FairValueMeasurementsRecurring0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:OtherAssetsNoncurrent us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument

us-gaap:FairValueMeasurementsRecurring, us-gaap:CorporateDebtSecurities


Other
Period End2021-06-302021-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Value4.04.00.00.040798510198119128
Percentage of OtherAssetsNoncurrent0.30.40.00.06.816.423.442.835.651.374.9
Percentage of Assets0.00.00.00.00.00.10.10.10.10.10.1
Percentage of Assets us-gaap:FairValueMeasurementsRecurring us-gaap:CorporateDebtSecurities0.00.00.00.00.00.00.00.00.00.00.0

us-gaap:FairValueMeasurementsRecurring, us-gaap:EquitySecurities


Other
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Value11701054100710758219320485528427309182211168171
Percentage of OtherAssetsNoncurrent93.292.592.359.143.977.984.288.890.188.484.977.176.772.4100.0
Percentage of Assets1.31.21.10.10.10.30.40.60.60.50.40.20.20.20.2
Percentage of Assets us-gaap:FairValueMeasurementsRecurring us-gaap:EquitySecurities0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:FairValueMeasurementsRecurring, us-gaap:USGovernmentAgenciesDebtSecurities


Other
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
Value82818474746260617797161166224225207
Percentage of OtherAssetsNoncurrent6.57.17.740.956.122.115.811.213.120.144.270.381.597.0121.1
Percentage of Assets0.10.10.10.10.10.10.10.10.10.10.20.20.30.30.2
Percentage of Assets us-gaap:FairValueMeasurementsRecurring us-gaap:USGovernmentAgenciesDebtSecurities0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Equity Securities Fv Ni

us-gaap:EquitySecuritiesFvNi

us-gaap:EquitySecuritiesFvNi


Equity
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-30
Value15791596178714771307779838691756636456378375
Percentage of EquitySecuritiesFvNi100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets1.71.82.01.61.40.91.00.80.90.80.60.40.4

us-gaap:EquitySecuritiesFvNi us-gaap:FairValueByFairValueHierarchyLevel, us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument

us-gaap:FairValueInputsLevel1, us-gaap:FairValueMeasurementsRecurring, us-gaap:EquitySecurities


Equity
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302017-12-31
Value40954278013701249560518206228209147196164104
Percentage of EquitySecuritiesFvNi25.934.043.692.895.671.961.829.830.232.932.251.943.70.0
Percentage of Assets0.50.60.91.51.40.70.60.20.30.30.20.20.20.1
Percentage of Assets us-gaap:FairValueInputsLevel1 us-gaap:FairValueMeasurementsRecurring us-gaap:EquitySecurities0.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:EquitySecuritiesFvNi us-gaap:FairValueByMeasurementFrequency, us-gaap:FinancialInstrument

us-gaap:FairValueMeasurementsRecurring, us-gaap:EquitySecurities


Equity
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302017-12-31
Value40954278013701249560518206228209147196164104
Percentage of EquitySecuritiesFvNi25.934.043.692.895.671.961.829.830.232.932.251.943.70.0
Percentage of Assets0.50.60.91.51.40.70.60.20.30.30.20.20.20.1
Percentage of Assets us-gaap:FairValueMeasurementsRecurring us-gaap:EquitySecurities0.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Accounts Payable Current

us-gaap:AccountsPayableCurrent

us-gaap:AccountsPayableCurrent


Accounts
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-31
Value38974034459437443448357237383198314230183318309130243162310226202934248428072481251422412533202323352091262522792326243422742469225320841753180416742358246222822143240223082244
Percentage of AccountsPayableCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets4.34.45.04.23.84.24.43.83.73.74.03.63.63.73.52.93.22.62.92.52.62.32.52.02.31.92.72.22.42.22.22.32.12.01.71.71.62.22.32.12.02.32.22.0

Accrued Income Taxes Current

us-gaap:AccruedIncomeTaxesCurrent

us-gaap:AccruedIncomeTaxesCurrent


Accrued
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-31
Value9711490157598412661033736873634807197175966171770839619792330223912081213186415602119187824501606246719259525112984091075120015121091119078114621174132612431167
Percentage of AccruedIncomeTaxesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets1.11.61.71.11.41.20.91.00.81.02.40.90.80.80.80.42.12.42.31.21.31.91.52.11.82.31.62.40.20.50.21.20.41.01.11.41.01.10.71.41.11.31.21.0

Debt Current

us-gaap:DebtCurrent

us-gaap:DebtCurrent


Debt
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-31
Value248872516431242047186361361034113816317553083656337920553057515731815037568148764421132585254324834728270492754477855945213976558247364315202939222930199024552523220224001379
Percentage of DebtCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets2.78.07.02.75.27.54.34.14.53.96.44.34.02.43.55.63.45.20.61.50.72.12.52.52.44.42.79.14.67.94.33.75.24.54.11.93.72.81.92.32.42.12.31.2

us-gaap:DebtCurrent us-gaap:ShortTermDebtType

mrk:NotesSubjectToRepaymentAtOptionOfHolder


Debt
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
Value7322614973267226143370328
Percentage of DebtCurrent1.16.32.82.447.08.75.38.27.6
Percentage of Assets0.10.30.20.10.30.20.10.40.3
Percentage of Assets mrk:NotesSubjectToRepaymentAtOptionOfHolder0.00.00.00.00.00.00.00.00.0

us-gaap:CommercialPaper


Debt
Period End2020-12-312019-12-312018-12-312014-12-312013-12-312012-12-31
Value400014005100150016001700
Percentage of DebtCurrent62.238.896.155.535.439.4
Percentage of Assets4.41.76.21.51.51.6
Percentage of Assets us-gaap:CommercialPaper0.00.00.00.00.00.0

Dividends Payable Current

us-gaap:DividendsPayableCurrent

us-gaap:DividendsPayableCurrent


Dividends
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-31
Value16621675167415671564158515871434143914621458130413091317132013021301131413161292129213071309128812951306130812881303132713211289128613381343131513081281128111661176117711761189
Percentage of DividendsPayableCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets1.81.81.81.71.71.91.91.71.71.81.81.51.51.51.51.41.41.41.41.31.31.31.31.31.31.21.31.31.31.21.31.21.21.31.31.21.21.21.21.11.11.11.11.1

Liabilities Current

us-gaap:LiabilitiesCurrent

us-gaap:LiabilitiesCurrent


Liabilities
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-31
Value2190626361273272040522178234832222020684200851854322206185861812816960186141946718758198231720415555149181756819203175831750820442187662592717928224701786818215184021880218348155831691216582162451659315763156621564115641
Percentage of LiabilitiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets24.229.029.822.724.527.726.324.823.922.526.921.821.319.721.221.220.220.518.015.815.517.818.917.417.118.919.125.518.320.716.917.117.217.717.314.716.015.715.515.614.814.814.813.9

us-gaap:LiabilitiesCurrent us-gaap:CounterpartyName, us-gaap:BalanceSheetLocation, us-gaap:TypeOfArrangement

mrk:AstraZeneca, us-gaap:AccountsPayableAndAccruedLiabilities, us-gaap:CollaborativeArrangement


Liabilities
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-31
Value418417423309324326577
Percentage of LiabilitiesCurrent1.91.61.51.51.51.42.6
Percentage of Assets0.50.50.50.30.40.40.7
Percentage of Assets mrk:AstraZeneca us-gaap:AccountsPayableAndAccruedLiabilities us-gaap:CollaborativeArrangement0.00.00.00.00.00.00.0

mrk:Eisai, us-gaap:AccountsPayableAndAccruedLiabilities, us-gaap:CollaborativeArrangement


Liabilities
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-31
Value600300335325325425700
Percentage of LiabilitiesCurrent2.71.11.21.61.51.83.2
Percentage of Assets0.70.30.40.40.40.50.8
Percentage of Assets mrk:Eisai us-gaap:AccountsPayableAndAccruedLiabilities us-gaap:CollaborativeArrangement0.00.00.00.00.00.00.0

Long Term Debt Current

us-gaap:LongTermDebtCurrent

us-gaap:LongTermDebtCurrent


Long
Period End2020-12-312019-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
Value2300190030003002300100021001800
Percentage of LongTermDebtCurrent100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets2.52.33.40.32.31.02.01.7

Operating Lease Liability Current

us-gaap:OperatingLeaseLiabilityCurrent

us-gaap:OperatingLeaseLiabilityCurrent


Operating
Period End2020-12-312019-12-31
Value300236
Percentage of OperatingLeaseLiabilityCurrent100.0100.0
Percentage of Assets0.30.3

Other Liabilities Current

us-gaap:OtherLiabilitiesCurrent

us-gaap:OtherLiabilitiesCurrent


Other
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302010-12-31
Value1288811911130531169011182109321254911768110541008110151977697559709104279992936386581027490879255100431121696109517986710523980888298707950191838872956997378923891788239731922887478514
Percentage of OtherLiabilitiesCurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets14.213.114.313.012.312.914.914.113.212.212.311.511.511.311.910.910.19.010.89.29.610.211.09.59.39.110.79.69.08.09.08.68.39.09.28.48.58.49.38.78.28.0

Liabilities Noncurrent

us-gaap:LiabilitiesNoncurrent us-gaap:CounterpartyName, us-gaap:BalanceSheetLocation, us-gaap:TypeOfArrangement

us-gaap:LiabilitiesNoncurrent

mrk:AstraZeneca, us-gaap:AccountsPayableAndAccruedLiabilities, us-gaap:CollaborativeArrangement


Liabilities
Period End2020-09-302020-06-302019-12-31
Value4004000.0
Percentage of LiabilitiesNoncurrent100.0100.00.0
Percentage of Assets0.40.40.0
Percentage of Assets mrk:AstraZeneca us-gaap:AccountsPayableAndAccruedLiabilities us-gaap:CollaborativeArrangement0.00.00.0

mrk:BayerAG, us-gaap:OtherNoncurrentLiabilities, us-gaap:CollaborativeArrangement


Liabilities
Period End2021-06-302021-03-312020-09-302020-06-302020-03-312019-12-31
Value400400375375375375
Percentage of LiabilitiesNoncurrent0.00.093.893.80.00.0
Percentage of Assets0.40.40.40.40.40.4
Percentage of Assets mrk:BayerAG us-gaap:OtherNoncurrentLiabilities us-gaap:CollaborativeArrangement0.00.00.00.00.00.0

mrk:Eisai, us-gaap:OtherNoncurrentLiabilities, us-gaap:CollaborativeArrangement


Liabilities
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-31
Value300600570570300525
Percentage of LiabilitiesNoncurrent0.00.0142.5142.50.00.0
Percentage of Assets0.30.70.60.60.40.6
Percentage of Assets mrk:Eisai us-gaap:OtherNoncurrentLiabilities us-gaap:CollaborativeArrangement0.00.00.00.00.00.0

Long Term Debt Noncurrent

us-gaap:LongTermDebtNoncurrent

us-gaap:LongTermDebtNoncurrent


Long
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-31
Value2403324002253602632126156216372273622677227712272119806199361995921501213532183821706234372427423656236422365623929241242406925506186991856618590195892053922647225261608916254175711505715228155251569215783156441548216095
Percentage of LongTermDebtNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets26.526.427.729.328.925.526.927.227.127.624.023.423.525.024.323.823.424.325.524.124.524.023.523.823.523.519.018.219.018.119.421.321.115.115.316.514.314.414.814.714.914.814.614.3

Deferred Income Tax Liabilities Net

us-gaap:DeferredIncomeTaxLiabilitiesNet

us-gaap:DeferredIncomeTaxLiabilitiesNet


Deferred
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312016-12-31
Value1489120410151777209119431470196020891835170220652159220622195077
Percentage of DeferredIncomeTaxLiabilitiesNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets1.61.31.12.02.32.31.72.42.52.22.12.42.52.62.55.3

Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent

us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent us-gaap:RetirementPlanSponsorLocation, us-gaap:RetirementPlanType

us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent

country:US, us-gaap:PensionPlansDefinedBenefit


Pension
Period End2020-12-312019-12-312018-12-312017-12-312016-12-31
Value185915509259491033
Percentage of PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent100.0100.0100.0100.0100.0
Percentage of Assets2.01.81.11.11.1
Percentage of Assets country:US us-gaap:PensionPlansDefinedBenefit0.00.00.00.00.0

us-gaap:ForeignPlan, us-gaap:PensionPlansDefinedBenefit


Pension
Period End2020-12-312019-12-312018-12-312017-12-312016-12-31
Value1413126811489551022
Percentage of PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent76.081.8124.1100.698.9
Percentage of Assets1.51.51.41.11.1
Percentage of Assets us-gaap:ForeignPlan us-gaap:PensionPlansDefinedBenefit0.00.00.00.00.0

us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent us-gaap:RetirementPlanType

us-gaap:OtherPostretirementBenefitPlansDefinedBenefit


Pension
Period End2020-12-312019-12-312018-12-312017-12-312016-12-31
Value377561637797892
Percentage of PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent20.336.268.984.086.4
Percentage of Assets0.40.70.80.90.9
Percentage of Assets us-gaap:OtherPostretirementBenefitPlansDefinedBenefit0.00.00.00.00.0

Minority Interest

us-gaap:MinorityInterest

us-gaap:MinorityInterest


Minority
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-31
Value9494878410295948710213118123423723323325124925122021389959192190152144136158258925612587260525772443246524792454242624562426245524292427
Percentage of MinorityInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.10.10.10.10.10.10.10.10.10.20.20.30.30.30.30.30.30.30.20.20.10.10.10.10.20.10.10.10.22.42.42.42.42.42.32.32.32.32.32.32.32.32.32.2

Other Liabilities Noncurrent

us-gaap:OtherLiabilitiesNoncurrent

us-gaap:OtherLiabilitiesNoncurrent


Other
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312012-12-31
Value98721224112482120271244611550119701108511283115851204111887120281147311117771380688324851487938378737473457887791376777813696881757956813610327
Percentage of OtherLiabilitiesNoncurrent100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets10.913.513.613.413.713.614.213.313.414.114.614.014.113.312.78.48.78.68.98.98.77.57.27.87.77.17.96.88.47.37.79.7

Operating Lease Liability Noncurrent

us-gaap:OperatingLeaseLiabilityNoncurrent

us-gaap:OperatingLeaseLiabilityNoncurrent


Operating
Period End2020-12-312019-12-31
Value1362768
Percentage of OperatingLeaseLiabilityNoncurrent100.0100.0
Percentage of Assets1.50.9

Lessee Operating Lease Liability Payments Due Year Two

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo


Lessee
Period End2020-12-31
Value277
Percentage of LesseeOperatingLeaseLiabilityPaymentsDueYearTwo100.0
Percentage of Assets0.3

Lessee Operating Lease Liability Payments Due Year Three

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree


Lessee
Period End2020-12-31
Value252
Percentage of LesseeOperatingLeaseLiabilityPaymentsDueYearThree100.0
Percentage of Assets0.3

Lessee Operating Lease Liability Payments Due Year Four

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour


Lessee
Period End2020-12-31
Value187
Percentage of LesseeOperatingLeaseLiabilityPaymentsDueYearFour100.0
Percentage of Assets0.2

Lessee Operating Lease Liability Payments Due Year Five

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive


Lessee
Period End2020-12-31
Value162
Percentage of LesseeOperatingLeaseLiabilityPaymentsDueYearFive100.0
Percentage of Assets0.2

Lessee Operating Lease Liability Payments Due After Year Five

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive


Lessee
Period End2020-12-31
Value665
Percentage of LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive100.0
Percentage of Assets0.7

Operating Lease Liability

us-gaap:OperatingLeaseLiability

us-gaap:OperatingLeaseLiability


Operating
Period End2020-12-312019-12-312019-09-302019-06-30
Value166210041020993
Percentage of OperatingLeaseLiability100.0100.0100.0100.0
Percentage of Assets1.81.21.21.2

Lessee Operating Lease Liability Payments Due

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue


Lessee
Period End2020-12-31
Value1879
Percentage of LesseeOperatingLeaseLiabilityPaymentsDue100.0
Percentage of Assets2.1

Lessee Operating Lease Liability Undiscounted Excess Amount

us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount


Lessee
Period End2020-12-31
Value217
Percentage of LesseeOperatingLeaseLiabilityUndiscountedExcessAmount100.0
Percentage of Assets0.2

Stockholders Equity

us-gaap:StockholdersEquity

us-gaap:StockholdersEquity


Stockholders
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-31
Value3329426945253172918627642262052590726838276352753926701324223252933668343363824839463398374008843744433574380644676455874644847765486474522448358499754976547419475005302953020557475519454860545175514055496543845437659058
Percentage of StockholdersEquity100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets36.729.727.632.530.530.930.732.232.933.432.338.138.339.139.141.742.541.342.044.544.944.443.945.045.344.149.544.449.446.147.144.644.449.950.052.452.352.051.951.852.351.451.452.6

Stockholders Equity Including Portion Attributable To Noncontrolling Interest

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest


Stockholders
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312008-12-312007-12-31
Value33388270392540429270277442630026001269252773727670268823265632766339013456938499397124008840308439574344643901447674567946638479174879145360485165256452326500065010555606554635821257673573145694357596579225683956805580485765760335614852116720591
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets36.829.827.732.630.631.030.832.333.033.632.538.438.539.439.342.042.841.542.344.745.044.544.045.145.544.249.644.649.648.549.547.046.952.452.354.854.754.354.254.154.553.753.70.00.00.054.70.00.0

us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest us-gaap:StatementEquityComponents

us-gaap:AccumulatedDefinedBenefitPlansAdjustment


Stockholders
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312014-12-312013-12-31
Value-3028.0-4459.0-4540.0-4100.0-4162.0-4201.0-4261.0-3515.0-3530.0-3541.0-3556.0-3025.0-3065.0-3095.0-2787.0-3120.0-3133.0-3180.0-3206.0-2687.0-2543.0-2435.0-2407.0-2986.0-909.0
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-9.1-16.5-17.9-14.0-15.0-16.0-16.4-13.1-12.7-12.8-13.2-9.3-9.4-9.1-8.1-8.1-7.9-7.9-8.0-6.1-5.9-5.5-5.4-6.1-1.7
Percentage of Assets-3.3-4.9-5.0-4.6-4.6-4.9-5.0-4.2-4.2-4.3-4.3-3.6-3.6-3.6-3.2-3.4-3.4-3.3-3.4-2.7-2.6-2.5-2.4-3.0-0.9
Percentage of Assets us-gaap:AccumulatedDefinedBenefitPlansAdjustment0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedGainLossNetCashFlowHedgeParent


Stockholders
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312015-12-31
Value-26.0-36.0-266.0-122.01513531157661181669265-201.0-108.0-103.0-37.0106338404
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-0.1-0.1-1.0-0.40.10.50.10.60.20.40.60.30.2-0.6-0.3-0.3-0.10.30.80.9
Percentage of Assets-0.0-0.0-0.3-0.10.00.20.00.20.10.10.20.10.1-0.2-0.1-0.1-0.00.10.40.4
Percentage of Assets us-gaap:AccumulatedGainLossNetCashFlowHedgeParent0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedOtherComprehensiveIncome


Stockholders
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312008-12-312007-12-31
Value-4628.0-6622.0-6634.0-6383.0-6393.0-6391.0-6193.0-5390.0-5362.0-5346.0-5545.0-5151.0-5122.0-5060.0-4910.0-4945.0-5094.0-5080.0-5226.0-4252.0-4086.0-4194.0-4148.0-4573.0-4332.0-4167.0-4323.0-2998.0-2444.0-2179.0-2197.0-4698.0-4760.0-4629.0-4682.0-3040.0-3126.0-3217.0-3132.0-2713.0-2776.0-3170.0-3216.0-3490.0-4659.0-3572.0-2767.0-2554.0-826.0
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-13.9-24.5-26.1-21.8-23.0-24.3-23.8-20.0-19.3-19.3-20.6-15.8-15.6-14.9-14.2-12.8-12.8-12.7-13.0-9.7-9.4-9.6-9.3-10.0-9.3-8.7-8.9-6.6-5.0-4.1-4.2-9.4-9.5-8.3-8.4-5.2-5.4-5.6-5.5-4.7-4.8-5.6-5.7-6.0-8.1-5.9-4.5-12.1-4.0
Percentage of Assets-5.1-7.3-7.2-7.1-7.1-7.5-7.3-6.5-6.4-6.5-6.7-6.1-6.0-5.9-5.6-5.4-5.5-5.3-5.5-4.3-4.2-4.2-4.1-4.5-4.2-3.8-4.4-2.9-2.5-2.0-2.1-4.4-4.5-4.4-4.4-2.9-3.0-3.0-3.0-2.5-2.6-3.0-3.00.00.00.0-2.50.00.0
Percentage of Assets us-gaap:AccumulatedOtherComprehensiveIncome0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AccumulatedTranslationAdjustment


Stockholders
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312014-12-312013-12-31
Value-1574.0-2127.0-1828.0-2161.0-2246.0-2325.0-1981.0-2063.0-1946.0-1927.0-2077.0-2094.0-1958.0-1597.0-1954.0-1932.0-1999.0-2046.0-2355.0-1739.0-1821.0-2065.0-2186.0-1978.0-1474.0
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-4.7-7.9-7.2-7.4-8.1-8.8-7.6-7.7-7.0-7.0-7.7-6.4-6.0-4.7-5.7-5.0-5.0-5.1-5.8-4.0-4.2-4.7-4.9-4.1-2.8
Percentage of Assets-1.7-2.3-2.0-2.4-2.5-2.7-2.3-2.5-2.3-2.3-2.5-2.5-2.3-1.9-2.2-2.1-2.2-2.1-2.5-1.8-1.9-2.1-2.1-2.0-1.4
Percentage of Assets us-gaap:AccumulatedTranslationAdjustment0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:AdditionalPaidInCapital


Stockholders
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312008-12-31
Value44039396133958839489393733969739660395613948438768388083976239741398743990239823397763989939939398973991140145402224013940114403554042340340401994045040508399093989140727406464047140550406524066340717406574069040701405574033840197396838319
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest131.9146.5155.8134.9141.9150.9152.5146.9142.4140.1144.4121.8121.3117.6115.4103.4100.299.599.190.891.991.489.887.986.084.282.888.982.977.077.479.879.673.273.369.570.370.971.470.770.271.671.769.970.066.664.539.3
Percentage of Assets48.643.643.244.043.546.847.047.547.047.147.046.746.746.345.443.442.941.341.940.641.440.739.539.739.137.241.139.641.137.338.337.537.338.338.338.138.438.538.738.238.338.438.50.00.00.035.30.0
Percentage of Assets us-gaap:AdditionalPaidInCapital0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:CommonStock


Stockholders
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312008-12-312007-12-31
Value178817881788178817881788178817881788178817881788178817881788178817881788178817881788178817881788178817881788178817881788178817881788178817881788178817881788178817881788178817881786178617813030
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest5.46.67.06.16.46.86.96.66.46.56.75.55.55.35.24.64.54.54.44.14.14.14.03.93.83.73.73.93.73.43.43.63.63.23.23.13.13.13.13.13.13.13.13.13.13.02.90.10.1
Percentage of Assets2.02.02.02.02.02.12.12.12.12.22.22.12.12.12.02.01.91.91.91.81.91.81.81.81.71.71.81.81.81.61.71.71.71.71.71.71.71.71.71.71.71.71.70.00.00.01.60.00.0
Percentage of Assets us-gaap:CommonStock0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:NoncontrollingInterest


Stockholders
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312008-12-312007-12-31
Value949487841029594871021311812342372332332512492512202138995919219015214413615825892561258726052577244324652479245424262456242624552429245524262457242724092407
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest0.30.30.30.30.40.40.40.30.40.50.70.70.70.70.70.70.60.60.50.50.20.20.20.20.40.30.30.30.34.94.95.25.24.64.44.24.34.34.34.34.24.34.34.24.24.13.911.411.7
Percentage of Assets0.10.10.10.10.10.10.10.10.10.20.20.30.30.30.30.30.30.30.20.20.10.10.10.10.20.10.10.10.22.42.42.42.42.42.32.32.32.32.32.32.32.32.30.00.00.02.20.00.0
Percentage of Assets us-gaap:NoncontrollingInterest0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:RetainedEarnings


Stockholders
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312008-12-312007-12-31
Value48777488884736251107497244827246602458044529544065425794218941523411074135043701450464438744133460284512145192453484566045103456924602139989403663966139257397733991540272399854039039950394413899038763382433740037536392464008240511414054369939141
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest146.1180.8186.4174.6179.2183.5179.2170.1163.3159.3158.4129.2126.7121.3119.6113.5113.4110.7109.5104.7103.9102.9101.3100.096.795.494.388.283.275.575.079.579.772.472.169.469.368.868.567.366.065.866.167.669.567.167.3206.4190.1
Percentage of Assets53.853.851.756.954.956.855.255.053.953.551.549.648.847.847.147.748.546.046.346.846.845.844.645.144.042.246.839.341.236.637.237.437.337.937.738.037.937.437.136.436.035.335.50.00.00.036.90.00.0
Percentage of Assets us-gaap:RetainedEarnings0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:TreasuryStock


Stockholders
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312008-12-312007-12-31
Value-56682.0-56722.0-56787.0-56815.0-56850.0-57161.0-55950.0-54925.0-53570.0-51736.0-50929.0-46166.0-45401.0-44041.0-43794.0-42119.0-42053.0-41157.0-40546.0-39717.0-39377.0-39125.0-38534.0-37427.0-36225.0-35903.0-35262.0-33895.0-31551.0-29745.0-29591.0-29353.0-29334.0-25129.0-24717.0-23862.0-23968.0-23804.0-23792.0-23415.0-22416.0-22324.0-22433.0-22508.0-22316.0-21044.0-21044.0-30736.0-28175.0
Percentage of StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-169.8-209.8-223.5-194.1-204.9-217.3-215.2-204.0-193.1-187.0-189.5-141.4-138.6-129.9-126.7-109.4-105.9-102.7-100.6-90.4-90.6-89.1-86.1-81.9-77.7-74.9-72.3-74.7-65.0-56.6-56.6-58.7-58.5-45.2-44.6-41.0-41.6-41.5-41.8-40.7-38.7-39.3-39.5-38.8-38.7-34.9-34.2-145.2-136.8
Percentage of Assets-62.5-62.4-62.0-63.3-62.7-67.3-66.3-65.9-63.8-62.8-61.6-54.2-53.4-51.2-49.8-45.9-45.3-42.6-42.5-40.4-40.8-39.6-37.9-37.0-35.3-33.1-35.9-33.3-32.2-27.4-28.0-27.6-27.4-23.7-23.3-22.4-22.7-22.6-22.6-22.0-21.1-21.1-21.20.00.00.0-18.70.00.0
Percentage of Assets us-gaap:TreasuryStock0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Common Stock Value

us-gaap:CommonStockValue

us-gaap:CommonStockValue


Common
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-31
Value17881788178817881788178817881788178817881788178817881788178817881788178817881788178817881788178817881788178817881788178817881788178817881788178817881788178817881788178817881781
Percentage of CommonStockValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets2.02.02.02.02.02.12.12.12.12.22.22.12.12.12.02.01.91.91.91.81.91.81.81.81.71.71.81.81.81.61.71.71.71.71.71.71.71.71.71.71.71.71.71.6

Additional Paid In Capital Common Stock

us-gaap:AdditionalPaidInCapitalCommonStock

us-gaap:AdditionalPaidInCapitalCommonStock


Additional
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-31
Value4403939613395883948939373396973966039561394843876838808397623974139874399023982339776398993993939897399114014540222401394011440355404234034040199404504050839909398914072740646404714055040652406634071740657406904070139683
Percentage of AdditionalPaidInCapitalCommonStock100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets48.643.643.244.043.546.847.047.547.047.147.046.746.746.345.443.442.941.341.940.641.440.739.539.739.137.241.139.641.137.338.337.537.338.338.338.138.438.538.738.238.338.438.535.3

Retained Earnings Accumulated Deficit

us-gaap:RetainedEarningsAccumulatedDeficit

us-gaap:RetainedEarningsAccumulatedDeficit


Retained
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-31
Value4877748888473625110749724482724660245804452954406542579421894152341107413504370145046443874413346028451214519245348456604510345692460213998940366396613925739773399154027239985403903995039441389903876338243374003753641405
Percentage of RetainedEarningsAccumulatedDeficit100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets53.853.851.756.954.956.855.255.053.953.551.549.648.847.847.147.748.546.046.346.846.845.844.645.144.042.246.839.341.236.637.237.437.337.937.738.037.937.437.136.436.035.335.536.9

Accumulated Other Comprehensive Income Loss Net Of Tax

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax


Accumulated
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-31
Value-4628.0-6622.0-6634.0-6383.0-6393.0-6391.0-6193.0-5390.0-5362.0-5346.0-5545.0-5151.0-5122.0-5060.0-4910.0-4945.0-5094.0-5080.0-5226.0-4252.0-4086.0-4194.0-4148.0-4573.0-4332.0-4167.0-4323.0-2998.0-2444.0-2179.0-2197.0-4698.0-4760.0-4629.0-4682.0-3040.0-3126.0-3217.0-3132.0-2713.0-2776.0-3170.0-3216.0-3490.0-4659.0-3572.0-2767.0
Percentage of AccumulatedOtherComprehensiveIncomeLossNetOfTax100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets-5.1-7.3-7.2-7.1-7.1-7.5-7.3-6.5-6.4-6.5-6.7-6.1-6.0-5.9-5.6-5.4-5.5-5.3-5.5-4.3-4.2-4.2-4.1-4.5-4.2-3.8-4.4-2.9-2.5-2.0-2.1-4.4-4.5-4.4-4.4-2.9-3.0-3.0-3.0-2.5-2.6-3.0-3.00.00.00.0-2.5

Treasury Stock Value

us-gaap:TreasuryStockValue

us-gaap:TreasuryStockValue


Treasury
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-31
Value5668256722567875681556850571615595054925535705173650929461664540144041437944211942053411574054639717393773912538534374273622535903352623389531551297452959129353293342512924717238622396823804237922341522416223242243321044
Percentage of TreasuryStockValue100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets62.562.462.063.362.767.366.365.963.862.861.654.253.451.249.845.945.342.642.540.440.839.637.937.035.333.135.933.332.227.428.027.627.423.723.322.422.722.622.622.021.121.121.218.7

Minority Interest

us-gaap:MinorityInterest

us-gaap:MinorityInterest


Minority
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-31
Value9494878410295948710213118123423723323325124925122021389959192190152144136158258925612587260525772443246524792454242624562426245524292427
Percentage of MinorityInterest100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.10.10.10.10.10.10.10.10.10.20.20.30.30.30.30.30.30.30.20.20.10.10.10.10.20.10.10.10.22.42.42.42.42.42.32.32.32.32.32.32.32.32.32.2

Minority Interest Decrease From Distributions To Noncontrolling Interest Holders

us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders

us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders


Minority
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value0.0221.01.00.0214.0115.05.08.03.01.04.010.01.06.06.01.02.03.015581.059582.01.0170-53.02.01.0581.0592.0581.0591.0
Percentage of MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders0.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders us-gaap:StatementEquityComponents

us-gaap:NoncontrollingInterest


Minority
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value0.0221.01.00.0214.0115.05.08.03.01.04.010.01.06.06.01.02.03.015581.059582.01.0170-53.02.01.0581.0592.0581.0591.0
Percentage of MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders0.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Assets0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Percentage of Assets us-gaap:NoncontrollingInterest0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Net Cash Provided By Used In Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetCashProvidedByUsedInOperatingActivities


Net
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value1791400621733367707479442263084133635922793338211554015-1171.0331728636322971161521584247330525852284-1164.04348231523613026394923382341180931392920215432334577285217213539259233251366
Percentage of NetCashProvidedByUsedInOperatingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues14.832.017.331.05.940.434.126.212.432.725.932.311.538.5-11.333.43.035.928.216.423.241.632.826.424.2-11.141.221.223.026.735.821.221.915.427.323.718.426.338.123.514.929.323.329.312.0

Net Cash Provided By Used In Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:NetCashProvidedByUsedInInvestingActivities


Net
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value-738.0-4778.0-2155.0-882.0-1628.0-763.0191-2425.036821781660673-197.0-58.0671-1127.03193-2563.0-890.0-1498.01741-617.0-61.02525-6605.07204-3722.0-49.0-3807.01177-2037.0-1135.0-1153.0-4398.0-1839.0-298.0-270.0-1684.0-263.0-1048.0105-1007.0194464-3148.0
Percentage of NetCashProvidedByUsedInInvestingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues-6.1-38.2-17.2-8.1-13.5-6.41.5-20.63.419.815.46.4-2.0-0.66.5-11.333.8-25.3-8.4-15.218.7-6.0-0.625.8-70.168.7-35.3-0.4-37.110.4-18.5-10.3-10.8-37.5-16.0-2.4-2.3-13.7-2.2-8.60.9-8.31.74.1-27.6

Net Cash Provided By Used In Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:NetCashProvidedByUsedInFinancingActivities


Net
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value-2098.01372-3851.01137-1490.0-2011.0-3152.0-2084.0-1614.0-5566.0-1905.0-2967.0-2722.0-5785.0536-6218.01461-1977.0-835.0-3381.0-2851.0-2407.0-2533.0-5485.05155-9643.01279-8369.01620-2624.0-2915.0970-1421.0-1218.0-738.0-586.0-725.0-2231.0-2244.0-1257.0-1172.0-1295.0-1625.0-3463.0942
Percentage of NetCashProvidedByUsedInFinancingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues-17.411.0-30.710.5-12.4-16.9-25.4-17.7-14.9-50.6-17.6-28.4-27.1-55.45.2-62.615.5-19.5-7.9-34.3-30.6-23.6-25.1-56.154.7-92.012.1-76.515.8-23.2-26.48.8-13.3-10.4-6.4-4.8-6.2-18.1-18.7-10.3-10.1-10.7-14.6-30.58.2

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect


Cash
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value1619-1142.0764-3746.03687-2474.020631211-1417.01101392516826-1610.0-1805.0115-3922.05193
Percentage of CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues14.2-9.56.1-29.833.9-20.517.49.8-12.01.01.323.37.9-16.0-17.31.1-39.555.0

Deferred Income Tax Expense Benefit

us-gaap:DeferredIncomeTaxExpenseBenefit

us-gaap:DeferredIncomeTaxExpenseBenefit


Deferred
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value39-10.0-715.0-75.04082-170.0-237.0-343.0194-118.0-133.0-228.0-30.0-2020.0-329.0-218.0-54.0-1456.055-50.0-70.082-463.0-204.0-179.0-827.0-527.0-942.0-304.0202-213.0-248.0-71.095282-324.0-41.0-563.0-133.0-627.0-214.0-349.0-424.0-471.0152
Percentage of DeferredIncomeTaxExpenseBenefit100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Depreciation Depletion And Amortization

us-gaap:DepreciationDepletionAndAmortization

us-gaap:DepreciationDepletionAndAmortization


Depreciation
Period End2020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value8521048821936845973898109510611226113711281154116211931155117515501561156015701608163715731611175317541954170516551674166117231804179018611903183218311866188019481687
Percentage of DepreciationDepletionAndAmortization100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DepreciationDepletionAndAmortization us-gaap:ConsolidationItems

us-gaap:MaterialReconcilingItems


Depreciation
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value332358429395390381404382427359328324332350342334332370357365438430398383393396557595
Percentage of DepreciationDepletionAndAmortization0.00.00.046.437.246.443.245.243.940.030.030.527.130.830.328.928.631.030.931.128.327.525.524.424.424.235.436.9

Net Cash Provided By Used In Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities

us-gaap:NetCashProvidedByUsedInOperatingActivities


Net
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value1791400621733367707479442263084133635922793338211554015-1171.0331728636322971161521584247330525852284-1164.04348231523613026394923382341180931392920215432334577285217213539259233251366
Percentage of NetCashProvidedByUsedInOperatingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues14.832.017.331.05.940.434.126.212.432.725.932.311.538.5-11.333.43.035.928.216.423.241.632.826.424.2-11.141.221.223.026.735.821.221.915.427.323.718.426.338.123.514.929.323.329.312.0

Net Income Loss

us-gaap:NetIncomeLoss

us-gaap:NetIncomeLoss


Net
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value15453179-2094.02941300232192356190126702915182719501707736-1046.0-56.019461551-595.02184120511259771826687953731689520041705781112490615939071729179317381512169220241043-532.0342752299
Percentage of NetIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues13.626.3-16.723.427.626.719.915.322.727.016.618.116.37.3-10.0-0.519.616.4-5.920.712.212.19.618.17.010.169.88.518.316.66.910.28.214.97.715.114.614.812.314.116.79.0-4.43.16.62.6

us-gaap:NetIncomeLoss us-gaap:StatementEquityComponents

us-gaap:RetainedEarnings


Net
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value15453179-2094.02941300232192356190126702915182719501707736-1046.0-56.019451551-595.02185120511259771826686953731689520041705781112490615939071730179317381512169320241043-532.0342752299
Percentage of NetIncomeLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.099.9100.0100.0100.0100.0100.0100.0100.099.9100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.1100.0100.0100.0100.1100.0100.0100.0100.0100.0100.0
Percentage of Revenues13.626.3-16.723.427.626.719.915.322.727.016.618.116.37.3-10.0-0.519.616.4-5.920.712.212.19.618.17.010.169.88.518.316.66.910.28.214.97.715.114.614.812.314.116.79.0-4.43.16.62.6
Percentage of Revenues us-gaap:RetainedEarnings0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0

Profit Loss

us-gaap:ProfitLoss

us-gaap:ProfitLoss


Profit
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value3186-2091.02945301032192363190726442862177819581716741-1038.0-51.019511556-587.02188120911309821831688958732784220331731815115093516169491763182017671543172420541071-500.0372780330
Percentage of ProfitLoss100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues26.4-16.723.527.726.719.915.422.526.516.218.116.47.4-9.9-0.519.616.5-5.820.812.312.19.618.27.010.269.98.018.616.97.210.48.515.18.115.314.815.112.614.316.99.2-4.13.36.92.9

Share Based Compensation

us-gaap:ShareBasedCompensation

us-gaap:ShareBasedCompensation


Share
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value1231201211261211081111011119387919080807682747577806878758363697578566668756778889376828610793109126142132
Percentage of ShareBasedCompensation100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Net Cash Provided By Used In Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivities

us-gaap:NetCashProvidedByUsedInInvestingActivities


Net
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value-738.0-4778.0-2155.0-882.0-1628.0-763.0191-2425.036821781660673-197.0-58.0671-1127.03193-2563.0-890.0-1498.01741-617.0-61.02525-6605.07204-3722.0-49.0-3807.01177-2037.0-1135.0-1153.0-4398.0-1839.0-298.0-270.0-1684.0-263.0-1048.0105-1007.0194464-3148.0
Percentage of NetCashProvidedByUsedInInvestingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues-6.1-38.2-17.2-8.1-13.5-6.41.5-20.63.419.815.46.4-2.0-0.66.5-11.333.8-25.3-8.4-15.218.7-6.0-0.625.8-70.168.7-35.3-0.4-37.110.4-18.5-10.3-10.8-37.5-16.0-2.4-2.3-13.7-2.2-8.60.9-8.31.74.1-27.6

Payments To Acquire Productive Assets

us-gaap:PaymentsToAcquireProductiveAssets

us-gaap:PaymentsToAcquireProductiveAssets


Payments
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value9341134151415166689861137959782595929653583450715441393339551409375279493316271203490320302205429355413351778414431331603431365324660338337343
Percentage of PaymentsToAcquireProductiveAssets100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:PaymentsToAcquireProductiveAssets us-gaap:BusinessAcquisition

mrk:Dunboyne


Payments
Period End2020-09-30
Value256
Percentage of PaymentsToAcquireProductiveAssets16.9

Payments To Acquire Investments

us-gaap:PaymentsToAcquireInvestments us-gaap:AssetAcquisition

us-gaap:PaymentsToAcquireInvestments

mrk:OncoImmune


Payments
Period End2020-12-31
Value50
Percentage of PaymentsToAcquireInvestments100.0

us-gaap:PaymentsToAcquireInvestments us-gaap:BusinessAcquisition

mrk:OncoImmune


Payments
Period End2020-12-31
Value50
Percentage of PaymentsToAcquireInvestments100.0

us-gaap:PaymentsToAcquireInvestments us-gaap:CounterpartyName

mrk:Seagen


Payments
Period End2020-09-30
Value1000
Percentage of PaymentsToAcquireInvestments0.0

Net Cash Provided By Used In Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities

us-gaap:NetCashProvidedByUsedInFinancingActivities


Net
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value-2098.01372-3851.01137-1490.0-2011.0-3152.0-2084.0-1614.0-5566.0-1905.0-2967.0-2722.0-5785.0536-6218.01461-1977.0-835.0-3381.0-2851.0-2407.0-2533.0-5485.05155-9643.01279-8369.01620-2624.0-2915.0970-1421.0-1218.0-738.0-586.0-725.0-2231.0-2244.0-1257.0-1172.0-1295.0-1625.0-3463.0942
Percentage of NetCashProvidedByUsedInFinancingActivities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Percentage of Revenues-17.411.0-30.710.5-12.4-16.9-25.4-17.7-14.9-50.6-17.6-28.4-27.1-55.45.2-62.615.5-19.5-7.9-34.3-30.6-23.6-25.1-56.154.7-92.012.1-76.515.8-23.2-26.48.8-13.3-10.4-6.4-4.8-6.2-18.1-18.7-10.3-10.1-10.7-14.6-30.58.2

Proceeds From Issuance Of Long Term Debt

us-gaap:ProceedsFromIssuanceOfLongTermDebt

us-gaap:ProceedsFromIssuanceOfLongTermDebt


Proceeds
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302012-12-312012-09-30
Value0.0-26.044450.00.00.00.049580.00.00.00.010710.08.00.00.0-2.0-1.0794131450.01.00.00.00.0582504
Percentage of ProceedsFromIssuanceOfLongTermDebt0.0100.0100.00.00.00.00.0100.00.00.00.00.0100.00.0100.00.00.0100.0100.0100.0100.00.0100.00.00.00.0100.0100.0

Repayments Of Long Term Debt

us-gaap:RepaymentsOfLongTermDebt

us-gaap:RepaymentsOfLongTermDebt


Repayments
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value0.011533.02.01.019510.00.00.00.01280-1.0200510038020.01.03000.03515008511.00.03.0290266102.02.03.012600.09.0506182.00.02.02701212614.0652634.0622
Percentage of RepaymentsOfLongTermDebt0.0100.0100.0100.0100.0100.00.00.00.00.0100.0100.0100.0100.0100.00.0100.0100.00.0100.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.00.0100.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Payments Of Dividends Common Stock

us-gaap:PaymentsOfDividendsCommonStock

us-gaap:PaymentsOfDividendsCommonStock


Payments
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value1673164515421545157715511405139414681428127712851311129912831283130712941271127413001279126312721302128012591282133912901260125913321306128012771280127911651175117611751175118111891189
Percentage of PaymentsOfDividendsCommonStock100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Payments For Repurchase Of Common Stock

us-gaap:PaymentsForRepurchaseOfCommonStock

us-gaap:PaymentsForRepurchaseOfCommonStock


Payments
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302010-12-312010-09-30
Value0.00.00.01281105014051235109059339961596566170215911341019101684566091311811281709101516202670224611671962155525580115245452945656210450.0296
Percentage of PaymentsForRepurchaseOfCommonStock0.00.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0100.0

Effective Income Tax Rate Continuing Operations

us-gaap:EffectiveIncomeTaxRateContinuingOperations

us-gaap:EffectiveIncomeTaxRateContinuingOperations


Effective
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
Value29.38.04.514.10.1450.1610.0020.1870.1890.0670.0120.2650.1780.4490.3741.2550.20.223-0.0930.2420.1960.304-0.0680.2360.1470.3060.1510.435-0.0750.1720.0420.2460.249-0.0430.0010.2050.3210.295-0.0290.267-0.2280.380.0350.2530.3710.464
Percentage of EffectiveIncomeTaxRateContinuingOperations100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber


Share
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-31
Value19172336456476115165230272313
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice


Share
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-31
Value63.6459.8851.8946.7744.4741.6439.0538.7539.4639.5142.2643.02
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod us-gaap:AwardType

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

us-gaap:PerformanceShares


Share
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-30
Value0.9760.2230.00.0030.770.1540.00.00.6090.2260.00.0240.8310.0080.0
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod100.0100.00.0100.0100.0100.00.00.0100.0100.00.0100.0100.0100.00.0

us-gaap:RestrictedStockUnitsRSU


Share
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-30
Value0.075-0.3731.05.9420.058-0.189-1.05.930.070.270.06.8790.1210.0140.0
Percentage of ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod7.7-167.30.0198066.77.5-122.70.00.011.5119.50.028662.514.6175.00.0

Deferred Tax Liabilities

us-gaap:DeferredTaxLiabilities

us-gaap:DeferredTaxLiabilities


Deferred
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-31
Value121750104616464531592736666047950698481141613756
Percentage of DeferredTaxLiabilities100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Deferred Tax Assets Net

us-gaap:DeferredTaxAssetsNet

us-gaap:DeferredTaxAssetsNet


Deferred
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-31
Value255622511770217429892952352030584876552753336378
Percentage of DeferredTaxAssetsNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

us-gaap:DeferredTaxAssetsNet us-gaap:BalanceSheetLocation

us-gaap:OtherAssets


Deferred
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-31
Value894719656573546608401381527497
Percentage of DeferredTaxAssetsNet35.031.937.126.418.320.611.412.510.89.0

Unrecognized Tax Benefits

us-gaap:UnrecognizedTaxBenefits

us-gaap:UnrecognizedTaxBenefits


Unrecognized
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-31
Value15371225189317233494344835343503442542774919474336653690
Percentage of UnrecognizedTaxBenefits100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Deferred Tax Assets Valuation Allowance

us-gaap:DeferredTaxAssetsValuationAllowance

us-gaap:DeferredTaxAssetsValuationAllowance


Deferred
Period End2020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-31
Value43311001348900268304265205107246196
Percentage of DeferredTaxAssetsValuationAllowance100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

Proceeds From Repayments Of Short Term Debt

us-gaap:ProceedsFromRepaymentsOfShortTermDebt

us-gaap:ProceedsFromRepaymentsOfShortTermDebt


Proceeds
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-30
Value-4771.07882860-2278.0-1616.03583182-360.0603-4135.028302252070-1.0-1988.01986-3808.03784-909.0918-9.00.0-14.03.0-3706.02177-3537.04963-5035.03149-310.0-1551.0822880904-1917.01003634-280.0-40.01593-197.0-1483.0-85.0
Percentage of ProceedsFromRepaymentsOfShortTermDebt100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.00.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

mrk:AmortizationOfPurchaseAccountingAdjustments us-gaap:ConsolidationItems

mrk:AmortizationOfPurchaseAccountingAdjustments

us-gaap:MaterialReconcilingItems


Amortization
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-30
Value2892852992953143293783975206797327337347657797787607721024113411941184123812389841008
Percentage of AmortizationOfPurchaseAccountingAdjustments100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

mrk:ChargesRelatedToProgramDiscontinuation us-gaap:ProductOrService

mrk:ChargesRelatedToProgramDiscontinuation

mrk:COVID19


Charges
Period End2021-06-302021-03-31
Value37170
Percentage of ChargesRelatedToProgramDiscontinuation100.0100.0

mrk:CollaborativeArrangementProfitSharing us-gaap:CounterpartyName, us-gaap:IncomeStatementLocation, us-gaap:TypeOfArrangement

mrk:CollaborativeArrangementProfitSharing

mrk:AstraZeneca, us-gaap:Sales, us-gaap:CollaborativeArrangement


Collaborative
Period End2021-06-302021-03-312020-09-302020-06-302020-03-312019-09-302019-06-30
Value256233199178145123111
Percentage of CollaborativeArrangementProfitSharing100.0100.0100.0100.0100.0100.0100.0

mrk:BayerAG, us-gaap:Sales, us-gaap:CollaborativeArrangement


Collaborative
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value747465837953605051423947282535323153
Percentage of CollaborativeArrangementProfitSharing28.931.80.041.744.436.60.040.745.90.00.00.00.00.00.00.00.00.0

mrk:Eisai, us-gaap:Sales, us-gaap:CollaborativeArrangement


Collaborative
Period End2021-06-302021-03-312020-09-302020-06-302020-03-312019-09-302019-06-30
Value18113014215112810997
Percentage of CollaborativeArrangementProfitSharing70.755.871.484.888.388.687.4

mrk:CollaborativeArrangementProfitSharing us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:IncomeStatementLocation, us-gaap:TypeOfArrangement

mrk:AstraZeneca, mrk:AllianceRevenueKoselugo, us-gaap:Sales, us-gaap:CollaborativeArrangement


Collaborative
Period End2021-06-302021-03-312020-09-30
Value8.05.03.0
Percentage of CollaborativeArrangementProfitSharing3.12.11.5

mrk:AstraZeneca, mrk:AlliancerevenueLynparza, us-gaap:Sales, us-gaap:CollaborativeArrangement


Collaborative
Period End2021-06-302021-03-312020-09-302020-06-302020-03-312019-09-30
Value248228196178145123
Percentage of CollaborativeArrangementProfitSharing96.997.998.5100.0100.0100.0

mrk:CollaborativeArrangementSalesNet us-gaap:CounterpartyName, us-gaap:IncomeStatementLocation, us-gaap:TypeOfArrangement

mrk:CollaborativeArrangementSalesNet

mrk:BayerAG, us-gaap:Sales, us-gaap:CollaborativeArrangement


Collaborative
Period End2021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-31
Value5553555756575753485247474344383631
Percentage of CollaborativeArrangementSalesNet100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

mrk:CollaborativeArrangementSalesNet us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:IncomeStatementLocation, us-gaap:TypeOfArrangement

mrk:BayerAG, mrk:Adempas, us-gaap:Sales, us-gaap:CollaborativeArrangement


Collaborative
Period End2021-06-302020-06-30
Value7457
Percentage of CollaborativeArrangementSalesNet0.0100.0

mrk:BayerAG, mrk:Verquvo, us-gaap:Sales, us-gaap:CollaborativeArrangement


Collaborative
Period End2021-06-30
Value1.0
Percentage of CollaborativeArrangementSalesNet0.0

mrk:ContingentPaymentsCollaborativeArrangement us-gaap:CounterpartyName

mrk:ContingentPaymentsCollaborativeArrangement

mrk:Seagen


Contingent
Period End2020-09-30
Value2600
Percentage of ContingentPaymentsCollaborativeArrangement100.0

mrk:ContingentPaymentsCollaborativeArrangement us-gaap:CounterpartyName, us-gaap:ContingentConsiderationByType

mrk:Seagen, mrk:DevelopmentMilestones


Contingent
Period End2020-09-30
Value850
Percentage of ContingentPaymentsCollaborativeArrangement32.7

mrk:Seagen, mrk:RegulatoryMilestones


Contingent
Period End2020-09-30
Value850
Percentage of ContingentPaymentsCollaborativeArrangement32.7

mrk:Seagen, mrk:SalesBasedMilestones


Contingent
Period End2020-09-30
Value1750
Percentage of ContingentPaymentsCollaborativeArrangement67.3

mrk:ContingentPaymentsCollaborativeArrangement us-gaap:CounterpartyName, us-gaap:ContingentConsiderationByType, us-gaap:TypeOfArrangement

mrk:ArtivaBiotherapeuticsInc, mrk:DevelopmentMilestones, us-gaap:LicensingAgreements


Contingent
Period End2021-01-31
Value217
Percentage of ContingentPaymentsCollaborativeArrangement0.0

mrk:ArtivaBiotherapeuticsInc, mrk:RegulatoryMilestones, us-gaap:LicensingAgreements


Contingent
Period End2021-01-31
Value570
Percentage of ContingentPaymentsCollaborativeArrangement0.0

mrk:ArtivaBiotherapeuticsInc, mrk:SalesBasedMilestones, us-gaap:LicensingAgreements


Contingent
Period End2021-01-31
Value1050
Percentage of ContingentPaymentsCollaborativeArrangement0.0

mrk:ContingentPaymentsCollaborativeArrangement us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:ContingentConsiderationByType

mrk:Seagen, mrk:Tukysa, mrk:RegulatoryMilestones


Contingent
Period End2020-09-30
Value65
Percentage of ContingentPaymentsCollaborativeArrangement2.5

mrk:ContingentPaymentsCollaborativeArrangement us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement

mrk:AstraZeneca, mrk:Lynparza, mrk:RegulatoryMilestones


Contingent
Period End2020-09-302020-06-302020-03-312019-09-30
Value0.0-300.017000.0
Percentage of ContingentPaymentsCollaborativeArrangement0.00.00.00.0

mrk:ContingentPaymentsCollaborativeArrangement us-gaap:CounterpartyName, us-gaap:TypeOfArrangement

mrk:AstraZeneca, mrk:SalesBasedMilestones


Contingent
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302017-07-31
Value0.00.0-400.031000.00.0-300.03400-250.00.04100
Percentage of ContingentPaymentsCollaborativeArrangement0.00.00.00.00.00.00.00.00.00.00.0

mrk:BayerAG, mrk:SalesBasedMilestones


Contingent
Period End2020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
Value0.00.04000.00.00.04000.00.0
Percentage of ContingentPaymentsCollaborativeArrangement0.00.00.00.00.00.00.00.00.0

mrk:Eisai, mrk:RegulatoryMilestones


Contingent
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-03-31
Value-10.00.00.01350.00.00.0135-25.0385
Percentage of ContingentPaymentsCollaborativeArrangement0.00.00.00.00.00.00.00.00.00.0

mrk:Eisai, mrk:SalesBasedMilestones


Contingent
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-03-31
Value-100.00.0-300.03000-420.00.00.03420-210.03970
Percentage of ContingentPaymentsCollaborativeArrangement0.00.00.00.00.00.00.00.00.00.0

mrk:CostsExpensesAndOther

mrk:CostsExpensesAndOther


Costs
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-30
Value968586181450891237353821990771005085017749839481298379869285541012574917431114717649834076889399767689788044-1329.09067904381731009595079765912110403927096319224107139670104799851127951062710105
Percentage of CostsExpensesAndOther100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

mrk:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet

mrk:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet


Disposal
Period End2021-06-302020-06-30
Value234.0
Percentage of DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet100.0100.0

mrk:DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses

mrk:DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses


Disposal
Period End2021-06-302020-06-30
Value5038
Percentage of DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses100.0100.0

mrk:EstimateOfCumulativePreTaxCostsThatWillBeNoncash

mrk:EstimateOfCumulativePreTaxCostsThatWillBeNoncash


Estimate
Period End2021-06-302021-03-312020-12-31
Value030.0-10.0
Percentage of EstimateOfCumulativePreTaxCostsThatWillBeNoncash0.0100.0100.0

mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays

mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays


Estimate
Period End2021-06-302021-03-312020-12-31
Value070.010.0
Percentage of EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays0.0100.0100.0

mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther

mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther


Fair
Period End2021-06-302021-03-31
Value0.012
Percentage of FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther0.0100.0

mrk:Licenseoptionpaymentrelatedtocollaborativearrangement us-gaap:CounterpartyName

mrk:Licenseoptionpaymentrelatedtocollaborativearrangement

mrk:Eisai


Licenseoptionpaymentrelatedtocollaborativearrangementus-gaap:
Period End2021-03-312020-03-312019-03-31
Value125200325
Percentage of Licenseoptionpaymentrelatedtocollaborativearrangement100.0100.0100.0

mrk:Licenseoptionpaymentrelatedtocollaborativearrangement us-gaap:CounterpartyName, us-gaap:StatementScenario

mrk:Eisai, srt:ScenarioForecast


Licenseoptionpaymentrelatedtocollaborativearrangementus-gaap:
Period End2021-03-312020-03-31
Value125200
Percentage of Licenseoptionpaymentrelatedtocollaborativearrangement100.0100.0

mrk:MilestonePaymentsMadetoCollaborativePartner us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement

mrk:MilestonePaymentsMadetoCollaborativePartner

mrk:AstraZeneca, mrk:Lynparza, mrk:SalesBasedMilestones


Milestone
Period End2020-12-312020-09-302020-01-31
Value3000.0250
Percentage of MilestonePaymentsMadetoCollaborativePartner100.00.0100.0

mrk:Eisai, mrk:Lenvima, mrk:SalesBasedMilestones


Milestone
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
Value0.00.02003000.00.0
Percentage of MilestonePaymentsMadetoCollaborativePartner0.00.00.00.00.00.0

mrk:MilestonePaymentsSalesBased us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement

mrk:MilestonePaymentsSalesBased

mrk:Eisai, mrk:Lenvima, us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangement


Milestone
Period End2021-06-302021-03-31
Value0.0200
Percentage of MilestonePaymentsSalesBased0.0100.0

mrk:OtherNonoperatingIncomeExpenseOther

mrk:OtherNonoperatingIncomeExpenseOther


Other
Period End2021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-31
Value20215468-22.02815829-153.0-83.0-326.011238315601615332-468.04310749-565.043278-15.010774325707200-21.0-13.0-10.057
Percentage of OtherNonoperatingIncomeExpenseOther100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0

mrk:PremiumOnSharesAcquired us-gaap:AssetAcquisition

mrk:PremiumOnSharesAcquired

mrk:OncoImmune


Premium
Period End2020-12-31
Value17
Percentage of PremiumOnSharesAcquired100.0

mrk:PremiumOnSharesAcquired us-gaap:BusinessAcquisition

mrk:OncoImmune


Premium
Period End2020-12-31
Value17
Percentage of PremiumOnSharesAcquired100.0

mrk:ProbableContingentPaymentsCollaborativeArrangement us-gaap:CounterpartyName, us-gaap:SubsequentEventType, us-gaap:TypeOfArrangement

mrk:ProbableContingentPaymentsCollaborativeArrangement

mrk:BayerAG, us-gaap:SubsequentEvent, mrk:SalesBasedMilestones


Probable
Period End2021-01-31
Value400
Percentage of ProbableContingentPaymentsCollaborativeArrangement100.0

mrk:ProfitShare us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement

mrk:ProfitShare

mrk:GileadSciences, mrk:InjectableFormulation, us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangement


Profit
Period End2021-03-31
Value35.0
Percentage of ProfitShare100.0

mrk:GileadSciences, mrk:OralAndInjectableFormulations, us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangement


Profit
Period End2021-03-31
Value40.0
Percentage of ProfitShare114.3

mrk:GileadSciences, mrk:OralFormulation, us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangement


Profit
Period End2021-03-31
Value35.0
Percentage of ProfitShare100.0

mrk:ProfitShareCounterparty us-gaap:CounterpartyName, us-gaap:ProductOrService, us-gaap:TypeOfArrangement

mrk:ProfitShareCounterparty

mrk:GileadSciences, mrk:InjectableFormulation, us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangement


Profit
Period End2021-03-31
Value65.0
Percentage of ProfitShareCounterparty100.0

mrk:GileadSciences, mrk:OralAndInjectableFormulations, us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangement


Profit
Period End2021-03-31
Value60.0
Percentage of ProfitShareCounterparty92.3

mrk:GileadSciences, mrk:OralFormulation, us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangement


Profit
Period End2021-03-31
Value65.0
Percentage of ProfitShareCounterparty100.0

mrk:RestructuringReserveIncreaseDecreaseNoncashActivity

mrk:RestructuringReserveIncreaseDecreaseNoncashActivity


Restructuring
Period End2021-06-302021-03-31
Value8.02.0
Percentage of RestructuringReserveIncreaseDecreaseNoncashActivity100.0100.0

mrk:RestructuringReserveIncreaseDecreaseNoncashActivity us-gaap:RestructuringCostAndReserve

mrk:AcceleratedDepreciation


Restructuring
Period End2021-06-302021-03-31
Value-18.0-20.0
Percentage of RestructuringReserveIncreaseDecreaseNoncashActivity-225.0-1000.0

us-gaap:OtherRestructuring


Restructuring
Period End2021-06-302021-03-31
Value2622
Percentage of RestructuringReserveIncreaseDecreaseNoncashActivity325.01100.0

mrk:RestructuringReserveNoncashActivity

mrk:RestructuringReserveNoncashActivity


Restructuring
Period End2020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-31
Value7761811188287-97.0-37.0-39.0146.03.0-14.018-27.0223951217106
Percentage of RestructuringReserveNoncashActivity100.0100.0100.0100.0100.0100.01